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ABSTRACT OF DISSERTATION 
 
 
 
 
ANDROGEN INCREASES ANGIOTENSIN RECEPTOR TYPE 1A ON SMOOTH 
MUSCLE CELLS TO PROMOTE ANGIOTENSIN II-INDUCED ABDOMINAL 
AORTIC ANEURYSMS 
 
The purpose of this study was to determine whether androgen promotes 
AT1aR expression on smooth muscle to confer high prevalence of AngII-induced 
AAAs in hyperlipidemic mice. In addition, we also investigate the role of 
androgen in the progression of established AngII-induced AAAs. 
 
First, we sought to examine the role of endogenous androgen in the 
growth of established AngII-induced AAAs. By castrating male mice, we 
demonstrated that removal of endogenous androgen significantly decreased the 
progressive lumen dilation of established AngII-induced AAAs in male ApoE-/- 
mice, but had no effect on external AAA diameters. These results suggest that 
androgen contributes to the progression of established AAAs through distinct 
mechanisms that differentially influence aortic lumen and wall diameters. 
 
We also investigate whether androgen regulates aortic AT1aR expression 
to promote AngII-induced AAA formation. Our data demonstrated that in male 
and female mice, both endogenous and exogenous androgen stimulate AT1aR 
level particularly in abdominal aortas. This androgen-dependent enhanced 
expression of abdominal aortic AT1aR was correlated with increased AngII-
induced AAA formation in male and f emale mice. Smooth muscle AT1aR 
deficiency significantly reduced luminal and external diameters of abdominal 
aortas as well as the incidence of AngII-induced AAAs in adult female mice 
administered exogenous androgen. Collectively, these results indicate that in 
adult mice androgen stimulate smooth muscle AT1aR expression to promote 
AngII-induced AAA formation. 
 
To determine the role of androgen during development on AT1aR 
expression on SMC and AngII-induced vascular pathologies, we exposed 
neonatal female mice to one single dose of testosterone. Our data demonstrated 
that neonatal testosterone administration dramatically increased AngII-induced 
AAA, atherosclerosis and ascending aortic aneurysms in adult female mice. In 
addition, smooth muscle AT1aR deficiency reduced effects of neonatal 
testosterone to promote AAAs, but had no effect on the other two AngII-induced 
vascular pathologies. 
 
In summary, our findings demonstrated that androgen, both in adult life 
and during development, stimulate smooth muscle AT1aR expression and 
promote AngII-induced AAA in female hyperlipidemic mice. 
 
 
KEYWORDS: Androgen, Angiotensin receptor, Abdominal aortic aneurysm, 
Sexual dimorphism, Smooth muscle 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                 Student’s Signature 
                                                              
                                                                 Date 
                                                                  
 
 
 
ANDROGEN INCREASES ANGIOTENSIN RECEPTOR TYPE 1A ON SMOOTH 
MUSCLE CELLS TO PROMOTE ANGIOTENSIN II-INDUCED ABDOMINAL 
AORTIC ANEURYSMS 
 
 
By 
 
Xuan Zhang 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                       
                                                                 Director of Dissertation 
 
                                                                
                                                                                                                     
                                                                 Director of Graduate Studies 
 
                                                               
                                            
          
 
RULES FOR THE USE OF DISSERTATIONS 
 
Unpublished dissertations submitted for the Doctor's degree and deposited in the 
University of Kentucky Library are as a rule open for inspection, but are to be 
used only with due regard to the rights of the authors. Bibliographical references 
may be noted, but quotations or summaries of parts may be published only with 
the permission of the author, and with the usual scholarly acknowledgments. 
 
Extensive copying or publication of the dissertation in whole or in part also 
requires the consent of the Dean of the Graduate School of the University of 
Kentucky. 
 
A library that borrows this dissertation for use by its patrons is expected to secure 
the signature of each user. 
 
Name                                                                                                       Date 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISSERTATION 
 
 
 
 
 
 
 
 
 
 
Xuan Zhang 
 
 
 
 
 
 
 
The Graduate School 
University of Kentucky 
2011 
ANDROGEN INCREASES ANGIOTENSIN RECEPTOR TYPE 1A ON SMOOTH 
MUSCLE CELLS TO PROMOTE ANGIOTENSIN II-INDUCED ABDOMINAL 
AORTIC ANEURYSMS 
 
 
 
 
DISSERTATION 
 
 
A dissertation submitted in partial fulfillment of the 
requirements for the degree of Doctor of Philosophy in the 
Graduate Center for Toxicology 
at the University of Kentucky 
 
 
By 
Xuan Zhang 
 
Lexington, Kentucky 
 
Director: Dr. Lisa Cassis, Professor of Nutritional Sciences 
 
Lexington, Kentucky 
 
2011 
 
 
Copyright © Xuan Zhang 2011 
To My Loving Family 
iii 
 
ACKNOWLEDGMENTS 
My deep gratitude extends many people for the completion of the 
dissertation. Without them, this dissertation would not have been even started. 
First and foremost, I would like to thank my mentor, Dr. Lisa Cassis, for her 
patient and invaluable guidance through every step of my graduate experience. 
She inspires the inquisitive nature in me and shows me the beauty of scientific 
researches. I thank you, Lisa, for your guidance and encouragement for the last 
five years and for initiating me as an independent thinker and growing scientist. I 
utterly enjoy every sweet and bitter part of my dissertation. Next, I would like to 
thank the other members of my dissertation committee and the outsider 
examiner: Dr. Alan Daugherty, Dr. Nancy Webb, Dr. Daret St. Clair and Dr. Ming 
Gong. Every piece of valuable suggestion and challenging question over the past 
few years have been of great help with regard to shaping my dissertation project. 
A special thanks to Dr. Alan Daugherty and the Daugherty laboratory.  Their 
extensive knowledge, expertise and technical assistance have helped me 
immensely with the execution of my research projects. 
I also would like to thank the Cassis laboratory (current and former 
members) for their technical assistance to my research projects as well as their 
always warm companions and friendships. Manisha Gupte, Victoria English, Dr. 
Sean Thatcher, Kelly Putnam,Dr. Frederique Yiannikouris, Nicki Baker, Robin 
Shoemaker, Eboni Lewis, Michael Karounosand and many others former 
members, their caring hearts have made the lab a wonderful place to work over 
the years. 
iv 
 
Last, but not least, I thank my parents for their unconditional love and 
support in my life. I thank them for supporting me to take Ph.D. training abroad 
even it is very difficult for them that I live so far away. They have incredible faith 
in me when sometimes I do not even have it. 
The 5 years I have spent studying and working in Dr. Lisa Cassis lab is a 
wonderful journey to me. It has the perfect proportion of joy, bitterness, success 
and failure. People say happiness requires something to do, someone to love 
and something to hope for. I have much more in these 5 years of my life. I thank 
all of you for being part of my little perfect world. 
Thank you. 
v 
 
TABLE OF CONTENTS 
 
 
Acknowledgements .............................................................................................. iii 
 
List of Tables ........................................................................................................ ix 
 
List of Figures ....................................................................................................... x 
 
Chapter I.       Background  ................................................................................... 1 
            1.1      Abdominal Aortic Aneurysms in Humans ....................................... 1 
1.1.1   Overview  ............................................................................ 1 
1.1.2   Clinical risk factors .............................................................. 3 
1.1.3   Gender ................................................................................ 4 
            1.2      Renin-angiotensin system ............................................................. 5  
1.2.1   Current view ........................................................................ 5                
1.2.2   Angiotensin, inflammation and cardiovascular disease  .... 13              
1.2.3   Sex Hormones and the RAS ............................................. 15 
         1.3      AngII-induced AAA ...................................................................... 17 
1.3.1   Overview ........................................................................... 17    
1.3.2   Angiotensin receptors in AngII-induced AAAs  .................. 20    
1.3.3   Mechanistic insights into AngII-induced AAAs  ................. 21      
1.3.4   Gender in AngII-induced AAAs ......................................... 27 
1.3.5   Gender in elastase-induced AAAs .................................... 28      
1.4      Androgen ..................................................................................... 31       
1.4.1   Metabolism of androgen .................................................... 32       
1.4.2   Androgen receptor ............................................................ 33        
1.4.3   Mechanism of action of ARs ............................................. 35              
1.4.4   Androgens and cardiovascular disease ............................ 37     
1.4.5   Androgen during development and sex dimorphism ......... 40    
 
Chapter IA.     Statement of the problem ............................................................ 54 
 
Chapter IB.     Hypothesis ................................................................................... 56 
 
Chapter II.       Specific Aim ................................................................................ 58  
2.1      Summary ..................................................................................... 58                                                                                                    
vi 
 
2.2      Introduction .................................................................................. 60                                                                                                 
2.3      Methods ....................................................................................... 63     
2.3.1   Animals ............................................................................. 63      
2.3.2   AngII Infusion .................................................................... 63       
2.3.3   Orchiectomy ...................................................................... 64     
2.3.4   Ultrasound Imaging ........................................................... 64     
2.3.5   Atherosclerosis and AAA Quantification ............................ 65      
2.3.5   Statistical Analyses ........................................................... 65    
2.4      Results......................................................................................... 67    
2.4.1   Castration Reduces the Progressive Lumen Dilation of 
Established AngII-induced AAAs in Male ApoE-/- Mice ..... 67    
2.4.2   Castration Does not Alter Maximal External Diameters of 
AngII-induced AAAs or AngII-induced Atherosclerosis ...... 68 
2.5      Discussion ................................................................................... 69     
                                                                                               
Chapter III.     Specific Aim 2 .............................................................................. 77   
   3.1     Summary ..................................................................................... 77           
   3.2     Introduction .................................................................................. 79                                                                                                 
3.3      Methods ...................................................................................... 81   
3.3.1  Animals .............................................................................. 81  
3.3.2  Orchiectomy and Ovariectomy .......................................... 81     
3.3.3  Generation of AT1aRSM22 KO mice ................................ 82     
3.3.4  Genotyping ........................................................................ 82          
3.3.5  Aortic gene expression quantification by real time PCR .... 82       
3.3.6  Measurement of aortic contractility .................................... 83      
3.3.7  Quantification of atherosclerosis and AAAs ....................... 84        
3.3.8  Statistical Analyses ........................................................... 85       
3.4  Results ......................................................................................... 86    
3.4.1   Androgen Selectively Augments Abdominal Aortic AT1aR 
Expression in Both Male and Female ApoE-/- mice .......... 86      
3.4.2 Androgen Fails to Regulate Aortic AT1bR Expression in 
ApoE-/- Mice...................................................................... 86                                                               
3.4.3 Androgen enhances SMC AT1aR Expression to promote 
AngII-induced AAAs in Female Hyperlipidemic Mice ......... 87    
3.5  Discussion .................................................................................... 90 
vii 
 
 
Chapter IV.     Specific Aim 3 ............................................................................ 105                                                                                  
   4.1     Summary ................................................................................... 105                                                                
   4.2     Introduction ................................................................................ 108           
4.3      Methods ..................................................................................... 110      
4.3.1  Animals ............................................................................ 110      
4.3.2  Measurement of systolic blood pressure ......................... 111      
4.3.3 Quantification of Atherosclerosis, AAA and Ascending Aortic 
Aneurysm ........................................................................ 111                                                                                 
4.3.4  Aneurismal Tissue Characterization ................................ 112       
4.3.5  Blood Analysis ................................................................. 112        
4.3.6  Aortic gene quantification by Real Time PCR .................. 113     
4.3.7  Statistical Analysis ........................................................... 114     
4.4  Results ....................................................................................... 115 
4.4.1 Neonatal testosterone exposure developmentally programs 
increased AT1aR expression in abdominal aortas from adult 
female hyperlipidemic mice ............................................. 115                                                                         
4.4.2 Administration of testosterone to neonatal female ApoE-/- 
mice increases AngII-induced AAAs in adult females ..... 116 
4.4.3 Neonatal testosterone exposure developmentally programs 
AngII-induced atherosclerosis and ascending aortic 
aneurysms in female LDLR-/- mice independent of smooth 
muscle AT1aR ................................................................. 118 
4.4.4 Smooth muscle AT1aR deficiency attenuates neonatal    
testosterone programming of AngII-induced AAAs in adult 
female LDLR-/- mice ....................................................... 120                                                                        
4.5  Discussion .................................................................................. 122 
 
Chapter V.      General Discussion ................................................................... 143   
5.1      Summary ................................................................................... 145     
5.2      Potential mechanisms of androgen to influence the development 
of AngII-induced AAAs .............................................................. 145                                                     
5.2.1   The role of androgen during adult life in AngII-induced AAA 
formation and progression ............................................... 145    
5.2.2   The role of developmental androgen in AngII-induced AAA 
formation ......................................................................... 152                         
5.3      Future directions ........................................................................ 157     
viii 
 
5.4      Clinical application ..................................................................... 159                  
5.4.1  AAA prevention ............................................................... 159     
5.4.2  AAA treatment ................................................................. 160                               
5.5      Concluding remarks ................................................................... 161 
 
References ....................................................................................................... 163    
 
Vita ................................................................................................................... 213 
            
 
ix 
 
LIST OF TABLES 
 
Table 1.1 Summary of findings in AngII-induced AAAs ...................................... 45 
Table 1.2 Gender difference in AngII and elastase-induced AAAs ..................... 48 
Table 3.1 PCR primers and conditions used for AT1aRfl/fl and AT1aRSM22 KO 
mice genotyping .................................................................................. 94 
Table 4.1 Characteristics of female ApoE-/- mice subjected to neonatal 
administration with either vehicle or testosterone ............................. 127 
Table 4.2 Characteristics of adult female AT1aRfl/fl and AT1aRSM22 KO 
administered vehicle or testosterone as neonate .............................. 128 
 
 
 
 
 
 
 
 
x 
 
LIST OF FIGURES 
 
Figure 1.1   Current RAS with biologically active peptides highlighted in blue .... 49 
Figure 1.2   Signaling of the AT1 receptor .......................................................... 50 
Figure 1.3   Signaling of the AT2 receptor .......................................................... 51 
Figure 1.4   Regulation of the renin angiotensin system (RAS) by male and 
female sex hormones ....................................................................... 52 
Figure 1.5   The pathway leading to synthesis of testosterone from cholesterol 
and its subsequent metabolism to other hormones.......................... 53 
Figure 2.1   Body weights through AngII infusion and male sex organ tissue 
weights at study endpoint of both sham and castration group ......... 73 
Figure 2.2   Lumen diameters of suprarenal abdominal aortas were obtained from 
sham and castration groups using ultrasound through 3 months AngII 
infusion ............................................................................................ 74 
Figure 2.3   Castration does not significantly reduce maximal external diameters 
of AngII-induced AAA or have any impact on AngII-induced 
atherosclerosis in aortic arch ........................................................... 75 
Figure 2.4   Perfusion fixed aortas from sham and castration groups ................. 76 
Figure 3.1   Schematic representations of the experimental groups and study 
design as described in the methods section .................................... 95 
Figure 3.2   DHT augments AT1aR mRNA abundance in abdominal aortas from 
male and female ApoE-/- mice ......................................................... 96 
Figure 3.3   AT1bR mRNA abundance in abdominal and thoracic aortas from 
male (A) and female (B) ApoE-/- mice was not altered by castration 
(1 or 5 weeks), or by DHT administration (1 or 5 weeks) ................. 97 
Figure 3.4   Contractile responses of aortic (thoracic and abdominal) rings to 
AngII (1 μM, as a % of the KCl response) in male (A) and female (B) 
mice was not altered by castration, or by DHT administration ......... 98 
Figure 3.5   Androgen receptor (AR) mRNA abundance was greater in abdominal 
compared to thoracic aortas both male (A) and female (B) ApoE-/- 
mice ................................................................................................. 99 
Figure 3.6   AT1aR mRNA abundance in mouse aortic smooth muscle cells was 
increased by testosterone (10 nM; 24 hours of incubation) ........... 100 
Figure 3.7   Generation (A) and DNA genotyping (B) of smooth muscle AT1aR 
deficient LDLR-/- mice ................................................................... 101 
Figure 3.8   SMC AT1aR deficiency reduces AAAs in adult female mice 
administered DHT and infused with AngII ...................................... 102 
xi 
 
Figure 3.9   SMC AT1aR deficiency decreases abdominal aortic lumen diameters 
and maximal external abdominal diameters in adult female mice 
administered DHT and infused with AngII ...................................... 103 
Figure 3.10 SMC AT1aR deficiency has no effect on AngII-induced 
atherosclerosis in aortic arch or ascending aortic dilation ............. 104 
Figure 4.1   AT1aR mRNA abundance in adult female ApoE-/- mice (n = 8-
10/group) and LDLR-/- mice (n = 5-6/group) administered 
testosterone as neonates ............................................................... 129 
Figure 4.2   Neonatal testosterone administration significantly increases AngII-
induced AAAs in adult female ApoE-/- mice .................................. 130 
Figure 4.3   Neonatal testosterone administration significantly increases 
abdominal aortic lumen diameters in adult female ApoE-/- mice 
infused with 500, 750 or 1000 ng/kg/min AngII .............................. 131 
Figure 4.4   Neonatal testosterone administration significantly increases maximal 
external diameters of the abdominal aortas in adult female ApoE-/- 
mice infused with 500, 750 or 1000 ng/kg/min AngII...................... 132 
Figure 4.5   Serum lipoprotein cholesterol distributions in AngII-infused female 
ApoE-/- mice administered with either vehicle or testosterone as 
neonates ........................................................................................ 133 
Figure 4.6   Serum lipoprotein cholesterol distribution in AngII-infused female wild 
type and SMC AT1aR deficient mice administered with either vehicle 
or testosterone as neonates .......................................................... 134 
Figure 4.7   Neonatal testosterone administration increases AngII-induced 
atherosclerosis in adult AT1aRfl/fl and AT1aRSM22 KO female LDLR-/- 
mice ............................................................................................... 135 
Figure 4.8   Neonatal testosterone administration increases macrophage 
accumulation in aortic root atherosclerotic lesions from adult 
AT1aRfl/fl and AT1aRSM22 KO female LDLR-/- mice ........................ 136 
Figure 4.9   Neonatal testosterone administration increases AngII-induced 
ascending aortic aneurysms in adult AT1aR
fl/fl 
and AT1aR
SM22 
KO 
female LDLR-/- mice ...................................................................... 137 
Figure 4.10 Neonatal testosterone administration increases AngII-induced 
ascending aortic pathologies in adult AT1aR
fl/fl 
and AT1aR
SM22 
KO 
female LDLR-/- mice ...................................................................... 138 
Figure 4.11 Neonatal testosterone administration increases ascending aortic 
ulceration in adult AT1aR
fl/fl 
and AT1aR
SM22 
KO female LDLR-/- mice
 ...................................................................................................... 139 
Figure 4.12 Smooth muscle AT1aR deficiency reduces AngII-induced AAAs in 
adult female mice administered testosterone as neonates ............ 140 
xii 
 
Figure 4.13 Cross sections of AngII-induced AAA from AT1aRfl/fl and AT1aRSM22 
KO mice administered testosterone as neonates .......................... 141 
Figure 4.14 Aortic genes were differentially regulated by neonatal testosterone 
exposure in adult female LDLR-/- mice ......................................... 142 
 
 
1 
 
CHAPTER I. BACKGROUND 
 
1.1 Abdominal Aortic Aneurysms in Humans 
1.1.1   Overview 
According to the Society for Vascular Surgery and the International 
Society for Cardiovascular Surgery abdominal aortic aneurysms (AAAs) are 
defined as a permanent dilation of the infrarenal aorta with a ratio of ≥1.5 fold 
increase in normal abdominal aortic diameter (Johnston, Rutherford et al. 1991). 
Most investigators  also define an AAA as an infrarenal aortic diameter 
exceeding 3.0 cm (McGregor, Pollock et al. 1975; Sakalihasan, Limet et al. 
2005). The prevalence of unsuspected, asymptomatic AAA in men and women 
over the age of 60 years are 4% to 8.5% and 0.5% to 1.5%, respectively 
(Wilmink, Quick et al. 1999; Lawrence-Brown, Norman et al. 2001; Ashton, 
Buxton et al. 2002; Cornuz, Sidoti Pinto et al. 2004; Palombo, Lucertini et al. 
2010). AAAs tend to progressively expand over time with average growth rate 
between 0.25 and 0.32 cm/year (Lederle, Wilson et al. 2002) . The risk of 
aneurysmal rupture increases proportionally with AAA diameter, and becomes 
especially high when the diameter exceeds 5.5 cm.  Unfortunately, so far there 
are no pharmacologic treatments with proven efficacy to prevent AAA expansion 
and rupture. Currently the only effective way to prevent AAA rupture is open or 
endovascular surgical repair.  A threshold of 5.0 – 5.5 cm in AAA size is the 
current recommendation for open or endovascular surgical repair of an AAA 
(Powell and Brady 2004). Recent estimates of AAA prevalence are 1.1 million 
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people in the US between the ages of 50 to 84 (Kent, Zwolak et al. 2010).  
Ruptured AAA and complications after surgical treatment are responsible for at 
least 15,000 deaths per year in the United States (Gillum 1995). This number is 
considered as a likely understatement because about 5% of the 200,000 people 
who die of sudden death each year may have died from AAA ruptures 
(Schermerhorn 2009). 
The histopathologic features of human AAAs are characterized by chronic 
excessive transmural inflammatory (B-cells, T-cells and macrophage infiltration), 
destructive degradation of the elastic media, apoptosis of medial smooth muscle 
cells (SMCs) and significant medial neovascularization (Choke, Cockerill et al. 
2005). However, the detailed mechanisms involved in biochemical and cellular 
processes during the development of human AAAs remains largely unknown. It is 
now well accepted that AAA initiation, progression and rupture are multifactorial 
biological processes that involve distinct biochemical, cellular and proteolytic 
influences and biomechanical factors on the vessel wall during different 
developmental stage of AAA pathogenesis. It is well established that the 
destruction of elastin and collagen largely contributes to the decrease in aortic 
wall tensile strength followed by aneurysmal dilatation. In rodents, elastase 
infusion into infrarenal aortas induces AAA formation (Halpern, Nackman et al. 
1994).  Increased proteolytic activity in the vessel wall has been demonstrated to 
play a significant role in the pathogenesis of AAAs. Increased levels of matrix 
metalloproteinases (MMPs), specially MMP-2 and MMP-9, were found in 
aneurysmal tissues of both humans and experimental models (Freestone, Turner 
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et al. 1995; Goodall, Porter et al. 2002) and  the genetic deficiency of MMP 2 and 
9 inhibit AAA formation in an experimental AAA model (Longo, Xiong et al. 2002). 
As reviewed by Takagi et al, higher circulating MMP-9 concentrations are 
associated with AAA in human (Takagi, Manabe et al. 2009). Furthermore, 
plasma MMP-9 levels were elevated in patients with larger AAAs (Lindholt, 
Vammen et al. 2000; Petersen, Gineitis et al. 2000).  Increased MMP-9 level was 
detected at the ruputure site of AAAs (Wilson, Anderton et al. 2006).  Also a 4-
fold increase in pre-operative plasma MMP-9 levels was associated with 
increased mortality >30 days post-rupture surgery, compared to >30 days post 
surgery survivors (Wilson, Anderton et al. 2008).  All these findings demonstrate 
an important role of MMPs in the pathogenesis of human AAAs. 
 
1.1.2   Clinical risk factors 
Smoking, male gender, aging, and family history are considered as 
primary and independent risk factors of human AAA (Pleumeekers, Hoes et al. 
1995; Lederle, Johnson et al. 2000; Wanhainen, Bergqvist et al. 2005).  Smoking 
is a prominent risk factor that is strongly associated with AAAs development. 
Approximately 90% of people with AAAs have smoked (Powell and Greenhalgh 
2003; Isselbacher 2005). People who have smoked for more than 40 years are 
much more likely to develop AAAs compared to non-smokers (Powell and 
Greenhalgh 2003) A slow decline in risk was observed with each year after 
cessation of smoking (Wilmink, Quick et al. 1999; Lederle, Johnson et al. 2001; 
Kent, Zwolak et al. 2010). Age, hypertension, hyperlipidemia and atherosclerosis 
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were also found to be moderate risk factors for developing AAAs (Wanhainen, 
Bergqvist et al. 2005; Kent, Zwolak et al. 2010). Genetics also plays a role in the 
development of AAAs. For example, people with a family history of AAAs have a 
30% greater risk, and their aneurysms tend to develop at a younger age 
compared to those with no family history of the disease (Frydman, Walker et al. 
2003). Recently It has been reported that the relative risk of developing AAA for 
first-degree relatives to persons with diagnosed AAA is approximately doubled 
compared to persons with no family history (Larsson, Granath et al. 2009). 
Genetic variations in several chromosome loci, including 19q13, 4q31and 9p21, 
have been associated  with AAA formation  (Shibamura, Olson et al. 2004; 
Kuivaniemi, Kyo et al. 2006; Helgadottir, Thorleifsson et al. 2008). Recently 
obesity has been demonstrated to be associated with increased risk for AAA 
formation in human and experimental AAA model (Golledge, Clancy et al. 2007; 
Police, Thatcher et al. 2009). Interestingly, a negative association have been 
observed between AAA and diabetes mellitus (Blanchard, Armenian et al. 2000). 
Black and Asian race were also found to be associated with decreased risk of 
AAA (Iribarren, Darbinian et al. 2007).  
 
1.1.3   Gender 
Gender is considered a major independent risk factor for AAA 
development (Wanhainen, Bergqvist et al. 2005; Forsdahl, Singh et al. 2009). For 
example, men are 10 times more likely to develop an AAA of 4 cm or greater 
compared to age-matched women (Lederle, Johnson et al. 2001).  Overall, men 
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exhibit greater incidence and severity of AAA compared to women. In recent 
decades epidemiological studies have demonstrated increased AAA incidence 
and rupture in western societies, especially in male gender (Best, Price et al. 
2003; Acosta, Ogren et al. 2006). The well described risk of male gender has 
influenced clinical care, as men aged 65 to 75 years with a history of smoking are 
strongly recommended with regular ultrasound screening for AAA.  
However, female gender has been associated with higher rupture risk of 
small aneurysms (3 times more frequently and at a smaller diameter compared to 
men), and decreased survival rate after surgical AAA repair (Noel, Gloviczki et al. 
2001; Norman and Powell 2007; Grootenboer, van Sambeek et al. 2010).  
Furthermore, recent studies reported a significantly increased growth rate of 
AAAs in women compared to men (Solberg, Singh et al. 2005; Mofidi, Goldie et 
al. 2007; Norman and Powell 2007).   
 
1.2 Renin-angiotensin system 
1.2.1   Current view 
Ever since its first discovery in 1898, the renin-angiotensin system(RAS) 
has emerged as a vital system to modulate many physiological and pathological 
processes. Besides its classical effects on regulating blood pressure and 
maintaining fluid volume homeostasis, the RAS also plays a pivotal role in renal 
and cardiovascular pathologies. Angiotensin peptides are produced through 
sequential enzymatic cleavage of the only known precursor, angiotensinogen as 
illustrated in Figure 1.1.  Angiotensinogen, a 58 kD glycoprotein consisting of 452 
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amino acids, is mainly synthesized and secreted by hepatic cells into the 
circulation (Devenyi, Dauda et al. 1968; Kageyama, Ohkubo et al. 1984). 
However, angiotensinogen mRNA is also expressed in various tissues, including 
adipose tissue (Cassis 2000).  
Renin is an aspartyl protease that cleaves off 10 amino acids at the amino 
terminus of angiotensinogen to yield the peptide angiotensin I. Secretion of renin 
is activated primarily in response to decreases in blood pressure and sodium 
content. Circulating renin and its precursor, prorenin, is synthesized and released 
primarily from the juxtaglomerular cells located in the glomerular afferent 
arterioles (Levens, Peach et al. 1981). In addition, renin has been localized to the 
brain (Inagami, Celio et al. 1980); blood vessels (Mizuno, Gotoh et al. 1984), 
ovaries (Lightman, Jones et al. 1988), testis (Pandey, Melner et al. 1984), 
macrophages (Lu, Rateri et al. 2008), and adipose tissue (Cassis 2000).  
Prorenin is more abundant in the circulation. In human blood plasma, prorenin 
levels are about 10-fold higher than renin (Danser, Derkx et al. 1998).  For a long 
time prorenin had been considered to be a mere inactive precursor of renin until 
the (pro)renin receptor, a 350 amino acid protein with a single transmembrane 
domain, was identified and cloned in 2002 (Nguyen, Delarue et al. 2002). The 
(pro)renin receptor has been shown to bind both renin and prorenin. In humans, 
the prorenin receptor binds prorenin preferentially (Kd ~6-8 nM vs. >20 nM for 
renin) (Nabi, Kageshima et al. 2006; Jan Danser, Batenburg et al. 2007; Danser, 
Batenburg et al. 2008). Binding of prorenin to the (pro)renin receptor induces a 
conformational change in the prorenin molecule, allowing it to display full 
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enzymatic activity without undergoing proteolytic cleavage to renin (Batenburg, 
Krop et al. 2007). Recently it has been demonstrated that renin and prorenin also 
acted as agonists for the (pro) renin receptor and induce angiotensin-
independent effects, such as triggering activation of the mitogenactivated protein 
kinase (MAPK), extracellular signalregulated kinase (ERK) 1/2 signaling pathway 
and upregulating transforming growth factor β1 (TGF-β1) gene expression 
(Huang, Noble et al. 2007; Feldt, Batenburg et al. 2008). 
Angiotensin I (AngI) is biologically inactive and is rapidly converted to 
AngII through an enzymatic cleavage of the last 2 amino acids at the carboxy 
terminus by the angiotensin-converting enzyme (ACE). Two forms of ACE are 
produced from a single gene through alternate promoters (Ehlers and Riordan 
1989). Somatic ACE is the 160 to 170 kDa protein formed primarily in endothelial 
cells of the lung (Ryan, Ryan et al. 1975). It has also been found in kidney 
(Wallace, Bailie et al. 1978), intestine (Bruneval, Hinglais et al. 1986), placenta 
(Sim and Seng 1984) and adipose tissue (Karlsson, Lindell et al. 1998) as well as 
vascular endothelium, epithelium and macrophages (Fuchs, Xiao et al. 2004) 
Germinal ACE is a 100 to 110 kDa protein produced by germ cells in the 
testis (Ehlers and Riordan 1989; Bernstein, Howard et al. 1992). Mice with ACE 
deficiency exhibits reduced blood pressure, inability to concentrate urine, 
reduced aldosterone production and serum potassium concentrations and 
defects in renal structure and function (Kim, Krege et al. 1995; Esther, Howard et 
al. 1996). ACE inhibitors are widely used to treat hypertension and congestive 
heart failure. Besides Ang I, ACE acts on a number of natural substrates 
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including  bradykinin (Ryan, Ryan et al. 1975), cholecystokinin (Dubreuil, 
Fulcrand et al. 1989) substance P (Couture and Regoli 1981) and luteinizing 
hormone-releasing hormone (Skidgel and Erdos 1985). 
Recently a homologue of ACE, known as angiotensin-converting enzyme 
2 (ACE2), was identified. ACE2 is predominantly expressed in vascular 
endothelial cells of the heart and kidney (Donoghue, Hsieh et al. 2000; Tipnis, 
Hooper et al. 2000). ACE2 expression has also been detected in adipocytes, 
testes, colon and lung (Hamming, Timens et al. 2004; Gupte, Boustany-Kari et al. 
2008). Unlike ACE, ACE2 is a monocarboxypeptidase, cleaving a single 
carboxyl-terminal residue from its substrates. Both Ang I and AngII can be 
catabolized by ACE2 to generate Ang-(1-9), and Ang-(1-7), respectively 
(Donoghue, Hsieh et al. 2000; Tipnis, Hooper et al. 2000). However, ACE2 
exhibits a 400-fold higher catalytic efficiency to hydrolyze AngII as a substrate 
compared to AngI (Vickers et al. 2002). Interestingly, Ang-(1-7) is a vasodilator 
and exhibits vasoprotective effects. Ang-(1-7) mediates its effects via interaction 
with Mas, a G protein coupled receptor. It has been demonstrated that Ang-(1-7) 
induces vasodilation through endothelium-dependent nitric oxide involving 
bradykinin receptors (Brosnihan et al. 1996). Ang-(1-7) has also been 
demonstrated to have antiproliferative, antitrophic and apoptotic effects. Thus, 
ACE2/Ang-(1-7) has been suggested as the counter balancing arm of the RAS. 
As the most potent vasoconstrictor of the RAS, AngII plays a critical role in 
regulating blood pressure and fluid electrolyte balance (Peach, Cline et al. 1966). 
AngII has been demonstrated to increase blood pressure via eliciting 
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vasoconstriction in vascular smooth muscle cells (Chiu, Roscoe et al. 1991) and 
modulating vascular structure. In the vasculature, AngII exhibit mitogenic effects 
and cause vascular smooth muscle cell growth (Touyz and Schiffrin 1997), 
proliferation (Stouffer and Owens 1992) and hypertrophy (Chiu, Roscoe et al. 
1991). In addition, AngII increases intravascular volume to further enhance total 
peripheral resistance, therefore increasing blood pressure. AngII regulates water 
and sodium reabsorption by stimulating the synthesis and release of aldosterone 
from the adrenal cortex (Laragh, Ulick et al. 1960; Carpenter, Davis et al. 1961). 
AngII also induces water retention and a dipsogenic response by increasing the 
release of vasopressin from the pituitary (Epstein, Fitzsimons et al. 1969; Phillips, 
Rolls et al. 1985). In the adrenal medulla, AngII stimulates catecholamine release 
from the chromaffin cells (Peach, Cline et al. 1966). Moreover, Ang II also 
increases blood pressure by facilitating peripheral noradrenergic 
neurotransmission. AngII has been demonstrated to enhance vascular 
vasopressor responses to norepinephrine (Reams et al. 1987), facilitate 
norepinephrine release from sympathetic nerve terminals (Hughes et al. 1971) 
and inhibit norepinephrine reuptake during sympathetic stimulation (Campbell, 
Brooks et al. 1974). AngII can also act in the area postrema of the brain to 
increase sympathetic drive to the periphery, and thus increase blood pressure 
(Meldrum, Xue et al. 1984; Papouchado, Vatta et al. 1995).  
AngII exerts its physiological and pathophysiological biological actions via 
binding to specific receptors on the cell surface.  AngII receptors belong to the 
seven transmembrane class of G-protein-coupled receptors (GPCR), and are 
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divided into two main distinct subtypes:  angiotensin II type 1 (AT1) and 2 (AT2) 
receptors (Lin and Goodfriend 1970). These two receptors were initially defined 
based on their differential pharmacological and biochemical properties. The 
majority of the well-known AngII effects, which includes vasoconstriction (Touyz 
and Schiffrin 1997), cellular growth and differentiation (Huang, Richards et al. 
1996), tubular reabsorption (Navar, Harrison-Bernard et al. 1999) and 
aldosterone synthesis and secretion (Balla, Baukal et al. 1991) are mediated via 
AT1R.  The AT1R is ubiquitously expressed in many cells and tissues, such as 
vascular smooth muscle cells, kidney, heart, adrenal gland, brain, lung, and 
adipose tissues (Murphy, Alexander et al. 1991). The intracellular signaling 
pathways involved in AT1R action are illustrated by Figure 1.2. AT1R triggers the 
activation of classic G protein coupled intracellular signalling pathways, which 
includes coupling to a GTP-binding protein, activation of a phospholipase C 
resulting in inositol trisphosphate generation, and mobilization of intracellular 
Ca2+ stores and diacylglycerol formation leading to protein kinase C activation 
(Farese, Larson et al. 1984). In addition to the G protein mediated pathways, 
AngII also act through AT1R to cross talk with several tyrosine kinases and 
activate mitogen-activated protein kinases (MAPKs), including extracellular 
signaling regulation kinase (ERK1/2), JNK and p38MAPK (Mehta and Griendling 
2007).  Unlike human, rodents have 2 isoforms of AT1R that share 95% amino 
acid sequence similarity, AT1aR on chromosome 17 and AT1bR on chromosome 
2 (Elton, Stephan et al. 1992; Sasamura, Hein et al. 1992). Studies have 
demonstrated that mice with AT1aR deficiency, but not AT1bR deficiency, have 
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decreased blood pressure and an attenuated response to AngII (Ito, Oliverio et 
al. 1995; Chen, Li et al. 1997; Oliverio, Best et al. 2000), suggesting the AT1aR is 
the major receptor subtype involved in blood pressure regulation in mice. 
Recently, it has been demonstrated that AT1bR predominantly mediates 
contraction in the isolated abdominal aorta and femoral artery (Zhou, Chen et al. 
2003; Zhou, Dirksen et al. 2005; Swafford, Harrison-Bernard et al. 2007). 
Moreover, AngII infusion induces a pressor response in AT1aR deficient mice, 
which can be blocked by AT1R antagonists.  These data suggest that AT1bR 
receptors may play a role in blood pressure regulation in the absence of AT1aR 
(Oliverio, Best et al. 1997). 
In contrast to the AT1 receptor, the physiological significance of the AT2R 
is less understood.  AT2R seems to counterbalance some of the effects 
mediated by AT1R as illustrated in Figure 1.3. It has been demonstrated that AT2 
antagonize effects of the AT1 receptor by promoting vasorelaxation, growth 
inhibition, and proapoptotic effects (Akishita, Yamada et al. 1999). AT2R deficient 
mice exhibit a 10 mmHg increase in blood pressure (Gross, Obst et al. 2004) and 
enhanced sensitivity to the pressor effects of AngII infusion (Hein, Barsh et al. 
1995; Ichiki, Labosky et al. 1995).  Unlike AT1R, whose expression level remain 
relatively constant in adults, AT2R is mainly present during late embryonic 
development and in the neonate of the mouse and rat, but levels rapidly decline 
shortly after birth (Nakajima, Hutchinson et al. 1995; Shanmugam, Corvol et al. 
1996; Horiuchi, Yamada et al. 1997). AT2R is believed to play a role in 
physiological development, partially through its effects on vascular remodeling. In 
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adults, AT2R expression is largely restricted to kidneys, adrenals, uterus, ovary, 
heart and specialized nuclei in the brain. Interestingly, AT2R is upregulated in 
many cardiovascular pathological conditions associated with inflammation or 
tissue remodeling such as heart or renal failure (Ohkubo, Matsubara et al. 1997), 
myocardial infarction (Nio, Matsubara et al. 1995), vascular injury, and wound 
healing (Kimura, Sumners et al. 1992).   
Angiotensin (2-8) (AngIII), another biologically active peptide of the RAS is 
generated from Ang II by aminopepetidase A (Vaughan et al.1974; Kugler et 
al.1982). AngIII has high affinity for AT1 and AT2 receptors and can induce 
vasoconstriction, aldosterone release and sodium retention (Zini, Fournie-Zaluski 
et al. 1996). In the central nervous system, AngIII mediates central control of 
blood pressure and vasopressin release (Harding, Wright et al. 1994; Song, Wilk 
et al. 1997). However, AngIII was catabolized metabolically five times faster than 
Ang II because it is very sensitive to degradation by the enzyme aminopeptidase 
N, which cleaves the N-terminal arginine, generating AngIV (Zini, Fournie-Zaluski 
et al. 1996). AngIV is also short lived and is rapidly converted to inactive 
fragments by several peptidases. AngIV mediates its action via the AT4 receptor, 
also known as insulin-regulated amino peptidase receptor (IRAP) (Albiston, 
McDowall et al. 2001). AT4 receptors are expressed in brain, kidney, heart and 
vessels. Its signaling mechanisms are largely unknown, but it influences local 
blood flow and is associated with cognitive processes and sensory response (de 
Gasparo, Catt et al. 2000) 
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1.2.2   Angiotensin, inflammation and cardiovascular disease (CVD) 
It has been vastly recognized that RAS overactivation contributes to 
various cardiovascular diseases and many clinical studies have demonstrated 
that inhibition of the RAS through ACE inhibition or angiotensin receptor blockers 
(ARB) is beneficial for patients with CVD. In 1992 it was proved that an ACE-
inhibitor,enalapril, in combination with the conventional heart failure therapy,  
significantly improved the survival of patients with severe congestive heart 
failure(Kjekshus, Swedberg et al. 1992).  In the Survival of Myocardial Infarction 
Long-Term Evaluation (SMILE) study, the risk of myocardial infarction was 
reduced by about 37% with ACE inhibitors treatment (Borghi and Ambrosioni 
1995)  Results from the Heart Outcomes Prevention Evaluation (HOPE) study 
revealed that in patients without heart failure ACE inhibition reduced the rates of 
death, myocardial infarction, and stroke by 22% without major effects on blood 
pressure (Yusuf, Sleight et al. 2000). Furthermore, Losartan Intervention For 
Endpoint reduction (LIFE) trial revealed that among patients with hypertension 
and left ventricular hypertrophy losartan, an AT1 receptor blocker, significantly 
reduced the risk of combined morbidity and mortality compared to a beta-blocker, 
atenolol (Dahlof, Devereux et al. 2002).  
As a potent pro-inflammatory factor, AngII has been implicated in the 
pathogenesis of CVD. Inflammation involves: 1) activation of the endothelium of 
blood vessels (permeability) and 2) extravasation (adhesion/transmigration) of 
specific leukocyte populations to the site of injury. It has been demonstrated that 
AngII acts via AT1 receptors, induces the expression of endothelial adhesive 
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molecules including selectins, vascular cell adhesion molecules-1 (VCAM-1), 
intercellular adhesion molecules-1 (ICAM-1) and integrins to increase vascular 
permeability (Piqueras, Kubes et al. 2000; Pueyo, Gonzalez et al. 2000; Alvarez, 
Cerda-Nicolas et al. 2004). AngII also activates COX-2, which generates reactive 
oxygen species (ROS) and vasoactive prostaglandins including leukotriene C4 
and prostaglandins E2 to induce endothelial dysfunction (Wu, Laplante et al. 
2005; Welch 2008). In addition, vascular endothelial growth factor (VEGF), has 
been reported to be upregulated by AngII in human VSMCs (Williams, Baker et 
al. 1995) and rat heart endothelial cells (Chua, Hamdy et al. 1998).   
AngII facilitates the recruitment of infiltrating inflammatory cells into tissues 
by stimulating the production of specific cytokine/chemokines. For example, 
AngII induces the production of the potent monocyte chemoattractant MCP-1 in 
cultured monocytes (Dai, Xu et al. 2007). In spontaneously hypertensive rats 
(SHR) elevated AngII level has been associated with increased expression of 
MCP-1 and one of its receptors, the C–C chemokine receptor (CCR2) in 
macrophages. And AT1 receptor blockade reduced aortic inflammation and 
macrophage MCP-1/CCR2 expression in SHR rats (Dai, Xu et al. 2007). 
Moreover, in cultured mesangial and vascular smooth muscle cells, Ang II acts 
on AT1 receptors to stimulate the expression of the Toll-like receptor 4 (TLR-4), 
which promotes cellular oxidative injury, apoptosis and inflammation (Ji, Liu et al. 
2009; Lv, Jia et al. 2009). It has been reported recently that AT1 receptor 
blockade exerts protective effects against myocardial ischemia and reperfusion 
injury by reducing TLR-4 expression and cytokine release (Yang, Jiang et al. 
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2009). In addition, AngII also stimulates cytoskeletal rearrangements in T cells 
and triggers the release of specific cytokines and chemokines, thus facilitating T 
cell recruitment to the sites of inflammation (Jurewicz, McDermott et al. 2007; 
Crowley, Frey et al. 2008; Kvakan, Kleinewietfeld et al. 2009). 
Taken together, results from both clinical trials and experimental studies 
infer a critical role for the RAS in CVD pathogenesis and support the beneficial 
effect of AngII inhibition in CVD patients.  
 
1.2.3   Sex Hormones and the RAS 
Sex hormones exert differential effects on various components of the RAS 
as illustrated in Figure 1.4 (Fischer, Baessler et al. 2002).  The overall effect of 
physiological concentrations of estrogen is to inhibit the RAS while androgen 
generally stimulates the RAS.  
Angiotensinogen, the only known precursor of AngII, has an estrogen 
response element (ERE) in its gene promoter which markedly stimulates angio-
tensinogen synthesis (Clauser, Gaillard et al. 1989; Feldmer, Kaling et al. 1991). 
Women with oral administration of estrogen replacement therapy exhibit higher 
plasma angiotensinogen levels (De Lignieres, Basdevant et al. 1986; Schunkert, 
Danser et al. 1997). In rats, renal angiotensinogen mRNA expression was lower 
in females compared to males (Ellison, Ingelfinger et al. 1989; Yanes, Sartori-
Valinotti et al. 2009).  Furthermore, angiotensinogen mRNA expression was 
reduced by castration and increased by administration of exogenous androgen 
(Ellison, Ingelfinger et al. 1989). Similarly, renal and hepatic angiotensinogen 
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mRNA levels were higher in male than female SHR rats (Chen, Naftilan et al. 
1992). Castration of male SHR rats reduced, and testosterone replacement 
restored renal and hepatic angiotensinogen mRNA expression (Chen, Naftilan et 
al. 1992). Additionally, testosterone exerts considerable stimulatory effects on 
angiotensinogen gene expression in a variety of other tissues, including the 
adipose tissue (Ming, Sikstrom et al. 1993; Serazin-Leroy, Morot et al. 2000).  
In humans, plasma renin levels in postmenopausal women are lower 
compared to men and are further decreased by hormone replacement therapy   
(Schunkert, Danser et al. 1997; Danser, Derkx et al. 1998). In healthy young 
adult population, men exhibit higher ACE activity compared to women (Zapater, 
Novalbos et al. 2004). ACE is suppressed in women taking estrogen replacement 
therapy (Proudler, Ahmed et al. 1995; Schunkert, Danser et al. 1997). In 
experimental models, the circulating concentration of renin is decreased by 
estrogen (Oelkers 1996; Brosnihan, Weddle et al. 1997), but increased by 
testosterone (Wagner, Metzger et al. 1990; Chen, Naftilan et al. 1992; Kon, 
Endoh et al. 1995). Plasma ACE activity and ventricular ACE expression are 
significantly higher in male than female mice, and are reduced by castration of 
male mice.(Freshour, Chase et al. ; Lim, Retnam et al.)   
In studies with estrogen replacement therapy, estrogen appears to down 
regulate AT1 receptor mediated effects through reductions in the receptor density 
and down-stream activation steps (Nickenig, Baumer et al. 1998; Owonikoko, 
Fabucci et al. 2004).  In experimental rodents, AT1 receptor densities at heart, 
kidney and aortic tissues are decreased by estrogen and increased by 
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ovariectomy (Kisley, Sakai et al. 1999; Wu, Maric et al. 2003; Dean, Tan et al. 
2005) In contrast, testosterone upregulates the AT1 receptor as castration almost 
abolished the AT1 receptor protein in rat epididymis (Leung, Wong et al. 1999). 
AT1 receptor protein expression is higher in the renal cortex of male 
spontaneous hypertensive rats (Sullivan, Semprun-Prieto et al. 2007). In 
addition, elevated contractile responses to AngII in conjunction with greater AT1 
receptor mRNA and protein expression were detected in the rat aorta from male 
compared to female rats (Silva-Antonialli, Tostes et al. 2004). Renal AT2 
receptor expression in female mice is higher than in male mice (Armando, 
Jezova et al. 2002; Dean, Tan et al. 2005). It has been reported that castration 
increases AT2 expression in male rat bladder while exogenous testosterone 
administration reduces its expression (Nakazawa, Tanaka et al. 2007). Most 
recently, higher expression of renal ACE2 in female mice has been reported and 
ovariectomy reduces ACE2 levels (Ji, Menini et al. 2008). 
In summary, while estrogen exerts either stimulatory or inhibitory effects 
on different components of RAS, the overall effect of estrogen results in a down 
regulation of the RAS. In contrast, testosterone exerts a stimulatory effect on all 
major components of the RAS. 
 
1.3.     AngII-induced AAA  
1.3.1   Overview 
It has been well established that chronic infusion of AngII into 
hyperlipidemic mice (LDLR-/- or ApoE-/-) promotes the formation of AAAs 
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(Daugherty and Cassis 1999; Daugherty, Manning et al. 2000).  Based on the 
desired infusion rate (500-1000 ng/kg/min), osmotic mini-pumps are filled with a 
pre-determined concentration of AngII and implanted subcutaneously in the 
subscapular region of mice to achieve chronic AngII infusion. LDLR-/- or ApoE-/- 
mice are usually fed with a moderately high fat diet (44% kcal from fat) to 
augment hyperlipidemia prior to and during AngII infusion.   AAAs form at a high 
prevalence (80%-100%) with 28 days of chronic AngII infusion (1000 ng/kg/min) 
in male mice. AAAs that form from AngII infusion are typically localized in 
suprarenal region of the aorta, which is consistent in both ApoE-/- and LDLR-/- 
mice. AngII-induced AAAs are characterized by medial breaks, macrophage 
infiltration into media, thrombus formation, extracellular matrix degradation and 
adventitia remodeling. In comparison, infusion of AngII into a normolipidemic 
background strain, C57BL/6, results in only 10-30% AAA formation in male mice 
(Wang 2005).  It has been suggested that hyperlipidemia facilitates AngII-
induced AAA formation in mice via upregulating AT1R expression. Multiple 
studies also have demonstrated that chronic AngII infusion increased the extent 
of atherosclerosis in hyperlipidemic mice (Daugherty, Rateri et al. 2004). 
Atherosclerotic lesions are present in the abdominal aortas of mice infused for 
very chronic durations with AngII (Saraff, Babamusta et al. 2003). However, 
atherosclerosis does not appear to be a requirement for AAA formation. For 
example,  manipulations have been demonstrated to increase atherosclerosis, 
but yet decrease AngII-induced AAAs (Henriques, Huang et al. 2004).  In 
addition, AngII infusion in nonhyperlipidemic C57BL/6 mice result in modest 
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AngII-induced AAA formation, but does not induce atherosclerosis, further 
demonstrating that atherosclerosis is not a major contributor to AngII-induced 
AAA formation. 
As previously discussed, AngII is a potent vasoconstrictor and exerts 
potent effects on peripheral resistance. Mice infused with AngII (1000 ng/kg/min) 
typically exhibit an increased systolic blood pressure in the range of 20-30 mmHg 
(Daugherty, Manning et al. 2000; Manning, Cassis et al. 2002). Although 
hypertension has been debated as a risk factor for human AAA formation, AngII-
induces AAA formation in hyperlipidemic mice appears to be independent of 
AngII-induced hypertension (Daugherty, Manning et al. 2000; Weiss, Kools et al. 
2001). Infusion of norepinephrine to male LDLR-/- mice at the dose that resulted 
in a similar hypertensive response as AngII infusion, did not cause AAA 
formation (Cassis, Gupte et al. 2009). In addition, co-infusion of antihypertensive 
drug (hydralazine) with AngII abolishes the increased blood pressure response 
and has no impact on AngII-induced AAA formation (Cassis, Gupte et al. 2009).  
AngII infusions activate endogenous RAS and promote aldosterone 
release by the adrenal gland. However, aldosterone does not appear to 
contribute to AngII-induced AAA as it has been demonstrated that male ApoE-/- 
mice infused with multiple doses of aldosterone failed to generate AAAs (Cassis, 
Helton et al. 2005).  Furthermore, the aldosterone receptor antagonist 
spironolactone had no effect on AngII-induced AAAs.  These data demonstrate 
that aldosterone is not involved in the development of AngII-induced AAAs.   
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1.3.2   Angiotensin receptors in AngII-induced AAAs 
As discussed previously, AngII-induced inflammatory response and ROS 
production are mediated through AT1 receptor. It has been demonstrated that 
co-infusion of AngII and the AT1 receptor antagonist, losartan, completely 
prevented AngII-induced AAA formation, demonstrating that AngII infusion 
promotes AAA formation through its action on the AT1 receptor (Daugherty, 
Manning et al. 2001).  AT2 receptor activation by AngII is believed to 
counterbalance some of the effects of AT1 receptor. Co-infusion of AngII and the 
AT2 receptor antagonist PD123319 enhanced AngII-induced AAA formation in 
male ApoE-/- mice (Daugherty, Manning et al. 2001). These results demonstrate 
that the AT1 receptor plays a critical role in the development of AngII-induced 
AAA while the AT2 receptor protects against AAA formation.  Of the two AT1 
receptor subtypes in mice, results have demonstrated that, despite the 
abundance of AT1b receptor in the aortas, deficiency of the AT1a receptor 
subtype completely ablates the development of AngII-induced AAAs (Cassis, 
Rateri et al. 2007).  Furthermore, AT1aR deficient mice did not exhibit a pressor 
response to AngII infusion and AngII-induced atherosclerotic lesion formation 
was abolished by AT1aR deficiency (Cassis, Rateri et al. 2007).  Collectively, 
these data demonstrate that the AT1a receptor is pivotal for AngII-induced AAA 
and atherosclerosis formation in hyperlipidemic mice.  
Macrophages are abundantly evident in AngII-induced AAA tissues and 
atherosclerotic lesions and AT1aR are present on macrophage. To investigate 
whether the activation of AT1aR on infiltrating monocytes or resident vascular 
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cells contributes to AngII-induced AAA formation, a series of bone marrow 
transplantation studies were conducted to create chimeric mice lacking AT1aR 
on bone marrow-derived cells.  Both wild-type and AT1aR-/- recipients were 
irradiated and repopulated with bone marrow-derived cells from mice that was 
either wild type or AT1aR deficient.  Interestingly, only AT1aR deficient mice 
were dramatically protected from AngII-induced AAA and atherosclerosis, 
irrespective of the donor genotype.  These data indicate that AT1aR in resident 
vascular tissue is required for the development of AngII-induced atherosclerosis 
and AAAs (Cassis, Rateri et al. 2007). 
     
1.3.3   Mechanistic insights into AngII-induced AAAs 
Numerous publications have demonstrated various mechanisms 
contributing to the development of AngII-induced AAA (Table 1.1).  In agreement 
with human AAAs, results from AngII-induced AAAs in mice also support a role 
for matrix metalloproteinases (MMPs) in AAA formation.  Deficiency of MMP-2 or 
MMP-9 completely eliminates calcium chloride induced AAA formation (Longo, 
Xiong et al. 2002). Administration of doxycycline, a broad spectrum inhibitor of 
MMPs, has been demonstrated to attenuate AngII-induced AAA in LDLR-/- mice 
(Manning, Cassis et al. 2003). Metacept-1 (MCT-1), a synthezied histone 
deacetylase inhibitor can inhibit MMP-9 mRNA expression in metastatic cancer 
cells in vitro (Kim, Lee et al. 1999).  Administration of MCT-1 significantly 
reduced AAA formation in male ApoE-/- mice (Vinh, Gaspari et al. 2008). Further 
evidence for MMP involvement in AngII-induced AAAs comes from recent studies 
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demonstrating that deficiency of group X secretory phospholipase (sPLA2)  in 
ApoE-/- mice reduced AngII-induced AAAs (Zack, Boyanovsky et al. 2010).  
Aortas from group X sPLA2 that exhibited reduced AAA formation had blunted 
expression of MMP-2, -13 and 14.  Interesting recent studies demonstrated that 
deficiency of telomerase in bone marrow-derived cells reduced AngII-induced 
AAA in LDLR-/- mice, and that these effects were associated with reduced 
macrophage MMP-2 expression (Findeisen, Gizard et al. 2010).  Collectively, 
results from studies using many different approaches support a role for MMP 
activation in pivotal cell types in AngII-induced AAAs. 
In addition, the plasminogen system has been revealed to contribute to 
AngII-induced AAA formation, further supporting an important role of MMPs in 
AAA pathogenesis. Plasminogen is converted to plasmin by tissue plasminogen 
activator (tPA) or urokinase plasminogen activator (uPA).  Plasmin degrades 
multiple extracellular matrix (ECM) proteins and activates MMPs. Deficiency of 
plasminogen or uPA has been reported to protect mice from AngII-induced AAA 
(Deng, Martin-McNulty et al. 2003; Gong, Hart et al. 2008). Plasminogen 
activator inhibitor-1(PAI-1) is a major inhibitor of the plasminogen system and 
overexpression of PAI-1 has been demonstrated to reduce AngII-induced AAA 
formation (Qian, Gu et al. 2008). 
Inflammation and macrophage accumulation in AAA regions are 
consistent and profound features of AngII-induced AAAs.  Monocyte 
chemoattractant protein-1 (MCP-1), a prominent chemokine, interacts with its 
receptor, CCR2, to invoke macrophage- based immune responses.  Deficiency of 
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CCR2 markedly attenuated the development of AngII-induced AAAs (Ishibashi, 
Egashira et al. 2004).  Furthermore it has been revealed that CCR2 expression 
on bone marrow-derived cells is required for AngII-induced AAAs formation 
(Ishibashi, Egashira et al. 2004; Daugherty, Rateri et al. 2010). Interferon-γ (IFN-
γ) is a major T-helper type 1(Th1) cytokine and an important mediator of Th1 
immune response. In ApoE-/-mice AngII-induced AAA formation was greatly 
enhanced with deficiency of interferon-γ (IFN-γ) or IFN-γ-inducible T-cell 
chemokine, CXCL10 (King, Lin et al. 2009). Recently, our laboratory has 
demonstrated that obesity significantly promotes AngII-induced AAA formation in 
nonhyperlipidemic mice. The enhanced AAA formation was associated with 
increased macrophage accumulation in periaortic adipose tissue (Police, 
Thatcher et al. 2009).   
Cyclooxygenase (COX) products, mainly prostaglandin E2 (PGE2), are 
classic mediators of inflammation. COX- 2 is expressed in the vessel wall and 
macrophages of AAA tissues (Holmes, Wester et al. 1997; Walton, Franklin et al. 
1999).  In addition, COX-2 expression in human AAA is positively associated with 
the extent of macrophage infiltration and the degree of AAA neorevascualrization 
(Chapple, Parry et al. 2007).  With chronic AngII infusion mice exhibited 
increasing levels of COX-2 mRNA in abdominal aortas and deficiency of COX-2 
significantly eliminated AngII-induced AAA formation (Gitlin, Trivedi et al. 2007).  
Administration of Celecoxib, a COX-2 inhibitor, reduced AngII-induced AAA 
incidence and severity in male ApoE-/- mice (King, Trivedi et al. 2006).  An 
important source of PGE2 in the mouse is microsomal prostaglandin (PG) E2 
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synthase-1 (mPGES-1), which catalyzes the conversion of the COX product 
PGH2 to PGE2.  It has been demonstrated that mPGES-1 deficiency reduced 
oxidative stress, aortic MMP-2 activity and markedly attenuated AngII-induced 
AAA formation in LDLR-/- mice (Wang, Lee et al. 2008). Moreover, recent studies 
demonstrated that deletion of the EP4 receptor on bone marrow-derived cells 
enhanced AngII-induced AAAs in LDLR-/- mice, supporting a protective effect of 
PGE2 through the EP4 receptor (Tang, Shvartz et al. 2010).   
Similar to COX enzymes, lipoxygenases also produce a variety of 
bioactive lipids derived from arachidonic acid.  For example, 5-lipoxygenase (5-
LO) catalyzes the generation of Leukotriene B4, which exerts its effects through 
binding to its G protein coupled receptor, BLT-1.  Deficiency of BLT-1 reduced 
AngII-induced AAAs in ApoE-/- mice (Ahluwalia, Lin et al. 2007).  However, a 
recent study has demonstrated that both genetic deficiency and pharmacological 
inhibition of 5-LO failed to influence the AngII-induced AAAs in ApoE-/- mice 
(Cao, Adams et al. 2007). Thus, whether 5-LO signaling cascade contributes to 
AAA pathogenesis remains under debate. 
Human AAA tissues exhibit increased superoxide anion (O2-), hydroxyl 
radical and reactive nitrogen species compared to normal aortic tissue (Miller, 
Sharp et al. 2002). As discussed previously, AngII acts via AT1 receptors to 
activate NADPH oxidase and produce O2- in cultured vascular smooth muscle 
cells (Griendling, Minieri et al. 1994).  NADPH oxidase is a primary source of 
ROS in the vasculature. Oxidative stress can regulate inflammation, MMP 
activation, and vascular smooth muscle cell apoptosis, thus influencing AAA 
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development. Dietary enrichment of vitamin E, an antioxidant, has been shown to 
attenuate AngII-induced AAA formation in ApoE-/- mice (Gavrila, Li et al. 2005).  
In contrast, a recent study found no effect of dietary enrichment of vitamins E and 
C on AngII-induced AAA rupture in aged ApoE-/- mice (Jiang, Jones et al. 2007).  
However, it has been demonstrated that deficiency of p47phox, a cytosolic 
subunit of NADPH oxidase, decreases aortic macrophage, aortic MMP-2 activity 
and greatly reduced AngII-induced AAA formation in male ApoE-/- mice 
(Thomas, Gavrila et al. 2006). In addition, deficiency of NOX1, a transmembrane 
subunit of NADPH oxidase, has been reported to attenuate AngII-induced AAA in 
C57BL/6 mice (Gavazzi, Deffert et al. 2007). Recently, deficiency of cyclophilin, 
an oxidative stress response mediator, was demonstrated to ablate AngII-
induced AAA formation in ApoE-/- mice (Satoh, Nigro et al. 2009). Overall, these 
findings suggest a potential role of and oxidative stress and NADPH oxidase in 
the development of AngII-induced AAA. 
Initial studies demonstrated that administration of neutralizing antibody to 
TGF-β to ApoE-/-/Cxcl10-/- mice decreased AngII-induced aortic dilation (King, 
Lin et al. 2009).  However, recent studies demonstrated that inhibition of TGF-β 
has been reported to enhance inflammation and profoundly increase aortic 
dissection in AngII infused C57BL/6 mice (Wang, Ait-Oufella et al. 2010). The 
role of TGF-β in AngII-induced AAAs, as well as human AAA, is unclear.    
SMC apoptosis is another evident pathological features frequently 
observed in AAA tissues. Administration of nonspecific caspase inhibitor was 
reported to reduce SMC apoptosis, medial inflammation and AngII-induced AAA 
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formation (Yamanouchi, Morgan et al. 2010).  Several studies targeting 
intracellular signaling pathways have provided further mechanistic insights in 
AngII-induced AAAs. It has been reported that Fasudil, a Rho-kinasse inhibitor, 
reduces AngII-induced AAAs formation in ApoE-/- mice by inhibiting apoptosis 
and proteolysis (Wang, Martin-McNulty et al. 2005).  Administration of a JNK 
inhibitor, SP600125, attenuated the aneurysm development in CaCl2 induced 
AAA mouse model (Yoshimura, Aoki et al. 2005).  In addition, when SP600125 
was chronically administered for 8 weeks after 4 weeks AngII infusion, the 
luminal diameters of formed AngII-induced AAAs showed a significant 18% 
reduction and there was no change in aortic diameter of control mice 
administered with vehicle (Yoshimura, Aoki et al. 2005).   So far his is the only 
animal study that exhibits AAA regression with pharmacologic intervention. 
Further studies are required to confirm these findings and elucidate the 
mechanisms of AAA progression/regression. The investigation of factors and 
mechanisms influencing AAA expansion and progression may guide us to new 
drug targets and other nonpharmaceutical interventions for AAA treatments.  
A feature of human AAAs that has been recently explored in AngII-
induced AAAs is neovascularization to support continued aneurysm growth and 
progression.  ApoE-/- mice administered human recombinant vascular 
endothelial growth factor (VEGF) exhibited increased incidence and size of 
AngII-induced AAAs (Choke, Cockerill et al. 2010).  Studies in our laboratory 
demonstrated that weight loss in obese mice decreased adventitial 
neovascularization and prevented continued growth of established AAAs (Police, 
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Putnam et al. 2010).  These studies suggest that neovasculization is an 
important mechanism contributing to continued progression of AngII-induced 
AAAs.   
 
1.3.4   Gender in AngII-induced AAAs 
Similar to the human condition, male mice are much more susceptible to 
AngII-induced AAA formation. The AngII-induced AAA incidence of male mice is 
4-5 fold higher compared to that of females (Manning, Cassis et al. 2002; 
Henriques, Huang et al. 2004). Interestingly, AngII-induced atherosclerosis and 
hypertension are similar between males and females despite the striking gender 
difference in AAA formation. Multiple studies have been conducted to investigate 
if estrogen exerts some protective effects in female mice to limit AngII-induced 
AAA formation.  Martin-McNulty et al. demonstrated that administration of 17-
beta estradiol decreased AngII-induced AAA and atherosclerosis in male ApoE-/- 
mice (Martin-McNulty, Tham et al. 2003).  These reductions were associated with 
decreased levels of pro-inflammatory and adhesion molecules.  However, our 
laboratories have reported that elimination of endogenous estrogen by 
ovariectomy of female ApoE-/- does not alter AngII-induced AAAs or 
atherosclerosis (Henriques, Huang et al. 2004). Notably, orchiectomy of male 
ApoE-/- mice markedly reduced AngII-induced AAA formation, resulting in a 
similar AAA incidence as that of female mice (Henriques, Huang et al. 2004).  
Furthermore, AngII-induced AAA formation in castrated male mice was fully 
restored by exogenous androgen, dihydrotestosterone (DHT) (Henriques, Zhang 
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et al. 2008). Interestingly, even female ApoE-/- mice responded to DHT and 
exhibit a 3-fold increase in  AngII-induced AAA formation (Henriques, Zhang et 
al. 2008). As summarized in Table 1.2, all these results demonstrate that 
androgen is a primary mediator of gender difference in AngII-induced AAA 
formation. 
 
1.3.5   Gender in elastase-induced AAAs 
In vasculature elastin fibers are crucial for the maintenance of structural 
integrity of blood vessels.  Progressive destruction of structural matrix proteins, 
particularly elastin and collagen, is considered as one of the most important 
pathogenesis characteristics in human AAAs. First described in rats, transient 
intraluminal perfusion of abdominal aortas with porcine pancreatic elastase 
provides another widely used animal model of AAAs (Anidjar, Salzmann et al. 
1990; Anidjar, Dobrin et al. 1992; Anidjar, Dobrin et al. 1994). Briefly, a segment 
of infrarenal abdominal aorta is isolated by a distal suture and a perfusion 
catheter is introduced at the iliac bifurcation. Porcine pancreatic elastase is 
instilled into the isolated segment of infrarenal abdominal aorta for 5 minutes at 
100 mmHg pressure before restoration of flow.  This transient intraluminal 
infusion of elastase induces mild aortic dilation immediately after the perfusion.  
Aortic diameter remains stable for up to 7 days followed by a rapid and significant 
dilation of the abdominal aorta. AAAs, which are defined by at least 100% 
increase in aortic diameter over the normal (pre-perfusion) aortas, typically form 
by day 14.  The development of AAAs in this elastase perfusion model is 
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associated with transmural aortic wall infiltration by mononuclear phagocytes, 
increased local production of MMPs and massive destruction of the medial 
elastic lamellae (Thompson, Curci et al. 2006).  
Recently, the application of this elastase model to mice have assisted 
investigators identify and study various mediators of AAA formation. For 
example, administration of doxycycline, a broad-spectrum inhibitor of MMPs, 
significantly attenuated the development of elastase-induced AAA formation 
(Bartoli, Parodi et al. 2006).  In agreement to the findings in AngII-induced AAA 
model, deficiency of MMP-9 has been shown to totally ablate elastase-induced 
AAA formation (Pyo, Lee et al. 2000).  In contrast, deficiency of MMP-12, alone 
or with MMP-9 deficiency, did not influence the occurrence of elastase-induced 
AAAs (Pyo, Lee et al. 2000). Smoking, as a primary risk factor of human AAA, 
also significantly enhanced the development of elastase-induced AAAs (Buckley, 
Wyble et al. 2004).  Interestingly, inhibition of RAS by AT1 blocker administration 
has been demonstrated to suppress elastase-induced AAAs formation, 
suggesting RAS also contribute to the development of AAA in the elastase 
perfusion model (Fujiwara, Shiraya et al. 2008). 
As summarized in Table 1.2, elastase-induced AAA model also exhibits 
gender difference, similar to AngII-induced AAA model. For example, male rats 
had larger AAAs and higher AAA incidence than female rats (Ailawadi, Eliason et 
al. 2004). Male rat aortas showed more significant macrophage infiltrates and 
increased MMP-9 production and activity (Ailawadi, Eliason et al. 2004). In 
addition, male rats demonstrated smaller aneurysms, less 
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macrophage/neutrophil infiltrate and MMP-9 when treated with estradiol or 
tamoxifen, a selective estrogen receptor modulator (Ailawadi, Eliason et al. 2004; 
Grigoryants, Hannawa et al. 2005). Ovariectomized female rats exhibited a 
higher aneurysm dilatation rate and significantly higher MMP-2 and MMP-9 
expressions compared with sham-operated control females (Cho, Woodrum et al. 
2009; Wu, Zhang et al. 2009). Exogenous estrogen administration decreased 
aneurysm dilatation rate and MMPs expression in ovariectomized females (Cho, 
Woodrum et al. 2009; Wu, Zhang et al. 2009). It has been demonstrated that 
male rats shows higher MMP2 in aortic smooth muscle cells and in vivo estrogen 
exposure greatly decreases male aortic MMP2 production to levels seen in the 
female aorta (Woodrum, Ford et al. 2009). These data suggest an important 
protective role of estrogen in the development of elastase-induced AAAs. 
Furthermore, orchiectomized male rats had significantly smaller AAAs compared 
with sham control males and exogenous androgen administration significantly 
increased elastase-induced AAAs dilation in castrated male rats (Cho, Woodrum 
et al. 2009). It suggests that, in agreement to the observations in AngII-induced 
AAAs, androgen contributes to the pathogenesis of AAAs in elastase perfusion 
model. However, exogenous androgen had no effect on the development of 
elastase-induced AAA in female rats (Cho, Woodrum et al. 2009). Overall, these 
studies implicate a definitive protective role of estrogen and suggest a likely 
contribution of androgen in elastase-induced AAAs. 
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1.4      Androgen 
In males, androgens are essential for the development and function of the 
testes, maturation of secondary sexual characteristics, masculinization of the 
bone-muscle apparatus, libido, and stimulation of spermatogenesis. 
Testosterone and its more active metabolite, DHT, are the key androgens 
responsible for the development of male genitalia in utero as well as secondary 
sex characteristics during puberty. In adulthood, androgens remain essential for 
the maintenance of male reproductive function and sexual behavior. The primary 
circulating androgen in males is testosterone. The site of testosterone production 
in the testis is the Leydig cell. Both synthesis and secretion of testosterone are 
under regulation of pituitary luteinizing hormone (LH) and local factors (Lei et al. 
2001; Sriraman et al. 2005). It has been reported that in women androgens play 
a role in regulating libido, energy, muscle and bone strength (Schneider 2003; 
Bolour and Braunstein 2005).  
Like all steroid hormones, testosterone is derived from cholesterol. This 
transformation goes through different enzymatic steps in which the side chain of 
cholesterol is shortened through oxidation. The complete pathway for 
testosterone synthesis is depicted in Figure 1.5. The rate limiting step in the 
synthesis of testosterone is the cleavage of cholesterol to pregnenalone, which is 
catalyzed by the P450-linked side chain cleaving enzyme (P450scc) found in the 
mitochondria of steroid producing cells. Testosterone regulates its own synthesis 
through a negative feedback loop which regulates the secretion of follicle 
stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary and 
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gonadotropin releasing hormone (GnRH) by the hypothalamus. Low levels of 
circulating testosterone decrease the inhibition on GnRH synthesis, leading to 
elevated FSH and LH levels, resulting in increased testosterone synthesis. 
 
1.4.1   Metabolism of androgen 
Testosterone can be also converted to another  two important hormones: 
DHT through 5α-reduction and estradiol through aromatization. While only a 
small amount of circulating testosterone (<5%) gets converted to active 
metabolites, which typically occurs at the tissue level, this process can amplify 
and diversify testosterone function (Liu, Death et al. 2003). Conversion of 
testosterone to DHT is irreversibly catalyzed by the enzyme 5α-reductase. Like 
testosterone, DHT binds to androgen receptors and amplifies testosterone 
action. Importantly, DHT binds with higher molar potency due to greater affinity 
and a slower dissociation rate (Wilbert, Griffin et al. 1983; Grino, Griffin et al. 
1990). Furthermore, DHT activates gene expression more efficiently than 
testosterone (Deslypere, Young et al. 1992). Therefore, testosterone, through 
conversion to DHT, can exert more potent effects in tissues expressing 5α-
reductase compared to tissues where the enzyme is not expressed. Two forms of 
the 5α-reductase enzyme have been identified: type I, is predominantly found in 
nongenital skin and the liver, and type II, which is primarily located in urogenitals 
of men and genital skin in both men and women. Both forms of the enzyme have 
been located in vascular tissue based on immunoreactivity (Eicheler, Tuohimaa 
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et al. 1994; Eicheler, Dreher et al. 1995) and enzymatic activity (Milewich, Kaimal 
et al. 1987; Fujimoto, Morimoto et al. 1994).  
Testosterone actions are diversified by its conversion to estradiol and the 
subsequent binding to the ER. The conversion reaction is irreversible and 
catalyzed by the enzyme aromatase (CYP19). Aromatase is expressed in many 
tissues, particularly in the liver and adipose tissue. Additionally, aromatase gene 
expression, protein levels and enzymatic activity have been detected in vascular 
tissue, particularly in the endothelium and smooth muscle (Diano, Horvath et al. 
1999; Harada, Sasano et al. 1999; Murakami, Harada et al. 2001). Approximately 
85% of circulating estradiol in men is derived from testosterone conversion by 
aromatase, with the remainder being secreted by the leydig cells of the testes 
(Aiman, Griffin et al. 1979). 
 
1.4.2   Androgen receptor 
Like other steroid hormones, androgens mediate their biological action 
through binding to androgen receptors (AR), members of the steroid hormone 
receptor superfamily. AR is widely expressed in many various tissues (Wilson 
and McPhaul 1996). In the vasculature, ARs are expressed in various cell types, 
including endothelial cells, vascular smooth muscle cells, macrophages, and 
platelets. Interestingly, it has been demonstrated that males exhibits higher AR 
density in vascular tissue compared to females (Higashiura, Mathur et al. 1997). 
In macrophage, AR density has been reported to be 4-fold higher in males 
compared to females (McCrohon, Death et al. 2000; Ng, Quinn et al. 2003). 
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AR is produced from a single-copy gene located on the X-chromosome 
(Brown, Goss et al. 1989; Kokontis and Liao 1999). The genomic DNA encoding  
AR spans about 90 kb and codes for a 2,757-base pair open reading frame 
within a 10.6-kb mRNA and the coding sequence of human AR gene consists of 
eight exons (Roy, Tyagi et al. 2001). The AR is a ligand-inducible transcription 
factor which regulates the expression of target genes in response to ligand 
binding (Heinlein and Chang 2002). Similar to other members of the nuclear 
receptor superfamily, AR has four major functional regions; the N-terminal 
transactivation domain (TAD), a central DNA-binding domain (DBD), a C-terminal 
ligand-binding domain (LBD), and a hinge region connecting the DBD and LBD 
(Mangelsdorf, Thummel et al. 1995).  The DBD of the AR exhibits a high degree 
of amino acid sequence homology to other steroid hormone receptors including 
the glucocorticoid receptor (GR), the progesterone receptor (PR), and 
mineralocorticoid receptor (MR). Consequently, the four receptors recognize very 
similar hormone response elements (HREs). The transcriptional activity of AR is 
mediated by a constitutively active activation function (AF-1) originating in the N-
terminal TAD and a ligand-dependent activation function (AF-2) in the LBD 
(Gronemeyer and Laudet 1995).  The hinge region was initially considered to be 
a flexible linker between the DBD and LBD. However, this region has been 
revealed to be involved in DNA binding as well as AR dimerization and to 
attenuate transcriptional activity of the AR (Wang, Lu et al. 2001; Haelens, 
Tanner et al. 2007). 
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1.4.3   Mechanism of action of ARs 
The unbound AR is typically found in the cytoplasm of target cells,  where 
it is sequestered as a multi-protein complex with heat shock proteins and 
immunophillins (DeFranco 1999). In the absence of the agonist, the ligand-
binding domain (LBD) at the carboxyl terminus of the AR prevents the 
transactivation function of the N-terminal domain. Deletion of the LBD makes the 
receptor constitutively active by allowing its interaction with coactivator proteins 
(Roy, Tyagi et al. 2001). Upon ligand binding, a conformational change occurs 
which causes the dissociation of heat shock proteins, dimerization and 
translocation to the nucleus, thus activating androgen response elements (AREs) 
(Roy, Tyagi et al. 2001). Within the nucleus, the AR scans the genome for AREs 
in the promoters and enhancers of target genes. ARE is a 15-bp palindromic 
sequence which consist of two hexameric half-sites arranged as inverted repeats 
with a 3-bp spacer. Once bound to the hormone response element of a target 
gene, the receptor dimer recruits and interacts with classes of co-regulators and 
key transcriptional machinery to induce or inhibit transcription of a particular 
target gene.  Both testosterone and DHT bind to the LBD of the AR, allowing the 
receptor complex to bind to specific responsive genes and stimulate the 
expression of those target genes (Brinkmann and Trapman 2000). However, if 
the AR is antagonist bound, this receptor dimer binds to the ARE and recruits co-
repressors such as N-CoR and SMRT and, indirectly, histone deacetylases, 
leading to transrepression of target genes (Aarnisalo, Palvimo et al. 1998; 
Slagsvold, Kraus et al. 2001; Kinyamu and Archer 2004). 
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As described previously, one critical AR-mediated transcription through 
co-regulators is epigenetic chromatin modification (Heemers and Tindall 2007).  
It involves two primary types of coregulatory complexes (Kinyamu and Archer 
2004). The first is the adenosine triphosphate (ATP)-dependant chromatin 
remodeling complexes, such as the switch/sucrose nonfermenting (SWI/SNF) 
complex . The ATP-dependent chromatin remodeling complexes  primarily 
mediates the opening of chromatin (Cartwright, Hertzberg et al. 1983; Gross and 
Garrard 1988), facilitates formation of nucleosome arrays, homologous strand 
pairing and DNA transcription(Lusser and Kadonaga 2003). The second type of 
coregulatory is histone modifiers such as histone deacetylases (HDAC), histone 
acetyltransferases (HAT) and histone methyltransferases (HMT). Some 
androgen receptor coactivators, such as CBP/p300 and LSD1, mediate 
transcription through their histone motifying enzymatic activities (Baek, Ohgi et 
al. 2006; Kahl, Gullotti et al. 2006). Modification of a histone residue changes the 
net charge of the nucleosome, which results in loosening or tightening of the 
DNA-histone interactions, thus affecting transcription efficiency. Histone 
modifications mediate transcription through acetylation/deacetylation of lysine 
residues on histone H4, and through methylation of histone lysine and arginine 
residues (Strahl and Allis 2000; Kraus and Wong 2002).    
Furthermore, androgen also exert non genomic effects of androgens 
which are faster than genomic effect through AR (Losel and Wehling 2003). Most 
nongenomic effects involve a membrane receptor, and putative binding sites are 
described for all major classes of steroids, including androgens (Heinlein and 
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Chang 2002). In general, nongenomic androgen effects involve the rapid 
induction of conventional second messenger signal transduction cascades, 
including increases in cytosolic calcium and activation of protein kinase A, protein 
kinase C, and MAPK, leading to diverse cellular effects. Nongenomic androgen 
action is insensitivity to inhibition of RNA and protein synthesis  and classic AR 
antagonists (Liu, Death et al. 2003).  
 
1.4.4   Androgens and cardiovascular disease (CVD) 
In general, men are more than twice as likely as women to die from 
coronary heart disease in all populations and male gender is considered to be an 
independent risk factor for CVD (British Heart Foundation Statistics Database 
1998). Androgens, specifically testosterone, are believed to be associated with a 
higher risk of CVD in men (Foreman 1986; Kalin and Zumoff 1990). Increased 
premature cardiovascular events have been observed in  male athletes using 
high levels of anabolic steroids (Bagatell and Bremner 1996). Researchers in 
recent years have turned with increasing interest in elucidating the role of 
androgen on the development of CVD. Interestingly, a 10 year-follow up cohort 
study has revealed that testosterone levels are not different between men who 
develop CVD and their healthy cohorts (Arnlov, Pencina et al. 2006). In large 
prospective cohort studies (Smith, Ben-Shlomo et al. 2005; Arnlov, Pencina et al. 
2006), baseline testosterone levels had not been associated with incidence of 
cardiovascular events. These data do not support the hypothesis that androgen 
increases CVD risk. 
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In addition, a retrospective data analysis on male veterans showed an 
association of low androgen levels with increased mortality (Shores, Matsumoto 
et al. 2006). In a large cohort study older men with testosterone insufficiency 
were found to have an increased risk of death over 20 years of follow-up 
(Laughlin, Barrett-Connor et al. 2008).  It has been well demonstrated that men 
with coronary artery disease had a higher prevalence of hypoandrogenemia 
(Eckardstein and Wu 2003; Wu and von Eckardstein 2003; Pinthus, 
Trachtenberg et al. 2006). In many studies ultrasonography was used to evaluate 
vessel intima thickness, a marker used to investigate the progression of 
atherosclerosis. Using this method, plasma testosterone levels were negatively 
correlated with atherosclerosis progression (Demirbag, Yilmaz et al. 2005).  
Rosano et al examined 129 patients with CVD symptoms and found a clear 
inverse relationship between the degree of CAD and plasma testosterone levels 
(Rosano, Sheiban et al. 2007). Furthermore, a number of studies that correlated 
intima-media thickness to endogenous androgen levels seem to have confirmed 
similar findings.  As reviewed by Manolakou et al, in most clinical studies, 
subjects with high endogenous testosterone levels corresponded with statistically 
significant lower atherosclerosis compared to subjects with lower testosterone 
(Manolakou, Angelopoulou et al. 2009). Notably , this finding persisted in both 
genders, including men (van den Beld, Bots et al. 2003; Muller, van den Beld et 
al. 2004; Makinen, Jarvisalo et al. 2005), premenopausal and postmenopausal 
women (Bernini, Sgro et al. 1999; Golden, Maguire et al. 2002; Debing, Peeters 
et al. 2007) . The cardiovascular protective effect of endogenous androgen 
39 
 
observed in premenopausal women suggest  it involves direct androgen action, 
independent of conversion to estrogen., All these findings demonstrate low 
endogenous testosterone correlates positively with higher prevalence CVD and 
suggest that endogenous androgen exerts protective effects from CVD 
development. 
The effects of exogenous androgen on CVD pathogenesis are less well 
studied. Testosterone administration among 293 female-to-male transsexuals 
showed no increase in cardiovascular deaths in a 20-year follow up study (van 
Kesteren, Asscheman et al. 1997).  In addition, testosterone supplementation in 
low to normal levels has mostly been found to be beneficial to cardiovascular 
system in hypogonadal men. Several studies have reported beneficial actions of 
exogenous testosterone therapy on coronary blood flow and exercise-induced 
myocardial ischaemia in men (Malkin, Pugh et al. 2004; Malkin, Jones et al. 
2009). However, exogenous testosterone administration in supraphysiological 
doses, such as anabolic steroid abuse, seems to have adverse effects such as 
development of myocardial infarction, left ventricular hypertrophy, hypertension, 
arrhythmia, cardiac failure, pulmonary embolism, stroke, and sudden death 
(Ferrera, Putnam et al. 1997; Karila, Karjalainen et al. 2003; Maravelias, Dona et 
al. 2005). Androgen therapy is used as a performance enhancer in women. 
However, the role of testosterone role in the development of CAD in women is 
still not completely understood. The long-term cardiovascular effects of androgen 
replacement therapy in women have not been studied.  Thus, further studies are 
needed to clarify the exact roles of androgen in the development of CVD in 
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different genders and the knowledge can also help us understand the 
mechanisms underlying cardiovascular manifestations in general. 
 
1.4.5   Androgen during development and sex dimorphism 
Male sexual differentiation has been revealed to be initiated by the testis-
determining factor SRY, a transcription factor encoded on the Y chromosome 
(Sinclair, Berta et al. 1990). By interacting with other factors, SRY induces the 
development of testis, which secretes androgen responsible for male secondary 
sexual differentiation. The differentiated testis starts to synthesize low level of 
testosterone in Leydig cells from  day 15 in the rat (El-Gehani, Zhang et al. 1998) 
and at 12-17 weeks of pregnancy in humans (Diez d'Aux and Pearson Murphy 
1974)  In male rats, androgen secretion from the testis leads to 2 perinatal peaks 
of plasma testosterone concentration: the first occurs on day 18 of gestation and 
the second approximately 2 hour after birth (Weisz and Ward 1980; Corbier, 
Edwards et al. 1992). This perinatal androgen surge has been observed in many 
other species, such as mice, horses and primates (Corbier, Edwards et al. 1992).  
Androgen during embryonic and neonatal life mediates the initial growth and 
differentiation of the male reproductive tract, such as the Wolffian ducts, 
urogenital sinus, and external genitalia primordial (Bentvelsen, Brinkmann et al. 
1995).  
Besides the well characterized sexual dimorphism of the reproductive 
system, other tissues and organs, including kidney, liver, and brain, have been 
reported to exhibits sex differences with regard to expression of certain genes 
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(Waxman and Celenza 2003; Wiwi and Waxman 2005; Clodfelter, Holloway et al. 
2006). A recent microarray analysis of 23,574 transcripts revealed a much 
greater extent of sexual dimorphism in gene expression than previously 
recognized. In all the active genes that were tested, sexual dimorphism ranged 
from 14% (in the brain) to 70% (in the liver) (Yang, Schadt et al. 2006).   
A pioneering study in 1959 demonstrated that female guinea pigs exposed to 
prenatal androgen exhibited male-like behaviors (Phoenix, Goy et al. 1959). The 
experimental method used by Phoenix et al has been adapted by numerous 
investigators in the study of sex differences in the brain and behavior (Becker, 
Arnold et al. 2005).   In this approach, the short-term exogenous androgen 
exposure is imposed upon females prenatally or neonatally, mimicing effects of 
perinatal androgen surge in males during development (Motelica-Heino, 
Castanier et al. 1988; Corbier, Edwards et al. 1992).  As thoroughly reviewed, 
exposure of females during the prenatal or neonatal period to androgen has been 
used previously to induce male-like, or androgenized, behaviors (Pfaff and 
Zigmond 1971; Hrabovszky and Hutson 2002; Wallen 2005).  Sexual dimorphism 
in the brain may take many forms, including difference in structure (e.g., the size 
or number of neurons), connectivity (e.g., axon projection patterns or synapse 
number), and neurochemistry (e.g., the expression of neuropeptides, 
neurotransmitters or receptors). Previous results indicated that exposure of 
females to androgen during development mediates many cellular/molecular 
mechanisms, such as apoptosis, cell migration and synaptogenesis, that 
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influence neuron numbers, dendrite morphology and neurotransmitter 
phenotypes in the brain (Simerly 2002; Foecking, McDevitt et al. 2008).  
One of the well-studies sexual dimorphic features in mammalian brain is 
cell number. The sex dimorphism may exist either in the total number of cells in a 
specific brain region or in the number of cells of a particular phenotype. In many 
cases, sex differences in cell number have been attributed to the action of sex 
hormones during development, particularly testosterone and  testosterone 
metabolites such as estradiol (Forger 2006).  For example, the bed nucleus of 
the stria terminalis (BSNT) is a limbic forebrain structure involved in the control of 
sexual behavior, gonadotrophic release, stress and anxiety (Emery and Sachs 
1976; Beltramino and Taleisnik 1980). The principal nucleus of the BNST 
(BNSTp) is larger in males compared to females across many species including 
rats, mice, guinea pigs, and humans (Hines, Davis et al. 1985; Allen and Gorski 
1990; Walker, Toufexis et al. 2003). In rodents, the gender difference in BNSTp 
volume is attributed to an increased number of cells in males and neonatal 
testosterone administration in females elevated the cell number to a similar level 
of males (Guillamon, Segovia et al. 1988). Similarly, in spinal nucleus of the 
bulbocavernosus (SNB), which is a cluster of motoneurons located in the lumbar 
spinal cord, male rodents have more neurons than do females (Breedlove and 
Arnold 1980; Wee and Clemens 1987). SNB motoneurons innervate striated 
muscles of the perineum that control copulation, including the bulbocavernosus 
(BC) and levator ani (LA). Interestingly, these muscles also exhibit marked 
sexual dimorphism: the BC is completely absent and the LA is greatly reduced in 
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females (Breedlove and Arnold 1980; Wee and Clemens 1987). Neonatal 
testosterone was shown to increase SNB motoneuron number and BC/LA 
muscle volume (Breedlove and Arnold 1983). During development, over 50% of 
neurons initially generated in utero undergo apoptosis in a highly restricted time 
window that varies among different regions of the brain (Oppenheim 1991).  It 
has been well established that cell death contributes to sex dimorphism of cell 
numbers in the brain (Forger 2006). For example, perinatal testosterone 
administration has been reported to rescue cells in SNB from death (Breedlove 
and Arnold 1983). Bax and Bak are pro-apoptotic factors that belong to the Bcl-2 
family of apoptosis-regulating proteins. Deficiency of Bax has been reported to 
eliminate the gender difference in SNB motoneuron number (Jacob, Bengston et 
al. 2005). In addition, the BC and LA muscles were markedly increased in the 
female mice with both Bax and Bak deficiency (Jacob, Ray et al. 2008). 
These changes in brain neurons of females androgenized during 
development have been reported to be permanent and  are considered to be 
“organizational”, allowing for male-like behaviors that persist to adulthood (Arnold 
2009). A recent study in mice demonstrated that the male brain shows higher 
extent of chromatin modifications on histone 3, which are associated with both 
gene activation and suppression. Moreover,  in female brains prenatal 
testosterone exposure reversed this dimorphism (Tsai, Grant et al. 2009). These 
data suggest that epigenetic mechanisms have been implicated to contribute to 
the development of sexual dimorphism in the brain (Tsai, Grant et al. 2009). Most 
recently it has been reported that 2 hepatic steroid metabolizing enzymes, 
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Cyp2b9 and Cyp2a4, are expressed more abundantly in females compared to 
males and neonatal testosterone exposure diminishes these dimorphic gene 
expression patterns (Ramirez, Luque et al. 2010).  In contrast to studies focused 
on reproductive organs and the brain, little is known about developmental effects 
of sex hormones on other tissues/organs. 
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Table 1.1 Summary of findings in AngII-induced AAAs 
Mediator Application Mouse Effect on AAAs Reference Strain Gender 
Inflammation           
  CCR2 -/-: whole body   ApoE-/-      Male ↓ 
(Ishibashi, Egashira et al. 
2004; Daugherty, Rateri et 
al. 2010)  
  CCR2 -/-: bone marrow   ApoE-/-   Male ↓ (Ishibashi, Egashira et al. 2004)  
  COX-2 -/-   Hybrid     NS ↓ (Gitlin, Trivedi et al. 2007)  
  COX-2 inhibition: celecoxib   ApoE-/-    Male ↓ (King, Trivedi et al. 2006) 
  COX-1 inhibition: SC-560   ApoE-/-  Male ↔ (King, Trivedi et al. 2006) 
  5-LO -/-   ApoE-/-  Male ↔ (Cao, Adams et al. 2007) 
  5-LO inhibition: MK-0591   ApoE-/-    Male ↔ (Cao, Adams et al. 2007) 
  BLT1 -/-   ApoE-/-                  NS ↓ (Ahluwalia, Lin et al. 2007)  
  IFN-γ -/-   ApoE-/-  Male ↑ (King, Lin et al. 2009)  
  CXCL10-/-   ApoE-/-  Male ↑ (King, Lin et al. 2009)   
  TGF-β activity inhibition C57BL/6  Male ↑ (Wang, Ait-Oufella et al. 2010) 
  High fat diet induced obesity C57BL/6  Male ↑ (Police, Thatcher et al. 2009) 
  GX sPLA2 -/-   ApoE-/-    Male ↓ (Zack, Boyanovsky et al. 2010) 
  EP4 -/-: bone marrow LDLR-/- Male and Female ↑ (Tang, Shvartz et al. 2010)  
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Table 1.1 Summary of findings in AngII-induced AAAs (continued) 
Mediator Application Mouse Effect on AAAs Reference Strain Gender 
Oxidative Stress           
  p47phox -/-   ApoE-/-   Male ↓ (Thomas, Gavrila et al. 2006)  
  NOX-1 -/-   C57BL/6 (N6) Male ↓ (Thomas, Gavrila et al. 2006)  
  mPGES-1 -/-   LDLR-/-  Male ↓ (Wang, Lee et al. 2008)  
  Cyclophilin A -/- ApoE-/-   Male ↓ (Satoh, Nigro et al. 2009)  
  Vitamin E   ApoE-/-  Male ↓ (Gavrila, Li et al. 2005)  
  Vitamins E and C   ApoE-/-  Male ↔ (Jiang, Jones et al. 2007) 
Proteases           
  HDAC inhibititon: MCP-1   ApoE-/-  Male ↓ (Vinh, Gaspari et al. 2008) 
  MMP inhibitor: doxycycline   LDLR-/- Male ↓ (Manning, Cassis et al. 2003) 
  Plasminogen -/-   C57BL/6 (N6)  NS ↓ (Gong, Hart et al. 2008) 
  TERT-/- : bone marrow   LDLR-/- Male ↓ (Findeisen, Gizard et al. 2010)  
Intracellular 
signaling           
  Caspase inhibitor ApoE-/-  Male ↓ (Yamanouchi, Morgan et al. 2010)   
  Rho-kinase inhibition: fasudil ApoE-/-                  Male ↓ (Wang, Martin-McNulty et al. 2005)  
  JNK inhibition: SP600125 ApoE-/-       Male ↓ (Yoshimura, Aoki et al. 2005) 
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Table 1.1 Summary of findings in AngII-induced AAAs (continued) 
Mediator Application 
Mouse Effect 
on 
AAAs 
Reference Strain Gender 
RAS 
Components           
  AT1aR -/- : whole body   LDLR-/-         Male ↓ (Cassis, Rateri et al. 2007) 
  AT1aR -/- : bone marrow   LDLR-/-  Male ↔ (Cassis, Rateri et al. 2007)  
  MR antagonism: spironolactone   ApoE-/-   Male ↔ (Cassis, Helton et al. 2005) 
Hormonal           
  Orchidectomy ApoE-/-   Male ↓ (Henriques, Huang et al. 2004) 
  Ovariectomy ApoE-/-         Female ↔ (Henriques, Huang et al. 2004)  
Abbreviations : 5-LO-5-lipoxygenase; AAA-Abdominal aortic aneurysm; Apo-apolipoprotein; AT1aR-angiotensin II type 1a 
receptor; BLT1- G-protein coupled receptor for leukotriene B(4); CCR2-chemokine receptor 2; COX-cyclooxygenase; 
CXCL10-IFN-γ-inducible T-cell chemoattractant IP-10;  EP4-prostaglandin E receptor 4; GX sPLA2-group X secretory 
phospholipase;  HDAC-histone deacetylase; IFN-γ-interferon γ; JNK-c-Jun N-terminal kinase; LDLR-low-density 
lipoprotein receptor; MCP-1-monocyte chemoatractant protein-1; MMP-matrix metalloproteinase; mPGES-1-microsomal 
prostaglandin (PG) E2 synthase-1; MR-mineralocorticoid receptor; NS-not specified; TERT-telomerase reverse 
transcriptase. 
48 
 
Table 1.2 Gender difference in AngII and elastase-induced AAAs. 
 
AAA 
model Application gender species 
effect on 
AAA Reference 
AngII 
orchiectomy male mouse ↓ (Henriques, Huang et al. 2004)   
ovariectomy female mouse ↔ (Henriques, Huang et al. 2004)   
exogenous androgen male mouse ↑ (Henriques, Zhang et al. 2008)   
exogenous androgen female mouse ↑ (Henriques, Zhang et al. 2008)   
exogenous estrogen male mouse ↓ (Martin-McNulty, Tham et al. 2003)  
elastase 
orchiectomy male rat ↓ (Cho, Woodrum et al. 2009)  
ovariectomy female rat ↑ (Cho, Woodrum et al. 2009; Wu, Zhang et al. 2009)   
exogenous estrogen male rat ↓ (Ailawadi, Eliason et al. 2004; Cho, Woodrum et al. 2009)   
exogenous estrogen female rat ↓ (Cho, Woodrum et al. 2009; Wu, Zhang et al. 2009)   
exogenous androgen male rat ↑ (Cho, Woodrum et al. 2009)   
exogenous androgen female rat ↔ (Cho, Woodrum et al. 2009)   
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Figure 1.1 Current RAS with biologically active peptides highlighted in blue. 
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Figure 1.2 Signaling of the AT1 receptor. 
Abbreviations: Gq, G protein; PLC, PLD, PLA2, phospholipase C, D, and A2, 
respectively; IP3, inositol-1, 4, 5-triphosphate; DAG, diacylglycerol; PKC, protein 
kinase C; MAP, mitogen activated protein; JAK, Janus kinase; STAT, signal 
transducers and activators of transcription. Adapted from Dinh et al Clinical 
Science 100(5): 481–92 (2001).  
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Figure 1.3 Signaling of the AT2 receptor. 
Abbreviations: cGMP, cyclic guanosine monophosphate; Gi, inhibitory G protein; 
PTP, protein tyrosine phosphatase; PP2A, serine/threonine phosphatase 2A; 
ERK, extracellular signal-regulated kinase; NO, nitric oxide. Adapted from Dinh et 
al Clinical Science 100(5): 481–92 (2001). 
 
 
52 
 
 
 
Figure1.4  Regulation of the renin angiotensin system (RAS) by male and female 
sex hormones. The overall effect of estrogen is to tune down the RAS while 
androgen tends to stimulate the RAS. Adapted from Fischer et al Cardiovascular 
Research 53: 672-677. 
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Figure 1.5 The pathway leading to synthesis of testosterone from cholesterol and 
its subsequent metabolism to other hormones. Adapted from 
http://www.hemingways.org/GIDinfo/hrt_intro.htm. 
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CHAPTER IA. STATEMENT OF THE PROBLEM 
 
Abdominal aortic aneurysms (AAA) are commonly found in 4% to 8.5% of 
men and 0.5% to 1.5% of women in the population over the age of 60 (Wilmink, 
Quick et al. 1999; Lawrence-Brown, Norman et al. 2001; Ashton, Buxton et al. 
2002; Cornuz, Sidoti Pinto et al. 2004; Palombo, Lucertini et al. 2010). Recently it 
has been estimated that AAA prevalence in the United States are 1.1 million 
people between the ages of 50 to 84 (Kent, Zwolak et al. 2010). AAA is the 13th 
leading cause of the death and causes at least 15,000 deaths each year in the 
United States (Gillum 1995). Male gender is a strong independent risk factor for 
developing AAAs. Men exhibit greater incidence and severity of AAA compared 
to women. In recent decades AAA incidences and ruptures have been escalating 
in western societies, especially in male gender (Best, Price et al. 2003; Acosta, 
Ogren et al. 2006). Unfortunately, so far there is no effective pharmacological 
intervention to treat AAA.  
 Our laboratories have established that chronic infusion of AngII into 
hyperlipidemic mice induces the development of AAA the effect of AT1aR 
(Daugherty, Manning et al. 2000; Cassis, Rateri et al. 2007). Similar to human 
condition, AngII-induced AAAs also exhibit profound gender differences. The 
AngII-induced AAA incidence of male mice is 4-5 fold higher compared to that of 
females (Manning, Cassis et al. 2002; Henriques, Huang et al. 2004). Our 
laboratory has previously demonstrate that orchidectomy of male ApoE-/- mice 
markedly reduces AngII-induced AAA formation while ovariectomy of female 
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ApoE-/- does not have any influence on aneurysm formation (Henriques, Huang 
et al. 2004). Notably, exogenous androgen administration restored AngII-induced 
AAA formation in castrated male mice and significantly enhanced the 
development of AAA in female mice (Henriques, Zhang et al. 2008). All these 
results demonstrate that androgen is a primary mediator of gender difference in 
AngII-induced AAA formation. However, mechanisms underlying the effects of 
androgen to mediate enhanced susceptibility to AngII-induced AAAs have yet to 
be defined. 
Therefore, the purpose of the present research was to determine how 
androgens during different periods of life span promote AngII-induced AAA 
formation in hyperlipidemic mice. We hypothesized that androgen stimulate 
AT1aR expression in aortas to confer a higher prevalence of AngII-induced AAAs 
in male mice. We established that androgen increases SMC AT1aR expression 
in the vasculature to stimulate AngII-induced AAA formation in adult male and 
female mice. We also investigated the effect of short-term exogenous androgen 
exposure during development on aortic AT1aR expression and AngII-induced 
AAA formation in adult female hyperlipidemic mice. Moreover, we defined how 
castration influences the progression of established AngII-induced AAAs in male 
mice. 
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CHAPTER IB. HYPOTHESIS 
 
Androgen promotes angiotensin receptor type 1a expression on vascular 
smooth muscle cells to confer higher angiotensin II-induced AAA formation in 
male hyperlipidemic mice. 
 
To test this general working hypothesis, the following goals were outlined: 
Goal 1: To examine the role of androgen on the progression of established 
angiotensin II-induced AAA. 
Hypothesis 1: Removal of endogenous androgen will decrease the 
progression of established angiotensin II-induced AAA. 
Specific Aim 1: To determine the effect of castration on the 
progression of established angiotensin II-induced AAA in male 
ApoE-/- mice. 
 
Goal 2: To examine the role of androgen on the expression of aortic smooth 
muscle angiotensin receptor type 1a. 
Hypothesis 2: Androgen will stimulate aortic smooth muscle angiotensin 
receptor type 1a expression to promote higher angiotensin II-induced AAA 
formation. 
Specific Aim 2: To determine the effect of androgen on aortic 
angiotensin receptor type 1a expression and the effect of smooth 
muscle angiotensin receptor type 1a deficiency on angiotensin II-
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induced AAA formation in female hyperlipidemic mice administered 
exogenous androgen. 
 
Goal 3: To examine the role of androgen during development on the expression 
of aortic smooth muscle angiotensin receptor type 1a and angiotensin II-induced 
AAA in adult mice. 
Hypothesis 3: Administration of androgen during development in female 
mice will increase aortic smooth muscle angiotensin receptor type 1a and 
promote higher angiotensin II-induced AAA formation in adulthood. 
Specific Aim 3: To determine the effect of androgen administration 
in neonatal female mice on aortic smooth muscle angiotensin 
receptor type 1a expression and angiotensin II-induced AAA 
formation in adulthood. 
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CHAPTER II. SPECIFIC AIM 1 
 
Determine the effect of castration on the progression of established 
angiotensin II (AngII)-induced AAAs in male apolipoprotein E (ApoE) -/- mice. 
 
2.1   Summary 
Previous studies demonstrated that castration profoundly reduces AngII-
induced AAA incidence in males while exogenous androgen administration 
restores AAA formation in castrated male mice.  These results demonstrated that 
androgen is a primary regulator of AngII-induced AAA formation in male mice.  In 
this study, we sought to determine the effect of castration on the progression of 
established AngII-induced AAAs, with the hypothesis that removal of androgen 
will slow AAA progression and reduce the risk of aneurysmal rupture.   
Male ApoE-/- mice were infused with AngII for 4 weeks to induce AAA 
formation. Mice with AAAs were identified by ultrasound.  Mice with AAAs of 
different sizes were evenly distributed into groups that were sham-operated or 
castrated. After surgery, mice from both groups were then chronically infused for 
an additional 8 weeks with AngII. During prolonged AngII infusion, mice from 
sham control groups exhibited marked progressive lumen dilation beyond that 
observed following 1 month of AngII infusion. Castration significantly decreased 
abdominal aortic lumen diameters of male mice chronically infused with AngII 
(day 56, 1.74 ± 0.05 vs 1.50 ± 0.04 mm; day 70, 1.87 ± 0.05 vs 1.62 ± 0.04 mm; 
day 84, 1.88 ± 0.05 mm vs 1.63 ± 0.04 mm; P<0.05; sham vs castration, 
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respectively). However, maximal external abdominal aortic diameters of cleaned, 
excised AAAs were not significantly different between sham-operated and 
castrated mice. AngII-induced atherosclerosis was not altered by castration. 
In conclusion, these data demonstrate that removal of endogenous 
androgen has a significant impact on the luminal dilation of established AngII-
induced AAA, but does not influence the aortic diameter of AAAs. 
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2.2   Introduction 
The natural history of AAA progression is gradual expansion of aortic 
diameters obtained by ultrasound with increased risk of rupture as AAA size 
increases. Ruptured AAAs are a leading cause of death in western countries and 
result in at least 15,000 deaths per year in the United States. Based on current 
clinical practice guidelines, the only effective therapeutic option to prevent AAA 
rupture is open repair or endovascular surgery if AAA size (by ultrasound) 
exceeds 5-5.5 cm. Patients with small AAAs are usually excluded from AAA 
surgical repairs and so far no pharmaceutical drugs have been proven to 
markedly reduce AAA size progression and/or prevent ruptures of small AAAs. It 
has been generally acknowledged that AAA rupture risk increases while 
aneurysms are growing and expanding. The mean growth rate of small AAAs is 
2.6 to 3.2 mm per year (Lederle, Wilson et al. 2002). It has been demonstrated 
that AAA expansion rate is positively associated with cigarette smoking and 
aneurysm diameter at baseline (Lindholt, Heegaard et al. 2001; Brady, 
Thompson et al. 2004) and negatively associated with diabetes and peripheral 
arterial diseases (Brady, Thompson et al. 2004). Therefore, it is highly likely that 
interventions that slow AAA progression will decrease the risk of AAA rupture in 
patients and immensely improve the outcome of AAA medical treatment.  
The renin angiotensin system (RAS) has been demonstrated to be 
important in AAA pathogenesis in experimental models, and is gaining 
importance as a contributor to human AAA pathology. Chronic infusion of AngII 
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induces AAA formation in hyperlipidemic male mice (Daugherty and Cassis 1999; 
Daugherty, Manning et al. 2000). Enhanced AngII levels and AngII producing 
enzymes, namely chymase and ACE, have been detected in human AAA tissues 
(Nishimoto, Takai et al. 2002; Tsunemi, Takai et al. 2002). Recently, gene 
polymorphisms of ACE and angiotensin type 1 receptors (AT1Rs) have been 
positively associated with increased AAA incidence at 3 different geographic 
areas (Fatini, Pratesi et al. 2005; Jones, Thompson et al. 2008). Moreover, 
administration of an ACE inhibitor has been linked to reduced AAA ruptures in 
human patients (Hackam, Thiruchelvam et al. 2006).  Recent data demonstrated 
that administration of an AT1R antagonist slowed AAA growth rate in a clinical 
study involving a 25-years of AAA surveillance (Thompson, Cooper et al. 2010). 
These data suggest that the RAS contributes to AAA progression; therefore, 
inhibition of the RAS may slow AAA progression and potentially decrease the risk 
of AAA rupture. 
Our previous studies have demonstrated that with chronic AngII infusion 
male mice exhibit a 4-5 fold higher prevalence of AAAs compared to female 
mice, and this effect is abolished by orchiectomy (Daugherty, Manning et al. 
2000; Manning, Cassis et al. 2002; Henriques, Huang et al. 2004). Exogenous 
androgen administration restored AngII-induced AAA incidence in castrated male 
mice and promoted aneurysm formation in female mice (Henriques, Zhang et al. 
2008), suggesting androgen is a primary regulator of pronounced gender 
differences in AngII-induced AAA formation.   Relevance of these findings in mice 
to humans is demonstrated by a strong effect of male gender as a risk factor for 
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human AAA formation (ref).  However, while male sex has been implicated as a 
risk factor for AAA formation, results demonstrated that median growth rate of 
AAAs was significantly greater in women than men (Mofidi et al., 2007).  Thus, it 
is unclear whether effects of androgen to promote formation of AngII-induced 
AAAs extend to an increased progression of established AAAs.  
To investigate if androgen also plays a role in AAA progression, we 
hypothesized that castration reduces the growth rate of AngII-induced AAAs. We 
performed orchiectomy to remove endogenous androgen from the male ApoE-/- 
mice with established AngII-induced AAAs. Results from this study demonstrate 
that castration significantly slows the progressive dilation of abdominal aortic 
lumen in male ApoE-/- chronically infused with AngII. 
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2.3   Methods 
2.3.1 Animals 
Male ApoE-/- mice were purchased from The Jackson Laboratory (2 
months of age; n = 60; Bar Harbor, MA). All mice were maintained in a pathogen-
free environment. Water and normal laboratory diet were available ad libitum. At 
2 month of age, all mice were infused with AngII (1,000 ng/kg/min) for 4 weeks to 
induce AAA formation. On day 25 of AngII infusion, abdominal aortas of all mice 
were scanned by noninvasive high-frequency ultrasound to measure aortic lumen 
diameter as an index of AAA formation. An AAA was defined as a >30% increase 
in lumen diameter compared to baseline (day 0 of infusion).  Only mice defined to 
have an AAA continued in the study. These mice were assigned to either sham-
operated or castration groups (n=23/group). Large and small AAAs, reflected by 
abdominal aortic lumen diameters, were evenly assigned to both sham and 
castration groups to control for differences in AAA size as a mediator contributing 
to AAA progression. After surgery on day 28, mice in each group continued to be 
infused with AngII for an additional 8 weeks. Abdominal aortic lumen diameters 
were monitored by ultrasound on days 42, 56, 70 and 84. 
 
2.3.2 AngII Infusion 
Alzet (Durect Corp; Cupertino, CA) osmotic pumps (model 1004) were 
filled with AngII (infusion rate of 1000 ng /kg/min) as described previously 
(Daugherty and Cassis 1999; Daugherty, Manning et al. 2000).  Pumps were 
implanted subcutaneously on the right flank via an incision in the scapular region. 
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AngII infusions were continued each month by replacement of new osmotic 
minipumps containing fresh AngII. 
 
2.3.3 Orchiectomy 
Male ApoE-/- mice were anesthetized with ketamine/xylazine (100/10 
mg/kg, i.p.). Both testes were pushed down into the scrotal sacs by gently 
applying pressure to the abdomen.  An 8-10 mm incision through the skin was 
made along the midline of the scrotal sac. Another incision was made into the 
midline wall between the testes sacs under the covering membranes. The testis, 
the vas deferens and epididymal fat pad were carefully pulled out through the 
incision.  The blood vessels supplying the testis were clamped with a hemostat 
and the testis was dissected away. The vas deferens and the fat pad were 
cauterized and placed back into the scrotal sac. This procedure was repeated for 
the other testis. The incision through the skin was closed using wound clips.  For 
sham-operated controls, mice were anesthetized, both incisions were made and 
sex organs were localized. 
 
2.3.4 Ultrasound Imaging 
Abdominal aortas of mice were visualized with high-frequency ultrasound 
(Vevo 660, VisualSonics, Toronto, Canada) at baseline, days 25, 42, 56, 70 and 
84 of AngII infusion, as previously described (Barisione, Charnigo et al. 2006). 
Briefly,mice were anesthetized with isoflurane and restrained in a supine position 
for ultrasonography. Short axis scans of aortas were performed on abdominal 
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aortas from the level of the left renal arterial branch moving vertically to the 
suprarenal region. Cine loops of 300 frames were acquired throughout the renal 
region of abdominal aortas and maximal luminal diameters in the suprarenal 
region of abdominal aortaswere measured on images at maximal dilation. 
 
2.3.5 Atherosclerosis and AAA Quantification 
Mice were sacrificed and fixed with formalin by gravity perfusion (~120 
mmHg) to quickly preserve vessel morphology. Aortas were removed and fixed 
with formalin overnight at room temperature. Extraneous tissue, including fat and 
connective tissues were carefully removed from aortas. Atherosclerotic lesions 
were quantified en face on the luminal surface of aortic arches as described 
previously (Daugherty and Cassis 1999; Daugherty, Manning et al. 2000). Briefly, 
atherosclerotic lesions were determined by measuring the area of the intimal 
surface covered by grossly discernible atherosclerotic plaque, using ImagePro 
Plus software (Media Cybernetics,Bethesda, MD). The extent of AngII-induced 
atherosclerosis was expressed as the percentage of total lesion area to the total 
aortic arch intimal area. Maximal diameters of suprarenal abdominal aortas were 
measured on cleaned aortas by ImagePro Plus software (Media Cybernetics, 
Bethesda, MD). 
 
2.3.6 Statistical Analysis 
Data are represented as mean ± SEM. To compare 2 groups, student’s t 
test was performed for parametric data and Mann-Whitney Rank Sum Test was 
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utilized for nonparametric data. Two-way repeated measures ANOVA with Holm-
Sidak post hoc analysis were performed to compare body weight and ultrasound 
data. The incidences of AAA were analyzed using Fisher exact test. P<0.05 was 
considered statistically significant. All statistical analyses were performed using 
SigmaStat (SPSS Inc). 
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2.4      Results 
2.4.1 Castration Reduces the Progressive Lumen Dilation of Established AngII-
induced AAAs in Male ApoE-/- Mice 
To define the role of androgen on the expansion of established AngII-
induced AAAs, we infused adult male ApoE-/- mice with AngII for 4 weeks to 
induce AAA formation before they were subjected to sham-operation or 
orchiectomy. After surgery, we continued chronic AngII infusion in all mice for 
another 2 months to study progression of established AAAs. After castration, 
male mice exhibited significantly reduced body weights compared to sham 
controls (Figure 2.1A). At the study endpoint, castrated male mice exhibited 
marked atrophy in the weights of prostate, seminal vesicle and vas deferens 
(Figure 2.1B).  
At the end of 1 month of AngII infusion, we obtained abdominal aortic 
lumen diameter measurements from AngII-infused AAAs by ultrasound.  
Abdominal aortic lumen diameters at baseline and day 28 were not different 
between sham controls and castrated mice (baseline, 1.07 ± 0.05 vs 1.05 ± 0.04 
mm; day 28, 1.56 ± 0.05 vs 1.56 ± 0.04 mm; sham vs castration, respectively) 
(Figure 2.2), demonstrating that AAAs of different sizes were evenly assigned to 
sham control and castrated groups. In sham control mice, suprarenal aortic 
lumen diameters progressively increased with continued infusion of AngII, with 
significant increases in lumen diameter at days 70 and 84 of AngII infusion 
compared to day 25 (day 25 vs day 70, 1.56 ± 0.05 vs 1.87 ± 0.05 mm; P<0.001) 
(Figure 2.2). In contrast, aortic lumen diameters did not exhibit a progressive 
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increase with continued AngII infusion in castrated male mice (day 25 vs day 70, 
1.56 ± 0.04 vs 1.62 ± 0.04 mm; day 84, 1.56 ± 0.04 vs 1.63 ± 0.04 mm; P>0.23) 
(Figure 2.2). As a result, aortic lumen diameters were reduced by castration on 
days 56, 70 and 84 compared to sham operated controls (day 56, 1.74 ± 0.05 vs 
1.50 ± 0.04 mm; day 70, 1.87 ± 0.05 vs 1.62 ± 0.04 mm; day 84, 1.88 ± 0.05 mm 
vs 1.63 ± 0.04 mm; P<0.05; sham vs castration respectively) (Figure 2.2). 
 
2.4.2 Castration Does not Alter Maximal External Diameters of AngII-induced 
AAAs or AngII-induced Atherosclerosis. 
During prolonged AngII infusion after the surgery, the castrated male mice 
showed a tendency of decreased AAA rupture incidence compared with sham 
controls (sham vs castration 13% vs 4%; P=0.60). At the study endpoint, aortas 
were formalin fixed and cleaned for quantitative measurements of AngII-induced 
AAA and atherosclerosis (Figure 2.4). Maximal external diameters of cleaned, 
excised suprarenal aortas were reduced modestly (by 0.45 mm), but not 
significantly by castration (sham vs castration, 2.32 ± 0.24 vs 1.87 ± 0.17 mm; 
P=0.09) (Figure 2.3A). AngII-induced atherosclerosis in aortic arches was not 
different between sham and castrated mice (sham vs castration, 6.2 ± 0.5 vs 6.6 
± 0.7 %; P=0.27) (Figure 2.3B). 
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2.5    Discussion 
The major finding of this study is that castration substantially reduces 
luminal dilation of established AngII-induced AAAs in male ApoE-/- mice. Our 
data support that prolonged AngII infusion causes progressive elevations in 
suprarenal aortic lumen diameters of male ApoE-/- mice, consistent with previous 
studies (Barisione, Charnigo et al. 2006).  Interestingly, despite an ability of 
castration to significantly blunt progressive dilation of suprarenal aortic lumen 
diameters with prolonged AngII infusion, castration only modestly reduced AAA 
external diameters.  These data suggest that inhibition of androgen suppresses 
AAA progression.   
In contrast to an ability of castration to blunt progressive increases in 
aortic lumen diameters, castration of male mice had no effect on atherosclerotic 
lesions formed from chronic AngII infusion.  These results are in agreement with 
previous data from our laboratory demonstrating that sex differences in AngII-
induced vascular diseases are restricted to AAAs (Henriques et al., 2004).  
Although male gender is linked to higher risks of cardiovascular diseases 
including AAAs, low serum testosterone in men has also been associated with 
increased cardiovascular risk and mortality (Shores, Matsumoto et al. 2006; 
Maggio, Lauretani et al. 2007; Laughlin, Barrett-Connor et al. 2008). Recently it 
has been demonstrated that androgen deprivation therapy for prostate cancer 
increased the risk of cardiovascular events (Levine, D'Amico et al.). Moreover, 
women often have more adverse outcomes after a cardiovascular event 
compared to men of a similar age (Kostis, Wilson et al. 1994; Vaccarino, Parsons 
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et al. 1999; Vaccarino, Parsons et al. 2009). It has been suggested that 
androgen plays an important role in cardiovascular repair and regeneration 
through stimulating erythropoietin production and angiogenesis via VEGF-related 
mechanisms (Sieveking, Chow et al.). Recent animal studies also revealed that 
androgen is required for the preservation of NO bioavailability and exerts 
protective effects against AngII-induced vascular remodeling in coronary arteries 
and thoracic aortas from male mice by regulating oxidative stress (Ikeda, Aihara 
et al. 2009).  Our results do not support a protective role for testosterone in the 
progression of AngII-induced atherosclerosis.  It is possible that augmentation of 
atherosclerosis by chronic infusion of AngII occurs through mechanisms that are 
independent of those suggested to be favorably influenced by testosterone.  
In contrast to a lack of effect on atherosclerosis, castration totally ablated 
progressive increases in suprarenal aortic lumen diameters of AngII-infused male 
mice.  Male gender has been identified as a prominent risk factor of human AAA 
formation by numerous epidemiological and clinical studies. However, whether 
male gender influences the growth rate of formed AAA remains largely under 
debate. Results from the United Kingdom Small Aneurysm Trial demonstrated no 
association of gender with AAA growth (Brady, Thompson et al. 2004). 
Interestingly, despite a higher AAA incidence in males compared to females, 
some studies have noted increased AAA expansion rate and aneurysmal 
ruptures in female AAA patients (Solberg, Singh et al. 2005; Mofidi, Goldie et al. 
2007; Norman and Powell 2007). In contrast, female gender also has been 
negatively associated with AAA progression (Thompson, Cooper et al.). A 
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interesting recent study genotyped 74 single-nucleotide polymorphisms (SNPs) 
in genes determining circulating sex hormones and their action in males with and 
without AAAs, and demonstrated that one SNP in CYP19A1 was strongly 
associated with aortic diameter (Golledge, Biros et al. 2010).  However, similar 
studies have not been performed in females.  To our knowledge, no studies have 
examined the association of AAA progression and male/female gender in AAA 
animal models.   
In agreement with human AAAs, we have previously demonstrated that 
castration strikingly reduces AngII-induced AAA incidence in male mice while 
exogenous androgen administration restored AAA formation in castrated males, 
indicating an important role of androgen in the formation of AngII-induced AAAs 
(Henriques, Huang et al. 2004; Henriques, Zhang et al. 2008). In this study, we 
demonstrate that castration significantly reduced the progressive lumen dilation 
of established AngII-induced AAAs, suggesting that androgen also plays a role in 
luminal expansion of AAAs in male mice.   While castration is not an amenable 
therapy to treat AAAs in humans, these results suggest that androgen receptor 
blockade may be of benefit in advancing AAAs, or alternatively that use of 
anabolic steroids may be contraindicated in males of advancing age with a family 
history of AAAs.  
Despite the ability of castration to significantly reduce aortic lumen dilation 
of progressing AAAs, external AAA diameters were modestly, but not significantly 
decreased by castration. External diameters of cleaned AAAs encompass lumen 
diameters and abdominal aortic vascular wall remodeling.  A reduction in lumen 
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diameter in the face of a modest but yet insignificant decrease in external 
diameter suggests that aortic wall remodeling was not appreciably reduced by 
castration with prolonged AngII infusion.  Recent studies demonstrated that 
testosterone inhibits vascular calcification (Son, Akishita et al. 2010), suggesting 
that continued aortic remodeling in castrated male mice may have resulted from 
removal of the inhibitory effects of castration on vascular calcification. It is 
unclear whether changes in lumen diameter, as compared to aortic wall 
diameter, are more closely linked to rupture of AAAs.  This is especially difficult 
to ascertain as ultrasound can be used to accurately quantify aortic lumen, but 
not aortic wall diameters in mice, while in humans ultrasound assesses aortic 
diameters (lumen plus wall).  Our results demonstrate a modest reduction in 
aneurismal rupture in castrated male mice compared to sham controls, 
suggesting that castration-induced decreases in aortic lumen diameter are more 
closely linked to rupture of AngII-induced AAAs.   
In conclusion, castration significantly decreased the progressive lumen 
dilation of established AngII-induced AAAs in male ApoE-/- mice, but had no 
effect on external AAA diameters.  These studies suggest that androgen 
contributes to the progression of established AAAs through distinct mechanisms 
that differentially influence aortic lumen and wall diameters. 
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Figure 2.1 Body weights through AngII infusion (A) and male sex organ tissue 
weights at study endpoint (B) of both sham and castration group. Data are mean 
± SEM.  *, P < 0.001 compared to day 28 within each group; **, P < 0.001 
compared to control group. 
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Figure 2.2 Lumen diameters of suprarenal abdominal aortas were obtained from 
sham and castration groups using ultrasound through 3 months AngII infusion. 
Data are mean ± SEM.  *, P < 0.001 compared to day 28 measurements within 
each group; **, P < 0.05 compared to control group. 
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Figure 2.3 Castration does not significantly reduce maximal external diameters of 
AngII-induced AAA (A; P=0.09) or have any impact on AngII-induced 
atherosclerosis in aortic arch (B; NS). Each circle represents the measurement 
from each individual sample.  
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Figure 2.4 Perfusion fixed aortas from sham and castration groups. 
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CHAPTER III. SPECIFIC AIM 2 
 
Determine the effect of androgen on aortic angiotensin receptor type 1a 
expression and the effect of smooth muscle angiotensin receptor type 1a 
deficiency on angiotensin II-induced AAA formation in female hyperlipidemic 
mice administered exogenous androgen. 
 
3.1 Summary 
Our previous studies have demonstrated that AngII infusion induce AAA 
formation through AT1aR. Castration of male ApoE-/- reduces AngII-induced 
AAA to that of female mice while androgen administration restores or stimulates 
AAA formation in castrated male mice or female mice. Thus, we sought to 
determine if androgen positively regulate aortic AT1aR expression to confer a 
higher AngII-induced AAA incidence and if SMC AT1aR deficiency reduce the 
effect of androgen on increasing AAA formation in female mice. 
AT1aR mRNA abundance in the AAA-prone region of abdominal aortas 
was 7-fold greater compared to thoracic aortas of male but not female mice. 
AT1aR mRNA abundance decreased after castration in abdominal but not 
thoracic aortas of male mice. Exogenous androgen (dihydrotestosterone, DHT) 
administration to castrated male mice restored AT1aR mRNA abundance in 
abdominal aortas but had no effect in thoracic aortas. DHT also stimulated 
AT1aR mRNA abundance in abdominal aortas from female mice. When treated 
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with testosterone, primary cultured smooth muscle cells exhibited significant 
increase of AT1aR mRNA abundance. 
To investigate if exogenous androgen stimulates AT1aR expression on 
SMC to promote AngII-induced AAA in female mice, SMC specific AT1aR 
deficient mice were generated using Cre-LoxP technology.  Both AT1aR deficient 
mice and wild type littermate control female mice were administered DHT for 2 
week before infused with AngII.  AngII-induced AAA incidence was significantly 
reduced with SMC AT1aR deficiency (85% vs 50%; P<0.05). 
In conclusion, these studies demonstrate that enhanced abdominal aortic 
AT1aR level by androgen is highly correlated with increased AngII-induced AAA 
formation in adult mice. Furthermore, exogenous androgen positively regulates 
SMC AT1aR expression to promote AngII-induced AAA susceptibility in adult 
female hyperlipidemic mice. 
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3.2 Introduction 
Male gender has been consistently identified as a major risk factor for 
human AAAs. The incidence and severity of abdominal aortic dilations are 
greater in men than women (Singh, Bonaa et al. 2001; Isselbacher 2005). 
Experimental models of this disease also exhibit similar gender differences.  In 
the rat model of intraluminal elastase infusion induced AAAs, male rats had 
larger and more frequent aneurysms than females (Ailawadi, Eliason et al. 2004). 
Chronic AngII infusion into hyperlipidemic mice resulted in AAA formation at a 4-
5 fold higher incidence in male compared to female mice (Daugherty, Manning et 
al. 2000; Manning, Cassis et al. 2002; Henriques, Huang et al. 2004).  It has 
been demonstrated that removal of androgen by castration of male ApoE-/- mice 
profoundly reduced AngII-induced AAA incidence to a similar level of female 
ApoE-/- mice while ovariectomy had no significant influence on AngII-induced 
AAA formation in female ApoE-/- mice (Henriques, Huang et al. 2004). Recent 
studies also demonstrated that exogenous androgen administration restores 
AngII-induced AAA formation in castrated male ApoE-/- mice and significantly 
augments AAA incidence in female ApoE-/- mice (Henriques, Zhang et al. 2008). 
These data implicate androgen as a primary mediator of gender differences in 
AngII-induced AAAs; however, mechanisms of androgen to promote AAA 
formation are unknown.   
Androgen has been reported to increase the expression of each 
component of the renin-angiotensin system (RAS), including angiotensinogen, 
renin, ACE and AT1 receptors (Fischer, Baessler et al. 2002). Previous studies in 
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our laboratory demonstrated that both the AT1 receptor antagonist losartan 
administration and AT1aR deficiency abolishes AngII-induced AAAs in male 
mice, implicating a pivotal role of AT1aR in AngII-induced AAA formation 
(Daugherty, Manning et al. 2001; Cassis, Rateri et al. 2007). Moreover, using 
bone marrow transplantation, AT1aR deficiency of recipient mice, but not in cells 
used to repopulate, reduced AngII-induced AAAs (Cassis, Rateri et al. 2007).  In 
aortic vasculature, several cell types express AT1aRs. The expression level of 
AT1aR is highest in SMC of vessel wall (Mehta and Griendling 2007). SMC 
apoptosis has been found to contribute to AngII-induced AAAs, since 
administration of a caspase inhibitor reduced medial apoptosis and significantly 
decreased AAA formation (Yamanouchi, Morgan et al. 2010). Previous studies 
examining temporal changes in aneurismal pathology with AngII infusion 
demonstrated medial smooth muscle elastin degradation occurred early in AngII-
induced AAAs (Saraff, Babamusta et al. 2003). Collectively, these results 
demonstrate that AngII induces AAA formation through stimulation of AT1aRs, 
and support an essential role on vascular SMC in AAA formation. 
In this study, we tested the hypothesis that androgen increases AT1aR 
expression on aortic SMC to promote AngII-induced AAAs in female 
hyperlipidemic mice.  We first examined the effect of exogenous androgen on 
AT1aR mRNA abundance in thoracic versus abdominal aortas from castrated 
male and female ApoE-/- mice.  Then, we defined the role of AT1aR on aortic 
SMC in the effect of exogenous androgen to augment AngII-induced AAA 
formation in female mice. 
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3.3 Methods 
3.3.1 Animals 
For studies examining the effects of androgen on AT1aR mRNA 
abundance, Male and female apoE-/- mice (12 weeks old, backcrossed 10 times 
onto aC57BL/6 background) were purchased from Taconic Farms (Germantown, 
PA). All mice were maintained under barrier conditions. Water and normal 
laboratory diet were available ad libitum. Male and female mice were castrated 
as described previously and 1 week later implanted in the subcutaneous space 
with slow release pellets (Innovative Research of America, Sarasota, FL) 
containing vehicle or dihydrotestosterone (DHT; 10 mg pellets/60 day sustained 
release; 0.16 mg/d). Castrated male mice administered vehicle or DHT were 
examined at 1 or 5 weeks after DHT administration (n=10 to 13 per treatment per 
time point). A group of ovariectomized female apoE-/- mice were included, with 
vehicle or DHT (0.16 mg/d) administration beginning 1 week after castration for a 
total duration of 5 weeks (n=8 per treatment group).  
For the study determining the role of SMC AT1aR on androgen increasing 
AngII-induced AAA susceptibility in female mice, 3 month old female AT1aRfl/fl 
and AT1aRSM22 KO mice were implanted AT1aRSM22 KO micedihydrotestosterone 
(DHT; 10 mg pellets/60 day sustained release; 0.16 mg/day) 2 weeks before 
infused with AngII (1,000ng/kg/min, Bachem, Torrance, CA) by osmotic pumps 
(Alzet, model 1004, Durect Co., Cupertino, CA) for 4 weeks. 
 
 
82 
 
3.3.2 Orchiectomy and Ovariectomy 
Ovariectomy was performed on 3-month-old female apoE-/- mice. Mice 
were anesthetized with ketamine/xylazine, bilateral incisions (approximate 0.5 cm 
in length) were made into the abdominal cavity, and the uterus was exposed. The 
ovaries were carefully picked out of the incisions. Circulation to the fallopian 
tubes was cut off with a hemostat to minimize bleeding when dissecting the 
ovaries. Once the ovaries were excised, the cut end of the fallopian tubes was 
cauterized and all the tissues were neatly placed back into the abdominal cavity. 
The muscle was then sutured, and the skin was closed using wound clips. Sham 
controls were subject to a similar procedure without removing the ovaries. 
Orchiectomy surgeries were performed on 3-month-old male apoE-/- mice as 
previously described. 
 
3.3.3 Generation of AT1aRSM22 KO mice   
AT1aRfl/fl were generated by InGenious Targeting Laboratory (Stony Brook, 
NY) directly in ES cells of C57BL/6 mice and subsequently crossed to LDLR-/- 
mice.  SM22-Cre mice (The Jackson Laboratory, Tg(Tagln-cre)1Her/J, #004746, 
Bar Harbor, ME) were bred to LDLR-/- mice and were identified by speed 
congenic screening (The Jackson Laboratory) to be the equivalent of N10.  For 
experimental mice, male AT1aRSM22 KO mice were bred to female AT1aRfl/fl mice 
to generate approximately 50:50 distribution of Cre hemizygous transgenics 
(AT1aRSM22 KO) and non Cre expressing littermate controls (AT1aRfl/fl). 
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3.3.4 Genotyping   
AT1aRSM22 KO and AT1aRfl/fl littermate controls were genotyped by PCR 
of genomic DNA (tail) and smooth muscle AT1aR deficiency confirmed using 
aortic samples at study endpoint.  A small piece of infrarenal aorta was removed, 
cleaned of adventitia and endothelium and DNA was extracted (DNeasy; Qiagen, 
Alameda, CA). The primers and PCR conditions used for genotyping are listed in 
Table 3.1.  
 
3.3.5 Aortic gene expression quantification by real time PCR 
Total RNA was extracted from thoracic (aortic arch to diaphragm) and 
abdominal aortas (diaphragm to ileal bifurcation) using RNeasy fibrous tissue 
minikit (Qiagen, Valencia, CA). For in vitro experiments, primary mouse vascular 
smooth cells (passage 7-10) were treated with 10nM of testosterone propionate 
(Sigma Aldrich, St. Louis, MO) in 0.1% DMSO for 24 hours.  Total RNA was 
extracted with Trizol (Invitrogen, Carlsbad, CA). All RNA samples were treated 
with Turbo DNA-free (Ambion, Austin, TX) to remove genomic DNA.RNA quality 
was assessed using a Bio-Rad Experion Automated Electrophoresis System 
(Bio-Rad, Hercules, CA). Mouse AT1aR primers were obtained from Qiagen, 
while AT1bR primers were from Applied Biosystems TaqMan Gene Expression 
Assays. Relative quantification of AT1aR mRNA abundance was performed with 
an iCycler (BioRad, CA) based on a standard curve method using the SYBR 
Green PCR core reagent (Applied Biosystems, CA). The real-time PCR 
conditions were: 5 min at 94º, 40 cycles for 1 min at 94º, 1 min at the annealing 
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temperature, 1 min at 72º, and a final elongation step for 10 min at 72º. To verify 
specificity of primers for AT1aR, quantification was performed on tissues from 
AT1aR-/- mice. 18S rRNA was used to control for DNA loading, and data are 
expressed as AT1aR/18S RNA ratios.  
 
3.3.6 Measurement of aortic contractility 
Aortas from intact male, castrated male, and castrated male ApoE-/- mice 
administered DHT (5 weeks) were removed and adventitia was carefully 
dissected free. Measurement of contractile activity was performed using ring 
segments (3 mm) from thoracic and abdominal aortas as described previously 
(Babamusta, Rateri et al. 2006). Aortic segments were mounted by passing two 
tungsten wires through the arterial lumen and bathed in wells filled with Krebs 
Henseleit solution. Optimal resting tension (1 gm) was maintained continuously 
and recorded on a Micro-Med instrument. After 30 min for equilibration, tissues 
were incubated with KCl (60 mM), followed by AngII (1 µM). The contractile force 
generated in response to AngII was normalized as a percentage of the KCl 
response. 
 
3.3.7 Quantification of atherosclerosis and AAAs 
Atherosclerotic lesions were quantified in the aortic arch as described 
previously (Daugherty, Manning et al. 2000; Daugherty and Whitman 2003). AAA 
incidence was quantified by grading of excised, cleaned tissue by 3 independent 
observers blinded to the experimental design as described previously. Abdominal 
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aortic lumen diameter measurements were obtained on anesthetized mice using 
high-resolution ultrasound (Visualsonics, Vevo 660) at baseline, day 7, day 14 
and day 28 of AngII infusion. Maximal diameters of abdominal aortas were 
measured on cleaned, formalin-fixed aortas by ImagePro Plus software (Media 
Cybernetics, Bethesda, MD). AAAs were defined as > 50% dilation of lumen 
diameters from saline-infused mice.   
 
3.3.8 Statistical Analyses 
Data are represented as mean±SEM. Parametric data were initially 
analyzed using ANOVA. If differences existed between groups, post hoc 
analyses were performed (Tukey). The incidences of AAA were analyzed using 
Fisher exact test. P=0.05 was considered statistically significant. All statistical 
analyses were performed using SigmaStat (SPSS Inc). 
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3.4 Results 
3.4.1 Androgen Selectively Augments Abdominal Aortic AT1aR Expression in 
Both Male and Female ApoE-/- mice  
To determine if aortic AT1aR was regulated by androgen to promote 
AngII-induced AAA formation, male and female ApoE-/- mice were subjected to 
orchiectomy or ovariectomy operation and administerd exogenous androgen, 
DHT for 1 or 5 weeks. Abdominal aortas, where AngII-induced AAAs form in 
mice, exhibit strikingly higher (7-fold) AT1aR mRNA abundance than thoracic 
aortas in male but not female ApoE-/- mice (Figure 3.2). AT1aR mRNA 
abundance progressively decreased after castration in abdominal aortas to levels 
observed in thoracic aortas. Administration of DHT for 1 week to castrated male 
apoE-/- mice resulted in complete restoration of AT1aR mRNA abundance in 
abdominal aortas, but had no effect in thoracic aortas (Figure 3.2A). Longer 
exposures to DHT (5 weeks) also increased AT1aR mRNA abundance in 
abdominal aortas to levels not different from intact male mice (Figure 3.2A). 
Interestingly, administration of DHT (total of 5 weeks) to ovariectomized female 
apoE-/- mice also resulted in increased AT1aR mRNA abundance in abdominal 
but not thoracic aortas (Figure 3.2B). 
 
3.4.2. Androgen Fails to Regulate Aortic AT1bR Expression in ApoE-/- Mice 
To determine whether androgen regulation of AT1 receptors was 
restricted to the AT1aR subtype, we examined AT1b mRNA abundance in 
thoracic and abdominal aortas from male and female mice in each group. AT1bR 
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mRNA abundance was greater in abdominal compared to thoracic aortas from 
male and female ApoE-/- mice, with similar expression levels in aortas from male 
and female mice (Figure 3.3). In addition, AT1bR mRNA abundance in 
abdominal aortas was not altered by castration or by DHT administration to 
castrated male or female ApoE-/- mice (Figure 3.3).  Despite the presence of 
both AT1aR and AT1bR in aortas, aortic AT1bR has been demonstrated to be 
primarily responsible for AngII-mediated contractile responses of abdominal 
aortas (Zhou, Dirksen et al. 2005; Swafford, Harrison-Bernard et al. 2007).  We 
defined the contractile response to Ang II in aortic rings from thoracic versus 
abdominal aortas of male and female ApoE-/- mice. In agreement to previous 
findings (Zhou, Dirksen et al. 2003), The contractile response to Ang II was 
greater in abdominal than thoracic aortas from male and female ApoE-/- mice 
and was of similar magnitude in aortas from male and female mice (Figure 3.4). 
Moreover, there was no difference in Ang II–induced contractile responses in 
castrated (5 weeks) male or female mice or in mice administered DHT (5 weeks) 
(Figure 3.4). 
 
3.4.3. Androgen enhances SMC AT1aR Expression to promote AngII-induced 
AAAs in Female Hyperlipidemic Mice 
We examined effects of testosterone on AT1aR mRNA abundance using 
primary cultures of mouse aortic smooth muscle cells.  Incubation of mouse 
aortic smooth muscle cells with testosterone significantly increased AT1aR 
mRNA abundance, implicating smooth muscle cells as targets of androgen to 
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increase aortic AT1aR mRNA abundance (Figure 3.6).  Previous studies 
demonstrated that administration of DHT to adult female ApoE-/- mice increased 
AngII-induced AAAs, but had no effect on atherosclerosis (Henriques, Zhang et 
al. 2008).  Therefore, we first investigated the role of SMC AT1aR in DHT-
mediated promotion of AngII-induced AAAs and atherosclerosis in adult female 
LDLR-/- mice.   
We used Cre-LoxP technology to generate mice with deficiency of AT1aR 
in smooth muscle cells.  Mice were engineered with loxP sites flanking exon 3 of 
AT1aR which includes the entire coding region for the receptor protein (Figure 
3.7A).  AT1aRfl/fl females on an LDLR-/- background were mated to male mice 
expressing Cre recombinase under the control of an SM22 promoter to generate 
smooth muscle AT1aR deficient mice (Kuhbandner, Brummer et al. 2000; 
Holtwick, Gotthardt et al. 2002) and littermate controls (AT1aRfl/fl). Depletion of 
AT1aR exon 3 from smooth muscle cells was verified by PCR of genomic DNA 
from aortas (Figure 3.7B).  Female AT1aRfl/fl and AT1aRSM22 KO mice were 
administered DHT at 2 months of age beginning 2 weeks before AngII infusion. 
Consistent with previous findings (Henriques, Zhang et al. 2008), administration 
of DHT to adult AT1aRfl/fl female mice resulted in robust AngII-induced AAAs 
(Figure 3.7A; AAA incidence, 87%).  In contrast, AT1aRSM22 KO females 
exhibited significantly reduced AAA formation (AAA incidence, 50%; P<0.05), 
abdominal aortic lumen diameters (Figure 3.8A) and maximal aortic diameters of 
suprarenal aortas (1.90 ± 0.22 vs. 1.35 ± 0.14 mm; P<0.05) (Figure 3.8B).  In 
addition, aneurismal rupture in adult DHT-treated females was decreased by 
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AT1aRSM22 KO (WT, 40%; SMC AT1aR KO, 13%; Figure 3.7B).  In contrast, 
smooth muscle AT1aR deficiency had no effect on aortic arch atherosclerotic 
lesion sizes or ascending aortic dilation in DHT-treated females (Figure 3.9).  
These results indicate an important role for smooth muscle AT1aR in androgen-
mediated promotion of AngII-induced AAAs in adult female mice.   
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3.5 Discussion 
Results from this study demonstrate that male, but not female ApoE-/- 
mice, exhibit regional differences in AT1aR mRNA abundance in aortas, with 
greater receptor expression in abdominal compared to thoracic aortas.  
Moreover, castration of male ApoE mice resulted in a specific reduction in AT1aR 
mRNA abundance in abdominal aortas, which was restored by DHT 
administration.  Interestingly, DHT also increased AT1aR mRNA abundance in 
abdominal aortas from female ApoE-/- mice.  These effects of androgen to 
promote AT1aR mRNA abundance specifically in abdominal aortas were 
associated with increased AAA incidence and severity in both male and female 
castrated ApoE-/- mice.   
The effect of androgen on AT1 receptor expression has been relatively 
unexplored.  In rat epididymis, castration reduced AT1 receptor protein, that was 
restored when rats were treated with testosterone (Leung, Wong et al. 2002). 
Moreover, androgen was reported to increase AngII receptors in bovine adrenal 
glomerulosa cells (Carroll and Goodfriend 1984).  In contrast neither castration 
alone or combined with androgen administration regulated AT1 receptor mRNA 
abundance in homogenates of renal cortex punches from male New Zealand 
genetically hypertensive rats (Song, Kost et al. 2006). In addition, incubation of 
androgen-dependent human prostate cancer cells with DHT increased AT1 
receptor mRNA and protein (Uemura, Hasumi et al. 2006), supporting androgen 
regulation of human AT1 receptors. Our results demonstrate a specific effect of 
androgen to regulate AT1aR mRNA abundance in abdominal, but not thoracic 
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aortas.  Taken together, these results suggest that androgen exhibits tissue 
and/or cell-specific regulation of AT1 receptors.  Interestingly, recent studies 
demonstrated that smooth muscle cells of the ascending and arch portions of the 
aorta are derived from murine neural crest, while smooth muscle cells of the 
abdominal aorta are derived predominately from mesenchymal cells in 
splanchnic mesoderm (Majesky 2007). It has been demonstrated that these 
mesenchymal cells during development exhibits androgen receptor (AR) activity 
(Cunha, Shannon et al. 1981; Majesky 2007; Wasteson, Johansson et al. 2008). 
Interestingly, we also demonstrate that AR mRNA abundance is greater in 
abdominal aortas compared to in thoracic aortas in both male and female ApoE-
/- mice (Figure 3.5). This specific regional expression pattern of AR correlates 
with highly selective upregulation of abdominal aortic AT1aR by androgen in 
adult ApoE-/- mice. Overall, these results suggest that the differences in smooth 
muscle embryonic origins along the length of the aorta may have contributed to 
regional differences in AT1aR regulation by androgen.   
Previous investigators have demonstrated greater AngII-induced 
contractile responses in abdominal compared to thoracic aortic ring segments 
from male C57BL/6 mice (Zhou, Dirksen et al. 2003). Further studies 
demonstrated a prominent role for AT1b receptors in AngII-induced contractile 
responses  (Zhou, Chen et al. 2003; Swafford, Harrison-Bernard et al. 2007). Our 
results extend these findings by demonstrating greater AT1aR mRNA abundance 
in abdominal aortas from male, but not female mice. To define whether androgen 
effects were restricted to the AT1aR subtype, we measured AT1bR mRNA 
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abundance, and the contractile response to AngII as an index of AT1b receptor 
function. While the contractile response to AngII exhibited a similar regional 
specificity to the abdominal aorta of male and female ApoE-/- mice, AngII-
induced contraction was not regulated by androgen, nor was AT1bR mRNA 
abundance.  These results demonstrate that androgen specifically regulates 
aortic AT1a receptors.  Given that AT1a and AT1b receptor subtypes exhibit 
differential cell and tissue distribution, differences in the promoters of these 
distinct genes may contribute to androgen-specific effects to increase AT1aR 
mRNA abundance.  
Vascular SMC plays an essential role in AAA pathogenesis. Previous 
results implicated medial elastin degradation as an early event in AAA formation 
in adult male ApoE-/- mice (Saraff, Babamusta et al. 2003). Apoptosis of smooth 
muscle has been found to contribute to AngII-induced AAAs, since administration 
of a caspase inhibitor reduced medial apoptosis and significantly decreased AAA 
formation (Yamanouchi, Morgan et al.).  Moreover, genetic deficiency of 
cyclophilin A, a chaperone protein abundantly expressed in smooth muscle cells, 
abolished AngII-induced AAAs (Satoh, Nigro et al. 2009).   Our results 
demonstrate that testosterone increases AT1aR mRNA expression in primary 
cultured mouse aortic smooth muscle cells.  Moreover, deficiency of AT1aR in 
smooth muscle decreased effects of exogenous androgen to promote AngII-
induced AAAs in adult female mice, but had no effect on atherosclerosis or 
ascending aortic dilation induced by infusion of AngII.  Interestingly, in this study, 
AAAs that did form in female mice with smooth muscle cell AT1aR deficiency had 
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similar pathologic characteristics to those of wild type controls.  Thus, as 
opposed to downstream signaling pathways, androgen may influence initiating 
events in the formation of AngII-induced AAAs by promoting AT1aR expression 
in pivotal cell types, including vascular smooth muscle cells.  In conclusion, these 
data suggest that promotion of these AngII/AT1aR-mediated effects in smooth 
muscle cells contribute to enhanced AAA formation in adult female mice exposed 
to exogenous androgen.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Xuan Zhang 2011 
94 
 
Table 3.1 PCR primers and conditions used for AT1aRfl/fl and AT1aRSM22 KO 
mice genotyping. 
Gene 
screened 
Primers 
Product 
size 
PCR anealing 
temperature 
Cre 
transgene 
5'-CTAGGCCACAGAATTGAAAGATCT  
182 bp 57.5ºC 
5'-AGTAGGTGGAAATTCTAGCATCATCC 
IL-2 
5'-ACCTGAAGATGTTCGCGATT 
324 bp 57.5ºC 
5'-CGGCATCAACGTTTTCTTTT 
Floxed 
AT1aR  
5'-TGTTGCATCTACATCCTG 
262 bp 53ºC 
5'-TCTAAAGAAACCTCATGAAC 
Excised 
AT1aR 
5'-TGTTGCATCTACATCCTG 
531 bp 53ºC 
5'-TGTTTGGGGGTTTTTGTTGT 
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Group Gender Number Surgery Treatment 
1 Male 13 No No 
2 Male 9 
Orchiectomy 
1 week placebo 
3 Male 10 1 week DHT 
4 Male 12 5 week placebo 
5 Male 12 5 week DHT 
6 Female 7 
Ovariectomy 
5 week placebo 
7 Female 8 5 week DHT 
 
 
 
 
 
 
 
Figure 3.1 Schematic representations of the experimental groups and study 
design as described in the methods section. 
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Figure 3.2 DHT augments AT1aR mRNA abundance in abdominal aortas from 
male and female ApoE-/- mice. A, In males, AT1aR mRNA abundance was 
greater in abdominal than thoracic aortas. Castration decreased, whereas DHT 
restored AT1aR mRNA abundance in abdominal aortas. B, In females, DHT 
increased AT1aR mRNA abundance in abdominal aortas. Data are mean ± SEM. 
* P<0.05 compared to thoracic; **P<0.01compared to intact. 
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Figure 3.3 AT1bR mRNA abundance in abdominal and thoracic aortas from male 
(A) and female (B) ApoE-/- mice was not altered by castration (1 or 5 weeks), or 
by DHT administration (1 or 5 weeks). However, AT1bR mRNA abundance was 
greater in abdominal compared to thoracic aortas from male and female mice, 
and was similarly expressed in aortic regions from male compared to female 
mice. * P<0.01 compared to thoracic aortas within treatment group. 
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Figure 3.4 Contractile responses of aortic (thoracic and abdominal) rings to AngII 
(1 μM, as a % of the KCl response) in male (A) and female (B) mice was not 
altered by castration, or by DHT administration. However, AngII-induced 
contraction was greater in abdominal compared to thoracic aortas, and was 
similar between male and female ApoE-/- mice. * P<0.01 compared to thoracic 
aortas within treatment group. 
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Figure 3.5 Androgen receptor (AR) mRNA abundance was greater in abdominal 
compared to thoracic aortas both male (A) and female (B) ApoE-/- mice. * P<0.01 
compared to thoracic aortas within treatment group. **P<0.05 compared to 
ovariectomy. 
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Figure 3.6 AT1aR mRNA abundance in mouse aortic smooth muscle cells was 
increased by testosterone (10 nM; 24 hours of incubation).  All results represent 
3 replicates with each treatment performed in triplicate. *, P < 0.05 compared to 
DMSO vehicle control.
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Figure 3.7 Generation (A) and DNA genotyping (B) of smooth muscle AT1aR 
deficient LDLR-/- mice. (A) Gene map of partial AT1aR gene locus, floxed AT1aR 
allele and SM22-Cre driven deletion allele. (B) PCR reactions were performed 
with DNA samples extracted from aortic smooth muscle cells.  Left, PCR for IL-2 
was used to control for DNA loading, and primers for Cre were used to identify 
Cre1/0 mice.  Right, in mice expressing the Cre transgene (Cre 1/0), exon 3 of 
AT1aR was deleted as demonstrated by the presence of a 531bp DNA product 
(AT1aRSM22 KO) and the disappearance of 262bp DNA product (AT1aRfl/fl). 
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Figure 3.8 SMC AT1aR deficiency reduces AAAs in adult female mice 
administered DHT and infused with AngII. (A) AAA incidence in AT1aRfl/fl  or 
AT1aRSM22 KO female mice.  (B) Survival curves for AT1aRfl/fl  or AT1aRSM22 KO 
female mice.  *, P<0.05 compared to AT1aRfl/fl . 
 
103 
 
0 7 14 28
0.5
1.0
1.5
2.0
2.5 AT1aRfl/fl
AT1aRSM22KO
Time (days)
A
bd
om
in
al
 a
or
tic
lu
m
en
 d
ia
m
et
er
 (m
m
)
* * 
* 
                                 A 
 
 
 
 
 
 
 
                       
                           B 
 
 
 
 
 
 
 
 
 
Figure 3.9 SMC AT1aR deficiency decreases abdominal aortic lumen diameters 
(A) and maximal external abdominal diameters (B) in adult female mice 
administered DHT and infused with AngII. Triangles are individual mice with 
circles representing mean ± SEM. *, P<0.05 compared to AT1aRfl/fl . 
 
   
   
M
ax
im
al
 e
xt
er
na
l 
ab
do
m
in
al
 d
ia
m
et
er
 (m
m
)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
AT1aRfl/fl AT1aRSM22KO
* 
104 
 
Figure 3.10 SMC AT1aR deficiency has no effect on AngII-induced 
atherosclerosis in aortic arch or ascending aortic dilation. (A) Atherosclerotic 
lesion sizes in aortic arch of mice from each genotype. (B) Aortic arch areas, 
dictating ascending aortic dilation, from each genotype. Triangles are individual 
mice with circles representing mean ± SEM. 
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CHAPTER IV. SPECIFIC AIM 3 
 
Determine the effect of androgen administration in neonatal female mice 
on aortic smooth muscle angiotensin receptor type 1a expression and 
angiotensin II-induced AAA formation in adulthood. 
 
4.1 Summary 
Our previous studies have demonstrated that androgen promotes AAA 
pathology in adult males through upregulation of AT1aR in abdominal aortas.  
Mechanisms for regulation of AT1aR in abdominal aortas by testosterone are 
unclear, but may relate to developmental effects on vascular wall cells.  Thus, we 
sought to determine if administration of testosterone to neonatal female 
apolipoprotein E (ApoE) -/- or LDL receptor (LDLR)-/- mice confers adult 
susceptibility to AngII-induced AAAs.   
One day old female mice were administered testosterone and AngII-
induced vascular diseases were defined in adult females.  Neonatal exposure to 
testosterone increased aortic AT1aR expression and promoted a striking 
increase in AngII-induced atherosclerosis, ascending aortic aneurysm and AAA 
(20% vs 64%; P<0.05) in adult female hyperlipidemic mice.  These effects were 
independent of a requirement for circulating testosterone.  Deficiency of AT1aR 
in smooth muscle cells reduced effects of neonatal or adult testosterone to 
promote AAAs in adult females, but did not alter atherosclerosis or aortic arch 
aneurysms.   These data define a previously unrecognized role of sex hormone 
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exposures during development to confer enhanced susceptibility to distinct 
vascular diseases. 
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4.2 Introduction 
Pioneering studies by Barker et al initiated the concept that exposure to 
environmental stimuli, including sex hormones, during critical periods of 
development influence disease susceptibility in adult life. It is well established 
that several types of cardiovascular diseases exhibit sex differences, typically 
with enhanced disease development in males compared to females.  Sex 
hormone influences have been demonstrated to contribute to sex differences 
between adult males and females, most commonly studied in the context of loss 
of female sex hormones during menopause as a contributor to higher 
cardiovascular disease development in aging females.  By comparison, 
influences of sex hormone exposure during development on cardiovascular 
disease susceptibility in later life remains poorly defined.    
Previous studies in our laboratories demonstrated that chronic AngII 
infusion in hypercholesterolemic male mice increases atherosclerosis and 
induces formation of aneurysms in the ascending and suprarenal aorta 
(Daugherty and Cassis 1999; Daugherty, Manning et al. 2000; Daugherty, Rateri 
et al. 2010).  These AngII-induced vascular pathologies are mediated through 
angiotensin type 1a receptors (AT1aR) (Daugherty, Rateri et al. 2004; Cassis, 
Rateri et al. 2007).  Interestingly, despite being induced by infusion of the same 
peptide, only AAAs exhibit marked sex differences with higher prevalence (4-fold) 
in male compared to female mice (Daugherty and Cassis 1999; Daugherty, 
Manning et al. 2000; Manning, Cassis et al. 2002; Henriques, Huang et al. 2004). 
Testosterone was found to be the primary mediator of higher AAA prevalence in 
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adult AngII-infused male mice (Henriques, Huang et al. 2004; Henriques, Zhang 
et al. 2008).  As a mechanistic target of testosterone to promote AngII-induced 
AAAs, AT1aR mRNA abundance was greater in abdominal compared to thoracic 
aortas of male, but not female mice, and this regional difference was abolished 
by orchiectomy and restored in castrated males by androgen administration 
(Henriques, Zhang et al. 2008).   
Vascular wall cells along the aortic length derive from different embryonic 
origins that exhibit distinct sensitivity to testosterone during development (Cunha, 
Shannon et al. 1981; Majesky 2007; Wasteson, Johansson et al. 2008).  For 
example, smooth muscle of the abdominal aorta, where AT1aR expression is 
pronounced in males, derives from mesenchymal cell origin, and this embryonic 
cell type exhibits androgen receptor (AR) activity (Cunha, Shannon et al. 1981; 
Majesky 2007; Wasteson, Johansson et al. 2008).  It is unclear whether AR 
stimulation of mesenchymal cells during developmental testosterone surges 
contributes to regional differences in AT1aR expression in aortas of adult males 
and impacts AAA susceptibility.  Exposure of females during the neonatal period 
to testosterone has been used previously to induce male-like, or androgenized, 
behaviors (Pfaff and Zigmond 1971; Hrabovszky and Hutson 2002; Wallen 
2005).  This method, which imposes upon females exposure to testosterone 
shortly after birth, mimics developmental effects of androgen in males during the 
neonatal period (Motelica-Heino, Castanier et al. 1988; Corbier, Edwards et al. 
1992).  In this study, we sought to define effects of exposure of neonatal females 
to testosterone on regional expression of aortic AT1aR and susceptibility to 
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AngII-induced vascular diseases as adults.  Remarkably, we found that exposure 
of neonatal female mice to a single dose of testosterone increased AT1aR 
mRNA abundance specifically in abdominal aortas of adult females.  In addition, 
females exposed to testosterone as neonates exhibited a striking increase in 
adult susceptibility to AngII-induced AAAs, atherosclerosis and ascending aortic 
aneurysm.  Deficiency of AT1aR in smooth muscle cells reduced effects of 
neonatal testosterone to promote AngII-induced AAAs in adult females, but had 
no effect on atherosclerosis or ascending aortic aneurysm.   Our findings indicate 
that during a critical period of neonatal development transient exposure to 
testosterone in females is capable of developmentally programming enhanced 
susceptibility to three different AngII-induced vascular pathologies through 
distinct mechanisms.  
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4.3 Methods 
4.3.1 Aminals 
Female ApoE-/- and LDLR-/- mice (N10 C57BL/6 background) were bred 
to males in house.  Within 24 hours of birth, female mice were injected once with 
either vehicle (corn oil) or testosterone propionate (400 µg/mouse, s.c., Sigma 
Aldrich, St. Louis, MO). At 3 months of age, female ApoE-/- and LDLR-/- mice 
were sacrificed for aortic gene expression analysis.  Age-matched ApoE-/- 
females were infused with saline or AngII (500, 750 or 1,000ng/kg/min, Bachem, 
Torrance, CA) by osmotic pumps (Alzet, model 1004, Durect Co., Cupertino, CA) 
for 4 weeks.  Female ApoE-/- and LDLR-/- mice were maintained on standard 
diet through the study.  
AT1aRSM22 KO and littermate controls AT1aRfl/fl mice were generated and 
bred as previously described. Within 24 hours of birth, female AT1aRfl/fl and 
AT1aRSM22 KO mice were injected once with either vehicle (corn oil) or 
testosterone propionate (400 µg/mouse, s.c.). At 3 months of age, females were 
infused with saline or AngII (1,000ng/kg/min, Bachem, Torrance, CA) by osmotic 
pumps for 4 weeks as previously described.  The mice were fed a high fat diet 
containing 21% milk fat and 0.2% cholesterol (TD88137, Harlan Teklad, 
Indianapolis, IN) 1 week prior to pump implantation and through study endpoint. 
All experiments were performed in accordance with the University of Kentucky 
Institutional Animal Care and Use Committee. 
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4.3.2 Measurement of systolic blood pressure   
Systolic blood pressures were measured one week prior to osmotic mini 
pump implantation and during the third week of AngII infusion using a 
noninvasive tail-cuff system (BP-2000 Blood Pressure Analysis System, Visitech 
Systems). 
 
4.3.3 Quantification of Atherosclerosis, AAA and Ascending Aortic Aneurysm 
Atherosclerotic lesions were quantified in the aortic arch and root as 
described previously. Aortic roots from representative samples (n=5/group) were 
sectioned and immunostained for CD68 (5 μg/mL; rat monoclonal ab53444, 
Abcam, Cambridge MA).   AAA incidence was quantified by 3 independent 
observers blinded to the experimental design as described previously (Daugherty 
and Cassis 1999; Daugherty, Manning et al. 2000). Abdominal aortic lumen 
diameter measurements were made on anesthetized mice using high-resolution 
ultrasound (Visualsonics, Vevo 660) at baseline, day 7, day 14 and day 28 of 
AngII infusion. Maximal diameters of abdominal aortas were measured on 
cleaned, formalin-fixed aortas by ImagePro Plus software (Media Cybernetics). 
AAAs were defined as > 50% dilation of lumen diameters from saline-infused 
mice.   
The extent of ascending aortic dilation as an index of aortic arch 
aneurysms was quantified by measuring aortic arch intimal areas (to 3 mm distal 
to the subclavian branch) and ascending aortic diameters (Daugherty, Rateri et al. 
2010). Representative ascending aortic aneurysms (n=4-5/group) were sectioned 
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and stained with H&E, and macrophages (Accurate Chemical, catalog No. 
AIAD31240, dilution 1:1000).  Stained sections were magnified and 
photographed using a Nikon Eclipse 80i microscope and digital camera. Medial 
thickness was measured on H&E stained sections. 
 
4.3.4 Aneurismal Tissue Characterization 
To compare AAAs between different groups, three suprarenal aortas 
(closest to the mean external diameter of each group) were chosen for vascular 
characterization.  Briefly, cleaned, formalin-fixed aortas were injected with 
Tissue-Tek® O.C.T. (Optimal Cutting Temperature) compound (Ted Pella, Inc., 
Redding, CA).  The suprarenal aorta segment containing AAA was embedded in 
O.C.T. compound and serially sectioned using a cryostat as previously 
describled (Police, Putnam et al. 2010). Sections were fixed with absolute alcohol 
and stained with hematoxylin and eosin (H&E), and Movat’s staining for vascular 
characterization. 
 
4.3.5 Blood Analysis   
Blood was obtained from the right ventricle of anesthetized mice 
(ketamine/xylazine, 100/10 mg/kg, ip) for measurement of monocyte and red 
blood cell counts (Hemavet, Drew Scientific Group, Dallas, TX).  Total serum 
cholesterol concentrations were measured from individual mice using enzymatic 
assay kits (Wako Pure Chemical, Catalog No. 439-17501). Serum samples (50 ul; 
n = 5) were fractionated by size exclusion chromatography (Daugherty, Manning 
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et al. 2000), and cholesterol concentrations determined using enzymatic kits.  
Serum testosterone concentrations and plasma aldosterone concentrations were 
determined using commercial RIA DSL-4000 and RIA DSL-8600 kits, 
respectively (Diagnostic Systems, Inc.). 
 
4.3.6 Aortic gene quantification by Real Time PCR   
Thoracic (aortic arch to diaphragm) and abdominal aortas (diaphragm to 
ileal bifurcation) were harvested from age-matched adult female mice.  Aorta 
samples were stored in RNA Later (Ambion, Austin, TX) and cleaned of all 
adherent tissue.  Total RNA was extracted using Rneasy Fibrous Minikit (Qiagen, 
Alameda, CA) (Henriques, Zhang et al. 2008). For in vitro experiments, primary 
mouse vascular smooth cells (passage 7-10) were treated with 10nM of 
testosterone propionate (Sigma Aldrich, St. Louis, MO) in 0.1% DMSO for 24 
hours.  Total RNA was extracted with Trizol (Invitrogen, Carlsbad, CA). All RNA 
samples were treated with Turbo DNA-free (Ambion, Austin, TX) to remove 
genomic DNA.  RNA quantity was assessed spectrophotometrically, and quality 
was evaluated using a Bio-Rad Experion Automated Electrophoresis System 
(Bio-Rad, Hercules, CA). Mouse AT1aR primers were obtained from Qiagen 
(Alameda, CA). Relative quantification of aortic AT1aR mRNA abundance was 
performed using a BioRad iCycler (BioRad, Hercules, CA) (Henriques, Zhang et 
al. 2008). 18S rRNA was used to normalize for loading and data are expressed 
as AT1aR/18S ratios. 
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Customized PCR arrays were obtained from SABioscience (Frederick, MD) 
to test 43 genes that have been recently reported to differentially expressed in 
the between AAA-prone and non AAA-prone aortic segments in male ApoE-/- 
mice (Rush, Nyara et al. 2009). After total RNA samples were extracted from 
thoracic and abdominal aortas, reverse transcription and subsequent PCR 
reactions were performed using RT² First Strand Kit and RT² qPCR Master Mixes 
respectively, based on manufacturer recommendation (SABioscience, Frederick, 
MD).  
 
4.3.7 Statistical Analysis 
Data are represented as mean ± SEM. Comparison of AAA incidence 
between groups was analyzed using Fisher’s exact test. Unpaired student’s t test 
was used to compare parametric data on two groups. Multiple groups were 
analyzed with 2-way ANOVA followed by Tukey’s test for more than two groups.  
Analyses were performed using Sigmastat.  Statistical significance was defined 
as P<0.05.  
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4.4 Results 
4.4.1 Neonatal testosterone exposure developmentally programs increased 
AT1aR expression in abdominal aortas from adult female hyperlipidemic 
mice 
Previous results demonstrated a requirement for AT1aR in AngII-induced 
atherosclerosis and AAA formation in adult male mice (Daugherty, Rateri et al. 
2004; Cassis, Rateri et al. 2007).  Recent studies demonstrated greater AT1aR 
mRNA abundance in abdominal compared to thoracic aortas of male, but not 
female ApoE-/- mice (Henriques, Zhang et al. 2008).  Moreover, androgen-
mediated regulation of AT1aR mRNA abundance in abdominal aortas of male 
and female ApoE-/- mice paralleled susceptibility to AngII-induced AAAs 
(Henriques, Zhang et al. 2008).  Therefore, we determined if testosterone 
administration to neonatal females imparted regional differences in AT1aR 
expression along the aortic length in adult females.  We examined two 
hypercholesterolemic strains of female mice to determine if background genetics 
influenced developmental effects of testosterone.  As reported previously 
(Henriques, Zhang et al. 2008), adult female ApoE-/- or LDLR-/- mice 
administered vehicle as neonates exhibited a similar AT1aR mRNA abundance 
in thoracic compared to abdominal aortas (Figure 4.1).  In contrast, 
administration of testosterone to neonatal females increased AT1aR mRNA 
abundance in abdominal, but not thoracic aortas of adult female mice (P<0.001) 
(Figure 4.1). Thus, similar to observed results previously in males (Henriques, 
Zhang et al. 2008), exposure of neonatal female mice to testosterone imparted 
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increased localization of AT1aR mRNA expression specifically to abdominal 
aortas of adult females.  However, unlike males, increased abundance of AT1aR 
mRNA in adult females exposed neonatally to testosterone persisted even 
though adult females exhibited low serum concentrations of testosterone (Table 
4.1). 
A recent study utilizing whole genome expression analysis has 
demonstrated that over 300 transcripts are differentially expressed between 
AAA-prone and non AAA-prone aortic segments in male ApoE-/- mice (Rush, 
Nyara et al. 2009). To test if any of these genes were regulated by neonatal 
testosterone, we selected 43 gene targets and performed PCR array analysis to 
examine their mRNA expression levels along the length of the aorta. Interestingly, 
mRNA abundance of neutrophil cytosolic factor 1 (Ncf1, a component of NADPH 
oxidase) in thoracic aortas, and aryl hydrocarbon receptor nuclear translocator-
like (Arntl) in both thoracic and abdominal aortas were significantly increased in 
adult females administered testosterone as neonates (Figure 4.14), 
 
4.4.2 Administration of testosterone to neonatal female ApoE-/- mice increases 
AngII-induced AAAs in adult females.   
Since previous studies demonstrated that AngII-induced AAAs are 
promoted by a hypercholesterolemic environment in male mice (Daugherty and 
Cassis 1999; Daugherty, Manning et al. 2000), initial studies were performed in 
hypercholesterolemic female mice.  Female ApoE-/- mice were administered a 
single dose of testosterone or vehicle within the first 24 hours after birth to mimic 
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neonatal testosterone surges in males (Motelica-Heino, Castanier et al. 1988; 
Corbier, Edwards et al. 1992), and then adult female ApoE-/- mice were infused 
with different doses of AngII.  Neonatal administration of testosterone resulted in 
a modest but significant increase in body weight in adult females but had no 
effect on serum cholesterol concentrations, blood pressure, blood monocyte 
counts (Table 4.1) or serum lipoprotein cholesterol distribution (Figure 4.5).  
Moreover, serum testosterone concentrations  were not elevated in adult female 
mice administered testosterone as neonates (Table 4.1), and were 7-fold less 
than those observed previously in adult male ApoE-/- mice (Henriques, Huang et 
al. 2004).  
Infusion of AngII to adult females administered vehicle as neonates 
resulted in modest but significant increases in abdominal aortic lumen and 
external diameters, indicative of aneurysm formation in a small percentage of 
mice (Figure 4.2-4.4).  AAA incidence, which included mice that died from 
aneurismal rupture, was increased dose-dependently by AngII in female mice 
administered vehicle as neonates, but did not rise above 20% at the highest dose 
(1,000 ng/kg/min) of AngII infusion (Figure 4.3).  Notably, adult female mice that 
were exposed to testosterone as neonates exhibited striking increases in 
abdominal aortic lumen dilation (1.29 ± 0.10 vs. 1.69 ± 0.11mm; P<0.01) and 
external diameters (1.31 ± 0.115 vs. 1.85 ± 0.16mm; P<0.01) at the highest dose 
(1,000 ng/kg/min) of AngII infusion, with pronounced aneurismal pathology 
similar to that previously observed in adult males (Manning, Cassis et al. 2002; 
Henriques, Huang et al. 2004) (Figure 4.3, 4.4).  AAA incidence was greater at 
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each dose of infused AngII in adult females administered testosterone as 
neonates compared to vehicle controls (Figure 4.2), with a 3-fold increase in AAA 
incidence at the infusion dose of 1,000 ng/kg/min of AngII (21% vs. 64%; 
P<0.05).  An increase in mortality from aneurismal rupture contributed to higher 
AAA incidences in females administered testosterone as neonates (rupture:  
vehicle, 7%; testosterone, 20%; NS).  
 
4.4.3 Neonatal testosterone exposure developmentally programs AngII-induced 
atherosclerosis and ascending aortic aneurysms in female LDLR-/- mice 
independent of smooth muscle AT1aR 
Since smooth muscle cell AT1aRs were pivotal in androgen promotion of 
AngII-induced AAAs in adult females, we determined if smooth muscle AT1aR 
deficiency influenced effects of neonatal testosterone to promote AngII-induced 
vascular pathologies in adult females.  In addition, we quantified ascending aortic 
aneurysms (Daugherty, Rateri et al. 2010) and atherosclerosis (Daugherty, 
Manning et al. 2000) as additional vascular pathologies induced by infusion of 
AngII that do not exhibit sex differences between adult males and females (21, 
unpublished observations).  Female AT1aRfl/fl  control and AT1aRSM22 KO mice 
were administered a single dose of vehicle or testosterone at 1 day of age, and 
then infused with AngII at 3 months of age.  Neonatal administration of 
testosterone, as well as smooth muscle cell AT1aR deficiency, had no effect on 
baseline systolic blood pressures, AngII-induced hypertension, plasma 
aldosterone concentrations, serum cholesterol concentrations (Table 4.2) or 
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serum lipoprotein cholesterol distributions (Figure 4.6).  Moreover, serum 
testosterone concentrations did not differ across study groups (Table 4.2).  In 
females administered vehicle as neonates, AT1aRSM22 KO had no effect on 
AngII-induced atherosclerosis in the aortic arch or aortic root (Figure 4.7).  
Interestingly, administration of testosterone to neonatal female mice resulted in 
pronounced increases in AngII-induced atherosclerosis in both AT1aRfl/fl  (11.3 ± 
1.1 vs. 16.3 ± 1.6 %; P<0.01) and AT1aRSM22 KO (10.4 ± 1.0 vs. 14.9 ± 1.5 %; 
P<0.05) adult female mice (Figure 4.7).  Lesional macrophages, as evidenced by 
quantification of CD68 immunostaining in aortic root sections from adult females, 
were increased by neonatal administration of testosterone (Figure 4.8).  
However, deficiency of AT1aR in smooth muscle cells did not influence the ability 
of neonatal testosterone administration to promote AngII-induced atherosclerosis 
(Figure 4.7, 4.8).   
In addition to promoting atherosclerosis, neonatal testosterone 
administration to female LDLR-/- mice augmented AngII-induced increases in 
ascending aortic diameters (P<0.05) (Figure 4.9A) and ascending aortic intimal 
areas (P<0.05) (Figure 4.9B), indicative of aortic arch aneurysms.  Cross 
sections from ascending aortas of female mice exposed to testosterone as 
neonates and then infused with AngII as adults exhibited medial thickening 
(P<0.001) (Figure 4.10) and aortic ulceration (P<0.05) (Figure 4.11).  
Macrophage immunostaining was prominent in media and adventitia of aortic 
arch sections from AngII-infused adult female mice administered testosterone as 
neonates (P<0.05) (Figure  4.10), similar to results previously observed in aortic 
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arches of adult male mice (Daugherty, Rateri et al. 2010).  Deficiency of AT1aR 
in smooth muscle did not influence the ability of neonatal testosterone 
administration to promote AngII-induced aneurysms in the aortic arch (Figure 
4.9-4.11). 
 
4.4.4 Smooth muscle AT1aR deficiency attenuates neonatal testosterone 
programming of AngII-induced AAAs in adult female LDLR-/- mice 
Similar to findings in ApoE-/- females exposed neonatally to testosterone, 
adult AT1aRfl/fl females administered testosterone as neonates exhibited a 
striking increase in AngII-induced AAAs (AAA incidence, 15 vs. 64 %, P<0.001; 
Maximal external abdominal aortic diameter, 0.98 ± 0.10 vs. 1.55 ± 0.09 mm, 
P<0.001) (Figure 4.12,).  Interestingly, smooth muscle cell specific AT1aR 
deficiency reduced, but did not ablate effects of neonatal testosterone to promote 
AngII-induced AAAs (AAA incidence, 64 vs. 33 %, P<0.05; Maximal external 
abdominal aortic diameter, 1.55 ± 0.09 vs. 1.22 ± 0.12 mm, P<0.05) (Figure 
4.12).  The magnitude of effect of smooth muscle AT1aR deficiency to reduce 
AngII-induced AAAs was similar between neonatal and adult females exposed to 
androgen (Figure 4.12A vs Figure 3.8).  We examined tissue characteristics of 
AAAs of equivalent sizes that formed in female mice of each genotype exposed 
to neonatal testosterone.  AAAs that formed in both groups exhibited typical 
characteristics of medial elastin degradation and pronounced thrombus in the 
adventitia (Figure 4.13).  These data demonstrate that exposure of neonatal 
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females to testosterone increases adult susceptibility of females to AngII-induced 
AAAs partially through smooth muscle cell AT1aR.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
122 
 
4.5 Discussion 
 
Our findings reveal that neonatal exposure of female mice to testosterone 
developmentally programs three distinct AngII-induced vascular pathologies, 
namely atherosclerosis, ascending arch aneurysms, and AAAs.  As a mechanism 
contributing to sex differences in AngII-induced AAAs between adult males and 
females (Manning, Cassis et al. 2002; Henriques, Huang et al. 2004), exposure 
of neonatal females to testosterone developmentally programs a regional 
increase in abdominal aortic AT1aR mRNA abundance.  To gain insights into the 
cell target of testosterone during development to increase aortic AT1aR mRNA 
abundance and enhance AngII-induced vascular pathologies, we performed 
studies in female mice lacking AT1aR in smooth muscle cells.  Smooth muscle 
deficiency of AT1aR reduced neonatal effects of testosterone to promote AngII-
induced AAAs, but had no effect on augmented atherosclerosis or aortic arch 
aneurysms.  These results demonstrate that distinct mechanisms mediate effects 
of developmental testosterone to enhance three different AngII-induced vascular 
pathologies in adult females.  These studies are the first to demonstrate that sex 
hormone exposures during development can markedly alter vascular disease 
susceptibility in adults.     
Exposure of neonatal females to testosterone, designed to mimic a surge 
of testosterone in males shortly after birth (Motelica-Heino, Castanier et al. 1988; 
Corbier, Edwards et al. 1992), has been used by several investigators to study 
sexual differentiation of the brain.  Permanent changes in brain neurons of 
females androgenized during development are considered to be “organizational”, 
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allowing for male-like behaviors that persist to adulthood (Arnold 2009).  In 
contrast to studies focused on brain, little is known about developmental effects 
of sex hormones on other traits.  We focused on effects of sex hormones during 
development on regional variations in AT1aR abundance in aortas since previous 
studies demonstrated a critical requirement of AT1aR for all three AngII-induced 
vascular pathologies (Cassis, Rateri et al. 2007; Daugherty, Rateri et al. 2010).  
Moreover, previous results demonstrated higher expression of AT1aR in 
abdominal compared to thoracic aortas of male but not female mice (Henriques, 
Zhang et al. 2008).  In this study we demonstrated that administration of 
testosterone to neonatal female mice initiated greater abdominal aortic AT1aR 
mRNA abundance and markedly enhanced AAA formation in adult females.  
Interestingly, unlike males (Henriques, Huang et al. 2004; Henriques, Zhang et 
al. 2008), exposure of neonatal females to testosterone resulted in long-lasting 
effects that persist into adulthood and did not require the continued presence of 
circulating testosterone.   Thus, similar to effects of testosterone to permanently 
influence brain behaviors (Arnold 2009), aortic AT1aR abundance and AAA 
susceptibility can be programmed developmentally by testosterone and 
sustained in adulthood with low circulating testosterone in females. 
In mice, aortic smooth muscle cells are highly heterogeneous. The 
diversity of smooth muscle cell embryonic origins has been suggested to 
contribute to region-specific aortic pathologies, including those induced by 
infusion of AngII (Majesky 2007; Tromp, Kuivaniemi et al. 2010).  For example, 
thoracic and abdominal aortic smooth muscle cells respond distinctively to 
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transforming growth factor-β (TGF-β) (Topouzis and Majesky 1996). Inhibition of 
TGF-β has a beneficial effect in a mouse model of ascending aortic aneurysms 
while TGF-β protects against aortic dissection of AngII-induced AAAs (Habashi, 
Judge et al. 2006; Wang, Ait-Oufella et al. 2010).  Our results demonstrate that 
thoracic and abdominal aortas differ in the regulation of expression of AT1aR, 
and that effects of testosterone to increase aortic AT1aR expression were 
specific to abdominal aortas.  Recent results demonstrated that infusion of AngII 
to C57BL/6 male mice resulted in hyperplasia of smooth muscle cells in the 
ascending aorta, but hypertrophy of smooth muscle in other aortic regions 
(Owens, Subramanian et al. 2010).  Interestingly, despite differences in AT1aR-
mediated regulation of vascular smooth muscle growth along the aortic length, all 
growth-related responses of aortic smooth muscle to AngII were abolished in 
AT1aR deficient mice (Owens, Subramanian et al. 2010).  Our results 
demonstrate that even though testosterone promoted a region-specific increase 
in AT1aR mRNA abundance to abdominal aortas, all three AngII-induced 
pathologies were increased in neonatal females exposed to testosterone.  While 
smooth muscle cell specific deficiency of AT1aR reduced effects of testosterone 
to promote AngII-induced AAAs, aortic arch aneurysms and atherosclerosis were 
not influenced by AT1aR on this cell type.  Moreover, our results demonstrate 
that neonatal testosterone exposure increase mRNA abundance of neutrophil 
cytosolic factor 1 (Ncf1, a component of NADPH oxidase) in thoracic aortas, and 
aryl hydrocarbon receptor nuclear translocator-like (Arntl) in both thoracic and 
abdominal aortas of adult females (Figure 4.14), indicating that multiple genes 
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can be modulated by developmental androgen in a regional specific manner. 
These results demonstrate that distinct mechanisms, regulated differentially by 
testosterone, contribute to AngII-induced initiation of these vascular pathologies.   
In contrast to AAAs, previous findings from our laboratory do not support 
sex differences in AngII-induced atherosclerosis (Henriques, Zhang et al. 2008).  
Moreover, aortic arch aneurysms occur at similar levels between adult male and 
female hyperlipidemic mice infused with AngII (unpublished observations).  Our 
results demonstrate that even though adult males and females do not exhibit 
robust sex differences in these two AngII-induced vascular pathologies, 
androgenization of females during development programmed increases in 
atherosclerosis and aortic arch aneurysms.  These results suggest that male and 
female mice differ in their response to testosterone during the neonatal period of 
development.  Unfortunately, technical difficulties preclude measurement of 
testosterone concentrations in neonatal female mice to determine if levels of 
testosterone in androgenized females are different than those normally 
experienced by neonatal males.  It is conceivable that the dose (400 µg) of 
testosterone administered to neonatal females exceeded levels experienced by 
males, resulting in increased susceptibility to pathologies that do not typically 
exhibit sex differences.  Alternatively, recent studies demonstrated that sex 
chromosomes contribute to differences in AngII-induced hypertension between 
male and female mice (Ji, Zheng et al. 2010).  An ability of neonatal testosterone 
to mediate increased AngII-induced atherosclerosis and aortic arch aneurysms in 
adult females may have arisen from sex chromosome effects.  Future studies 
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examining sex chromosome effects on AngII-induced vascular pathologies may 
reveal a role for sex chromosomes as contributors to differences in effects of 
neonatal testosterone in males compared to females. 
In conclusion, these data demonstrate that developmental 
androgenization of female mice confers increased susceptibility to AngII-induced 
AAAs, atherosclerosis and ascending aortic aneurysms as adults.  An ability of 
testosterone to developmentally program three distinct vascular pathologies in 
females indicates that short term hormonal exposures can markedly impact 
vascular disease susceptibility of adults.  Based on these findings, targeting of 
specific environmental risk factors during development may provide new insights 
into the prevention, diagnosis and treatment of these life-threatening vascular 
diseases.   
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Table 4.1  Characteristics of female ApoE-/- mice subjected to neonatal administration with either vehicle or testosterone.   
 
Group BW (g) Liver (%BW) Serum testosterone (pg/ml) WBC (K/µl) RBC (M/µl) 
Vehicle 22.0±0.4 4.63±0.08 133±9 1.92±0.37 8.01±0.38 
Testosterone 23.5±0.3* 4.95±0.08* 94±9 2.24±0.32 8.75±0.40 
Group 
Systolic blood pressure (mmHg) 
Total serum 
cholesterol 
(mg/dl) baseline 
500  
ng/kg/min 
AngII 
750  
ng/kg/min 
AngII 
1000 
ng/kg/min 
AngII 
Vehicle 123±3 130±5   148±3**   160±6** 368.1±19.5 
Testosterone 120±2 133±8   142±5**   159±8** 351.7±18.3 
 
Data are represented as mean + SEM from n = 20-25 mice/group.   
*P<0.01 compared to vehicle group. 
**P<0.001 compared to baseline measurement within treatment (vehicle, testosterone). 
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Table 4.2  Characteristics of adult female AT1aRfl/fl and AT1aRSM22 KO administered vehicle or testosterone as neonates. 
 
Data are represented as mean + SEM.  
*P<0.001 compared to vehicle group within genotype. **P<0.001 compared to baseline blood pressure.
Groups N BW(g) 
Serum 
testosterone 
(pg/ml) 
Total 
serum 
cholesterol 
(mg/dl) 
Plasma 
aldosterone 
(pg/ml) 
Systolic blood 
pressure (mmHg) 
baseline AngII 
AT1aRfl/fl + vehicle 26 24.0 ± 0.6 185±28 1412 ± 136 739 ± 131 121 ± 4 154 ± 8** 
AT1aRSM22 KO + vehicle 22 24.4 ± 0.4 142±16 1456 ± 181 601 ± 123 112 ± 5 150 ± 8** 
AT1aRfl/fl + testosterone 33 26.6 ± 0.6* 155±15 1424 ± 119 548 ± 125 115 ± 3 156 ± 4** 
AT1aRSM22 KO + testosterone 18 27.0 ± 0.7* 130±20 1414 ± 147 456 ± 77 116 ± 6 153 ± 8** 
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Figure 4.1 AT1aR mRNA abundance in adult female ApoE-/- mice (A) (n = 8-
10/group) and LDLR-/- mice (B) (n = 5-6/group) administered testosterone as 
neonates.   *, P < 0.001 compared to vehicle group within aortic region; **, 
P<0.001 compared to thoracic within treatment. 
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Figure 4.2 Neonatal testosterone administration significantly increases AngII-
induced AAAs in adult female ApoE-/- mice. (A) Representative aortas from each 
AngII-infused group; scale bar, 2 mm. (B) AAA incidences in mice infused with 
500, 750 or 1000 ng/kg/min AngII (n=14-25/group). *, P<0.05 compared to 500 
ng/kg/min AngII infused group within testosterone treatment; **, P<0.05 
compared to vehicle within 1000 ng/kg/min AngII-infused group.  
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Figure 4.3 Neonatal testosterone administration significantly increases abdominal 
aortic lumen diameters in adult female ApoE-/- mice infused with 500, 750 or 
1000 ng/kg/min AngII (n=14-25/group). *, P<0.05 compared to 500 ng/kg/min 
AngII infused group within treatment; †, P<0.05 compared to 750 ng/kg/min AngII 
infused group within testosterone treatment; **, P<0.05 compared to vehicle 
within 1000 ng/kg/min AngII-infused group. Triangles represent measurements 
from individual mice, circles represent mean ±SEM. 
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Figure 4.4 Neonatal testosterone administration significantly increases maximal 
external diameters of the abdominal aortas in adult female ApoE-/- mice infused 
with 500, 750 or 1000 ng/kg/min AngII (n=14-25/group). *, P<0.05 compared to 
500 ng/kg/min AngII infused group within treatment; **, P<0.01 compared to 
vehicle within 1000 ng/kg/min AngII-infused group. Triangles represent 
measurements from individual mice, circles represent mean ±SEM. 
 
vehicle testosterone vehicle testosterone vehicle testosterone
M
ax
im
al
 e
xt
er
na
l a
bd
om
in
al
 d
ia
m
et
er
 (m
m
)
0.5
1.0
1.5
2.0
2.5
3.0
3.5
500 ng/kg/min AngII 750 ng/kg/min AngII 1000 ng/kg/min AngII
*,**
133 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Serum lipoprotein cholesterol distributions in AngII-infused female 
ApoE-/- mice administered with either vehicle or testosterone as neonates. 
Neonatal testosterone administration does not alter lipoprotein profiles in adult 
female mice. Data are the mean ± SEM of 5 individual mice per group. 
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Figure 4.6 Serum lipoprotein cholesterol distribution in AngII-infused female wild 
type and SMC AT1aR deficient mice administered with either vehicle or 
testosterone as neonates. Neither neonatal testosterone administration nor SMC 
AT1aR deficiency altered lipoprotein profiles in adult female mice. Data are the 
mean ± SEM of 5 individual mice per group. 
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Figure 4.7 Neonatal testosterone administration increases AngII-induced 
atherosclerosis in adult AT1aRfl/fl and AT1aRSM22 KO female LDLR-/- mice. (A) 
Atherosclerotic lesion formation (% intimal surface area) in the aortic arch. 
*P<0.05 compared to vehicle group within genotype. (B)  Quantification of 
atherosclerotic lesions stained with Oil Red O in aortic root sections. *, P<0.05 
compared to vehicle within genotype. 
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Figure 4.8 Neonatal testosterone administration increases macrophage 
accumulation in aortic root atherosclerotic lesions from adult AT1aRfl/fl and 
AT1aRSM22 KO female LDLR-/- mice. (A) Representative aortic root sections 
stained with oil red O (top) and CD68 (bottom). (B) Quantification of CD68 
positive staining as measurement of macrophages in aortic root atherosclerotic 
lesions. *, P<0.05 compared to vehicle within genotype.  
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Figure 4.9 Neonatal testosterone administration increases AngII-induced 
ascending aortic aneurysms in adult AT1aR
fl/fl 
and AT1aR
SM22 
KO female LDLR-/- 
mice.  (A) Ascending aortic diameters as an index of ascending aortic 
aneurysms. *, P<0.001 compared to vehicle group within genotype. (B) Aortic 
arch areas. *, P<0.05 compared to vehicle within genotype. Circles and triangles 
(A,B) represent individual mice, diamonds are means ±SEM. 
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Figure 4.10 Neonatal testosterone administration increases AngII-induced 
ascending aortic pathologies in adult AT1aR
fl/fl 
and AT1aR
SM22 
KO female LDLR-/- 
mice. (A) Cross sections of ascending aortas were stained with H&E (top), or for 
macrophages (bottom). The orientation of aortic sections is described by L, 
lumen; M, media; A, adventitia. Magnification, X200.  (B) Medial thickness of 
aortic arch sections (n=5-6/group). *, P<0.001 compared to vehicle within 
genotype.  
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Figure 4.11 Neonatal testosterone administration increases ascending aortic 
ulceration in adult AT1aR
fl/fl 
and AT1aR
SM22 
KO female LDLR-/- mice. (A) 
Representative example of aortic ulceration in ascending aorta. Scale bar, 1 mm. 
(B) The incidence of ascending aortic ulceration from each group. *, P<0.05 
compared to vehicle within genotype. 
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Figure 4.12 Smooth muscle AT1aR deficiency reduces AngII-induced AAAs in 
adult female mice administered testosterone as neonates. (A) AAA incidence.  
(B) Maximal external diameters of abdominal aortas.  Circles and triangles 
represent individual mice, diamonds are means ±SEM. *P<0.001 compared to 
vehicle group within genotype; **P<0.05 compared to WT within treatment. 
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Figure 4.13 Cross sections of AngII-induced AAA from AT1aRfl/fl and AT1aRSM22 
KO mice administered testosterone as neonates.  Top, H&E sections; 
Magnification, X40.  Bottom, Movat’s stain for elastin (black), collagen (yellow) 
and smooth muscle (red); Magnification, X200. 
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Figure 4.14 Aortic genes were differentially regulated by neonatal testosterone 
exposure in adult female LDLR-/- mice. (A) Ncf1, encoding the cystic unit 
p47phox of NADPH oxidase, was significantly increased by neonatal 
testosterone in thoracic, not abdominal aortas. N=3/each group. * P<0.01 
compared to thoracic within treatment; **, P<0.05 compared to vehicle within 
aortic region.  (B) Arntl was upregulated in both thoracic and abdominal aortas. 
N=3/each group. **, P<0.01 compared to vehicle within aortic region.   
 
 
 
 
 
143 
 
CHAPTER V. GENERAL DISCUSSION 
 
5.1      Summary 
The purpose of this study is to examine the hypothesis that androgen 
promotes AT1aR expression on SMC to confer high prevalence of AngII-induced 
AAAs in hyperlipidemic mice. In addition, we also investigate the role of 
endogenous androgen in the progression of established AngII-induced AAAs in 
male mice. 
First, we sought to examine the role of endogenous androgen in the 
growth of established AngII-induced AAAs in male mice. Since previous studies 
demonstrated that removal of endogenous androgen markedly reduced AAA 
formation in male mice (Henriques, Huang et al. 2004), we hypothesized that 
removal of endogenous androgen would also decrease the progressive 
expansion of established AAAs. Interestingly, castration significantly decreased 
the progressive lumen dilation of established AngII-induced AAAs in male ApoE-
/- mice, but had no effect on external AAA diameters. These results suggest that 
androgen contributes to the progression of established AAAs through distinct 
mechanisms that differentially influence aortic lumen and wall diameters. 
Next, we investigated if androgen regulates aortic AT1aR expression to 
promote AngII-induced AAA formation. We hypothesized that androgen promotes 
AT1aR expression on SMC to confer higher susceptibility of AngII-induced AAAs 
in male mice. Our data demonstrated that in male and female mice, both 
endogenous and exogenous androgen stimulate AT1aR level particularly in 
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abdominal aortas where AngII-induced AAAs are usually located. This androgen-
dependent enhanced mRNA abundance of abdominal aortic AT1aR was highly 
associated with increased AngII-induced AAA formation in male and female 
mice. To further examine if AT1aR on SMC were regulated by androgen to 
confer high prevalence of AngII-induced AAA formation in mice, we utilized mice 
with SMC specific AT1aR deficiency to determine the role of SMC AT1aR in 
enhanced AngII-induced AAA formation in female hyperlipidemic mice 
administered exogenous androgen. SMC AT1aR deficiency significantly reduced 
luminal and external diameters of abdominal aortas as well as the incidence of 
AngII-induced AAAs. Collectively, these results indicate that in adult mice 
androgen stimulate SMC AT1aR expression to promote AngII-induced AAA 
formation. 
Furthermore, we determined the role of androgen during development on 
AT1aR expression on SMC and AngII-induced AAA formation in adult female 
hyperlipidemic mice. We hypothesized that neonatal androgen administration in 
female mice stimulates aortic SMC AT1aR expression and results in increased 
susceptibility of AngII-induced AAAs in adulthood. Our data demonstrated that 
neonatal testosterone administration dramatically increased AngII-induced AAA 
formation in adult female mice and this was associated with long-lasting 
enhanced AT1aR expression specifically in abdominal aortas. In addition, 
deficiency of SMC AT1aR reduced effects of neonatal testosterone 
administration. AngII-induced atherosclerosis and ascending aortic aneurysms 
were also enhanced by neonatal administration of testosterone while SMC 
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AT1aR deficiency had no effect on the pathogenesis of these two AngII-induced 
vascular pathologies.In summary, these results demonstrated that androgen, 
both in adult life and during development, stimulates SMC AT1aR expression 
and promotes AngII-induced AAA formation in adult female hyperlipidemic mice.  
 
5.2      Potential mechanisms of androgen to influence the development of AngII-
induced AAAs 
5.2.1   The role of androgen during adult life in AngII-induced AAA formation and 
progression 
In humans, male gender is a strong independent risk factor of AAA. A 
similar gender difference has been observed in the experimental model of AngII-
induced AAA. In agreement with previous findings, results from this study confirm 
a critical role for testosterone as a primary mediator of gender differences in the 
pathogenesis of AngII-induced AAA. It has been demonstrated that removal of 
endogenous androgen profoundly reduced AngII-induced AAA formation in male 
ApoE-/- mice (Henriques, Huang et al. 2004). Our laboratory also demonstrated 
that exogenous androgen administration can restore a high incidence of AngII-
induced AAA in castrated male mice and also stimulate AAA formation in female 
mice (Henriques, Zhang et al. 2008). Interestingly, estrogen has been reported to 
exert protective effects against AAA development. For example, others 
demonstrated that male mice administered supraphysiological level of estrogen 
exhibited a significant reduction in AngII-induced AAA formation (Martin-McNulty, 
Tham et al. 2003) and a similar finding has been observed in male rats infused 
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with elastase in the abdominal aorta to  induce  aortic dilation (Ailawadi, Eliason 
et al. 2004; Cho, Woodrum et al. 2009) . The removal of endogenous estrogen 
was shown to enhance AAA incidence of female rats in elastase infusion induced 
AAAs (Wu, Zhang et al. 2009), but not in others (Cho, Woodrum et al. 2009). 
However, most studies indicate that testosterone promotes AAA formation in 
different models of this disease, including AngII-induced AAAs. 
To investigate mechanisms of androgen in promoting AngII-induced AAA 
formation, we hypothesized that androgen increases the expression of AT1aR in 
the abdominal aorta to confer a higher prevalence of AAA in male mice. This was 
primarily due to the observation that deficiency of AT1aR totally ablates AngII-
induced AAA formation in male mice, suggesting AT1aR is required for AAA 
development (Cassis, Rateri et al. 2007). In addition, bone marrow 
transplantation studies revealed that AT1aR on monocytes may not be involved 
in AngII-induced AAAs, indicating a potential role of AT1aR on resident cells 
presumably vascular wall cells of the abdominal aorta as targets of testosterone 
and/or AngII (Cassis, Rateri et al. 2007). Indeed, in these studies we 
demonstrate that in both male and female ApoE-/- mice, androgen positively 
regulates the mRNA abundance of AT1aR in abdominal, but not thoracic aorta 
(Chapter III). In the presence of androgen, either endogenous or exogenous, the 
increased level of abdominal aortic AT1aR is highly correlated with higher 
prevalence of AngII-induced AAAs in male and female mice. In contrast, the 
region specific pattern of aortic AT1bR was not altered by endogenous or 
exogenous androgen. Differences in the promoters of AT1aR and AT1bR genes 
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may contribute to androgen-specific effects to increase AT1aR mRNA 
abundance. We have performed a preliminary scan of the rat AT1 receptor 
promoter for potential transcription factor binding sites using Genomatix 
database. Several putative androgen response elements (AREs) binding sites 
were identified at around 515, 2660 and 2826 upstream of the transcription start 
site. In addition, it has been reported that the actions of AR coregulators also 
depend on the state of chromatin at the loci of target genes. For example, one of 
the AR coregulators, CBP acts as a corepressor of AR when recruited to 
pericentric regions, but as a coactivator when recruited to euchromatin (Zhao, 
Takeyama et al. 2009). AT1aR and AT1bR are encoded by two distinct genes 
located on two different chromosomes. It is possible that the differences in the 
context of chromatins at AT1aR and AT1bR loci may contribute to the specific 
stimulatory effect of androgen on AT1aR expression. In humans, there is one 
gene encoding the AT1 receptor. DHT increased AT1 receptor mRNA and 
protein levels in androgen-dependent human prostate cancer cells (Uemura, 
Hasumi et al. 2006). These results suggest that testosterone positive regulation 
of AT1 receptor expression is not restricted to mice.  However, no studies have 
examined whether human AT1 receptors are differentially expressed between 
thoracic and abdominal aorta. 
It has been previously reported AR are expressed at lower levels in the 
vasculature of female compared to male rats (Higashiura, Mathur et al. 1997).  
However, our results demonstrate that female ApoE-/- mice express abundant 
ARs in abdominal aortas and can respond to exogenous androgen similar to 
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males. Interestingly, our results also demonstrate that similar to AT1aR 
expression, the abdominal aortas of male and female ApoE-/- mice express 
higher levels of AR compared to the thoracic region. Collectively, these results 
demonstrate marked heterogeneity of the aorta along its length in males and 
females, with sex hormones contributing to differential expression of some of 
these region-specific genes. 
Furthermore, we utilized SMC AT1aR deficient mice to confirm that 
androgen positively regulates the expression of AT1aR on smooth muscle cells 
and promotes AngII-induced AAA formation. Deficiency of SMC AT1aR resulted 
in a 35% reduction of AAA incidence from 85% to 50% in adult female mice 
administered exogenous androgen. Although this significant 35% reduction 
suggests a pivotal role SMC AT1aR in AAA development, deficiency of SMC 
AT1aR did not totally ablate the effect of exogenous androgen on AngII-induced 
AAA formation in female mice. These results suggest that androgen may 
regulate AT1aR level on other cells in the vasculature, such as endothelial cells 
or fibroblasts in the adventitia, to promote AAA formation. Alternatively, there 
may be other potential mechanisms for androgen regulation of gender 
differences in AngII-induced AAA formation. For example, androgen has been 
demonstrated to stimulate MMP-2 expression in prostate cancer cells (Liao, 
Thrasher et al. 2003). Recently it has been demonstrated that male rats exhibit 
increased MMP-13 mRNA expression and proteins level in the aortic tissues as 
well as larger AAA compared to females in the experimental model of elastase 
infusion induced AAAs (Cho, Roelofs et al. 2009). 
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Overall, our studies demonstrate that AT1aR plays a critical role in the 
development of AngII-induced AAAs and is an important mechanism by which 
androgen mediates gender differences in experimental AAAs. Indeed, 
administration of losartan, an AT1 receptor inhibitor, fully protects male mice from 
developing AngII-induced AAAs (Daugherty, Manning et al. 2001). Recently, it 
has also been reported that AT1 receptor inhibition reduces macrophage 
infiltration, elastin degradation and prevents AAA formation in the rat model of 
elastase infusion induced AAA (Sweeting, Thompson et al. 2010).   
In humans, men are more likely to develop AAAs. As our results from the 
AngII infusion model of AAAs show a clear association of androgen with high 
AAA prevalence in males via regulation of AT1aR in abdominal aortas, it is 
conceivable that androgen may also influence the growth and expansion of 
formed AAAs. Therefore, we hypothesized that removal of endogenous androgen 
will decrease the progression of established Ang II-induced AAAs. As is shown in 
Chapter II, in male ApoE-/- mice with established AAAs, castration significantly 
reduced luminal dilation of abdominal aortas compared to sham control males 
during an additional 8 weeks of continuous AngII infusion.  A modest, but not 
significant decrease in maximal external diameters of abdominal aortas was also 
observed at the endpoint of the study. In contrast, it has been recently reported 
that formed AAAs in nonhyperlipidemic C57BL/6 mice exhibit no further lumen 
dilation when the mice are fed a high fat diet to induce obesity and then 
subjected to 3 month chronic AngII infusion (Police, Putnam et al. 2010).  The 
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discrepancy may be explained by the different mouse models and experimental 
design used in these studies.  
As discussed previously, androgen exerts stimulatory effects on most 
components of the RAS, including the AT1 receptor. It is conceivable that 
castration reduces the progressive luminal dilation of formed AngII-induced AAAs 
through inhibiting the RAS, possibly the AT1 receptor. We acknowledge that in 
the current study we have not measured components of the RAS, systemically or 
at local AAA tissues. Notably, a retrospective case-control study using a large 
Canadian administrative database showed that patients with an AAA taking ACE 
inhibitors were less likely to present with ruptured aneurysm (Hackam, 
Thiruchelvam et al. 2006). In the rat elastase model of AAA, an ACE inhibitor has 
been proven to significantly reduce AAA formation (Liao, Miralles et al. 2001). In 
the mouse model of fibrillin 1 deficiency mimicking Marfan syndrome, losartan 
has been demonstrated to effectively prevent the development of ascending 
aortic aneurysm by antagonizing TGF-β, which plays a role in the progression of 
tissue changes associated with Marfan syndrome (Neptune, Frischmeyer et al. 
2003; Habashi, Judge et al. 2006). In the future, comparing the levels of RAS 
components may provide us with insights how castration limits the luminal 
expansion of established AngII-induced AAAs. 
Our laboratory has previously demonstrated that weight loss in obese 
C57BL/6 mice limits adventitial expansion of established Ang II-induced AAAs, 
resulting in a reduction of external aneurysm diameters (Police, Putnam et al. 
2010). Limited adventitial expansion in mice undergoing weight loss was 
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associated with a striking decrease in neovascularization of the vessel wall 
(Police, Putnam et al. 2010). Importantly, it is well known that androgen acts via 
its receptor to regulate angiogenesis in the prostate and promote tumor 
neovascularization growth (Colombel, Filleur et al. 2005). Indeed, androgens 
have been reported to stimulate the expression of VEGF and hypoxia inducible 
factor-1 (HIF-1), key mediators of angiogenesis, in the prostate (Mabjeesh, 
Willard et al. 2003; Boddy, Fox et al. 2005). Therefore, one hypothesis to explain 
the ability of castration to blunt AAA progression is that castration decrease 
neovascularization within expanding aneurysms, limiting adventitial expansion 
and resulting in a reduction in the size of established AngII-induced AAAs.  
Unfortunately, this hypothesis is discordant with our findings that castration 
decreased aortic lumen diameters, but not aortic wall diameters of formed AAAs. 
Recent studies demonstrated that testosterone inhibits vascular calcification 
(Son, Akishita et al. 2010), suggesting that castration may increase vascular 
calcification and stimulate the remodeling of vessel wall. These findings suggest 
that androgen may exert differential effect on luminal dilation and aortic 
remodeling of established AngII-induced AAAs, via distinct mechanisms.  
In conclusion, androgen stimulates AT1aR expression, particularly on 
SMC, to promote AngII-induced AAA formation in adult mice. Furthermore, 
castration significantly decreased the progressive lumen dilation of established 
AngII-induced AAAs in male mice, suggesting that androgen plays a role in the 
formation and expansion of AAAs. 
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5.2.2   The role of developmental androgen in AngII-induced AAA formation 
As discussed previously, during development androgen plays a vital role 
in sexual differentiation of the brain and adult male behaviors as well as sexual 
dimorphism of other organs. We have identified that androgen in adult mouse 
mediates the prominent gender differences in AngII-induced AAAs partially by 
promoting AT1aR on vascular smooth muscle cells. To investigate if 
developmental androgen also contributes to a higher prevalence of AAAs in 
males, we hypothesized that administration of androgen during development to 
female mice will increase SMC AT1aR expression and promote Ang II-induced 
AAA formation in adult females. We administered a single dose of testosterone to 
female mice right after birth to mimic the effect of perinatal androgen surges 
which naturally occurs in males (Weisz and Ward 1980; Corbier, Edwards et al. 
1992). The neonatal administration of testosterone significantly stimulated 
abdominal aortic AT1aR expression and strikingly promoted AngII-induced AAA 
formation in adult female ApoE-/- and LDLR-/- mice (Chapter IV). Deficiency of 
SMC AT1aR ablated the effect of neonatal testosterone on AngII-induced AAA 
formation. 
 Notably, these effects of neonatal testosterone administration are 
independent of endogenous androgen in adulthood as serum testosterone 
concentrations in adult female mice were not altered by the short term exposure 
to androgen during development. However, as is thoroughly reviewed by 
Foecking et al, the neurosecretory control system of neonatally androgenized 
females is structurally and functionally altered and therefore incapable of 
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supporting cyclic GnRH and gonadotropin secretion in adulthood (Foecking, 
McDevitt et al. 2008). Females that were androgenized by testosterone as 
neonates exhibit a persistent estrus syndrome including anovulation, acyclic LH 
secretion and attenuated pituitary responsive to GnRH (Foecking, McDevitt et al. 
2008). Thus it is likely that these alterations in the endocrine system can lead to 
changes in the estrogen production and secretion in androgenized female mice. 
We acknowledge that estrogen measurements were not obtained in this study 
due to technical difficulties. However, since previous studies for our laboratory 
have demonstrated that endogenous estrogen does not regulate the formation of 
AngII-induced AAA (Henriques, Huang et al. 2004), changes in estrogen levels in 
androgenized females most likely did not mediate the striking increases in 
susceptibility to AngII-induced AAAs of adult female mice. 
Interestingly, in female mice administered testosterone as neonates 
increased expression levels of abdominal aortic AT1aR were acquired following a 
single exposure to testosterone and maintained through adulthood without a 
continued requirement for circulating testosterone. In contrast, our results 
demonstrate that male mice continue to require circulating androgen to maintain 
abdominal aortic AT1aR expression in adult life. This is important as males would 
be naturally under the influence of perinatal androgen surges during 
development.  AR mediated gene transcription often involves epigenetic 
mechanisms, in which the coregulatory factors of AR modulate chromatin 
structure and influence epigenetic marks. However, it has been demonstrated 
that the distribution and expression level of some AR coregulators vary between 
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males and females. For example, in rats many AR coregulatory factors, such as 
SCR-1, CBP/p300, NCoR and SMRT, are differentially expressed in various 
tissues (Misiti, Schomburg et al. 1998). Therefore, gender differences in the 
expression of AR coregulators may result in variable responses to androgen 
between male and female mice. In addition, recent studies have also revealed 
that sex chromosomes influence the different responses to sex hormones in the 
experimental model of AngII-induced hypertension (Ji, Zheng et al. 2010). It is 
also feasible that the presence of an additional X chromosome, or alternatively 
the absence of a Y chromosome in female mice may contribute to the different 
response to neonatal androgen between male and female mice. 
In addition, many investigators have discovered that the specific impacts 
of developmental androgen on the adult animal vary greatly, depending on: 1) at 
what “critical” period during development androgen is administered; 2) the dose 
and duration of androgen exposure and 3) the animal species. For example, it is 
well established that androgen (usually a single dose) is administered perinatally, 
during late gestation or right after birth, to induce neuroendocrine alterations and 
androgenized male-like behaviors in female rodents, sheep and non-human 
primate (Pfaff and Zigmond 1971; Hrabovszky and Hutson 2002; Wallen 2005). 
Recently excess androgen exposure in utero has emerged as a promising tool to 
generate experimental model of polycystic ovary syndrome (PCOS) (Xita and 
Tsatsoulis 2006). PCOS is a common endocrine and metabolic disorder 
characterized by excess androgen production of ovarian and/or adrenal origin, 
luteinizing hormone (LH) hypersecretion, hyperinsulinemia from insulin 
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resistance and reduced fecundity. PCOS imposes an increased risk for type 2 
diabetes and cardiovascular disease in women. It has been reported that PCOS 
phenotypes can be obtained from repeated injections of  pregnant rhesus 
monkeys carrying female fetuses with testosterone for 15 to 35 days starting on 
either days 40–60 (early gestation) or days 100–115 (late gestation) during a 
total 165-day gestation (Dumesic, Abbott et al. 2007). In comparison, the 
administration of testosterone during early gestation produces more traits of 
PCOS, such as LH hypersecretion and increased type 2 diabetes. In this study, 
we administered exogenous androgen neonatally to distinguish from the PCOS 
experimental model as the metabolic syndrome phenotypes in PCOS model 
would complicate the interpretation of our results.  However, it is not clear 
whether or not the effect of developmental androgen on abdominal aortic AT1aR 
expression and AngII-induced AAA formation would sustain if exogenous 
androgen was administered early in development. 
Interesting, in our studies neonatal testosterone administration also 
significantly enhanced AngII-induced atherosclerosis and ascending aortic 
aneurysm. Previously we have demonstrated that gender differences were 
restricted to AngII-induced AAAs, as male and female mice exhibited similar 
levels of atherosclerosis following AngII infusion (Henriques, Zhang et al. 2008). 
Recently the pathological characteristics of AngII-induced ascending aortic 
aneurysms have been reported (Daugherty, Rateri et al. 2010). Preliminary 
observations suggest that gender differences do not exist in AngII-induced aortic 
arch aneurysms.  We acknowledge that the dose of testosterone used in this 
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study (400 µg/mouse) is higher than what has been used by many investigators 
to androgenize females in the study of sexual dimorphism of brain (100 
µg/mouse). This may contribute to the unexpected observation that two AngII-
induced vascular pathologies that do not display gender differences were 
influenced by neonatal testosterone administration. In addition, SMC AT1aR 
deficiency reduced the effect of neonatal testosterone to promote AngII-induced 
AAAs, but had no effect on atherosclerosis or ascending aortic aneurysms in 
adult female mice infused with AngII.  However, theAT1aR is required for these 
AngII-induced vascular pathologies. It is possible that neonatal testosterone 
regulates AT1aR expression on other cells in the vasculature to promote AngII-
induced atherosclerosis and ascending aortic aneurysms. Furthermore, the 
mRNA abundance of p47phox, one of the cytosolic units of NADPH oxidase, was 
significantly increased in thoracic aortas of female mice administered 
testosterone as neonates. It is conceivable that the increased ROS production 
and oxidative stress in the vasculature of thoracic aortas may play a role in 
enhanced AngII-induced atherosclerosis and ascending aortic aneurysm in this 
region. Future studies should include full DNA  array analysis on the aortas from 
androgenized and control female mice to provide potential gene targets that may 
be regulated by neonatal testosterone exposure and contribute to these AngII-
induced vascular pathologies in female mice. 
In conclusion, our findings have demonstrated that a short-term exposure 
to testosterone during a critical period of development increases AngII-induced 
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AAA formation, via regulating SMC AT1aR,  as well as other AngII-induced 
vascular pathologies in adult female mice. 
 
5.3      Future directions 
Results from these studies demonstrate that androgen increases AT1aR 
expression, particularly in abdominal aortic SMCs, to promote AngII-induced AAA 
formation. Our studies focus on investigating the role of androgen in adult life and 
during development in the formation of AngII-induced AAAs. In both studies we 
have demonstrated that the enhanced AAA formation by androgen is highly 
associated with the increased expression of abdominal aortic AT1aR. However, 
we did not address the molecular mechanisms responsible for androgen 
stimulation of AT1aR expression, especially in the abdominal aortas. Therefore, 
an interesting study will be to examine the exact coregulatory factors that interact 
with ARs recruited to the AT1aR promoter to increase transcription of AT1aR in 
abdominal aortas. 
Our results suggest that female mice exhibit long-lasting enhancement of 
abdominal aortic AT1aR expression once exposed to neonatal androgen while 
male mice require constant high circulating androgen to maintain higher AT1aR 
expression. Our study did not address why female mice seem to be more 
sensitive to the effects of neonatal testosterone administration. It is possible that 
the dose of testosterone we used in the study (400 µg/mouse) causes the 
circulating testosterone level in fetal females to exceed those normally found in 
fetal males. Therefore, one of the future experiments could focus on defining 
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effects of a lower dose testosterone, 100 µg/mouse, on AngII-induced AAA 
formation as well as atherosclerosis and ascending aortic aneurysms in adult 
female mice. 
Another possibility is that sex chromosomes may influence the differential 
responses to neonatal testosterone between male and female mice. Recently, a 
powerful mouse model, name the 4 core genotypes, has been demonstrated to 
enable studying the sex chromosome effects independent of the influences of 
sex hormones (Arnold and Chen 2009). The 4 core genotypes includes 
alternative gonadal female mice (XY–) generated by the deletion of Sry gene, the 
dominant testis-determining gene, from the Y chromosome. The XY– mouse does 
not develop testes but develops ovaries and expresses a female gonadal 
hormone phenotype instead. Similarly, The Sry gene was also inserted onto an 
autosome, creating XY–Sry and XXSry transgenic mice which are gonadal male 
mice regardless of the sex chromosome complement. Therefore, by comparing 
among XX and XY females and XX and XY males the effect of sex chromosome 
complement can be uncoupled from the influences of sex hormone and studied 
independently. One interesting study in the future should utilize the 4 core 
genotype and compare XX and XY females to determine if neonatal testosterone 
administration induces the same extent of AngII-induced vascular pathologies 
between XX and XY females.  It will allow us to dissect out the possible effect of 
sex chromosomes in the different responses to neonatal androgen between the 
genders.  
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5.4      Clinical application 
5.4.1   AAA prevention 
In agreement to observations in human AAAs, our studies in experimental 
AngII-induced AAAs further confirm male gender is a potent risk factor for AAA 
pathogenesis. Moreover, our results suggest that male sex hormone, namely 
testosterone, is a primary contributor to AAA formation and progression.  In men, 
androgen replacement therapy has been used to treat a variety of symptoms 
associated with aging, including loss of energy, mood depression and erectile 
dysfunction. Women also use exogenous androgen administration as part of 
hormone replacement therapy to improve performance. Our data demonstrate 
that androgen promotes AngII-induced AAA formation in both male and female 
mice via upregulation of AT1aR. A significant increased risk of developing AAA 
may be identified in the aging men and women who take exogenous androgen as 
hormone replacement therapy as well as male and female athletes/bodybuilders 
who abuse anabolic hormones. These populations with a potentially high AAA 
risk should exercise precaution in using androgen as hormone replacement 
therapy, look for other alternative therapy options and undergo regular ultrasound 
monitoring to effective prevent AAA formation. 
 Although in general female gender is considered as a negative risk factor 
for AAAs, the consequences tend to be more vicious once AAAs are formed in 
women. For example, The UK Small Aneurysm trial reported that in patients kept 
under surveillance, a 3-times higher risk of aneurysm rupture for women was 
found even at a smaller diameter than men  (Brown and Powell 1999).  Women 
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also tend to have a lower survival rate after the surgical repair of AAAs (Dueck, 
Kucey et al. 2004). In addition, multiple studies have demonstrated a faster 
growth rate of AAAs in women compared with men (Solberg, Singh et al. 2005; 
Schouten, van Laanen et al. 2006; Mofidi, Goldie et al. 2007). Therefore, it is 
important to identify the particular female population that exhibits high risk of 
developing AAAs. In addition, our studies demonstrate that a short-term 
androgen exposure during a critical period of development dramatically 
predisposes to AAA in females when they become adults. In humans, women 
suffering from PCOS experience high circulating androgen levels after puberty. It 
has been reported that plasma androgen levels are higher in women with PCOS 
during pregnancy (Falbo, Rocca et al. 2010). Based on 6.6% estimated 
prevalence of PCOS in reproductive aged women, there are at least 4 million 
women with this disease in the United States. The female offspring of these 
PCOS women may become more susceptible to AAA and possibly other vascular 
pathologies in adult life due to the impact of excess androgen exposure during 
fetal development. It will be beneficial to raise the awareness of the potential high 
risk of AAA in this particular female population. 
 
5.4.2   AAA treatment 
Currently there is no effective pharmacologic treatment to slow AAA 
progression and reduce the chance of aneusymal ruptures.  Recently the drugs 
inhibiting the RAS, such as ACE inhibitors and AT1 receptor blockers, have been 
emerged as potential treatments for this disease due to the positively protective 
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effects against AAA formation observed in experimental models of AAA 
(Daugherty, Manning et al. 2001; Liao, Miralles et al. 2001; Sweeting, Thompson 
et al. 2010). Despite the promising findings in animal models, the effects of RAS 
inhibitors on human AAA remains controversial and requires more clinical studies 
to confirm the findings. For example, ACE inhibitor has been associated with 
reduced AAA ruptures in a retrospective study (Hackam, Thiruchelvam et al. 
2006), while in a  different study the use of ACE inhibitors was recently 
associated with increased growth rate of AAAs in human patients (Sweeting, 
Thompson et al. 2010) . In addition, preoperative RAS inhibition before AAA 
surgical repair has been reported to increase mortality in AAA patients (Railton, 
Wolpin et al. 2010). However, in a recent study involving 25 years of surveillance, 
treatment with an angiotensin receptor antagonist was reported to be associated 
with slower AAA growth rates (Thompson, Cooper et al. 2010). Our data 
demonstrate that androgen both in adult life and during development promotes 
AngII-induced AAA formation through stimulating SMC AT1aR expression of the 
abdominal aortas in female mice. Our findings support an important role of AT1 
receptors in the pathogenesis of AAAs and indicate ARB may be beneficial as a 
treatment of human AAA. 
 
5.5      Concluding remarks 
In conclusion, findings of this dissertation demonstrated that androgen, 
both during development and in adult life, mediates AngII-induced AAA formation 
in adult hyperlipidemic mice. These findings implicate increased expression of 
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AT1a receptor specifically in abdominal aortas as a potential mechanism 
underlying androgen as a primary mediator of high AAA prevalence in m ale 
gender. In addition, endogenous androgen modulates the lumen expansion of 
established AngII-induced AAAs. These findings support AT1 receptor blocker as 
a potential option to treat AAA and also raise the possibility of androgen 
deprivation as a pharmacologic therapeutic option to limit AAA progression and 
ruptures for patients diagnosed with AAA. 
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